John DiNicola

10/650931

```
=> file registry
FILE 'REGISTRY' ENTERED AT 18:00:51 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     6 MAR 2007  HIGHEST RN 925228-12-2
DICTIONARY FILE UPDATES:    6 MAR 2007  HIGHEST RN 925228-12-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> file caplus
FILE 'CAPLUS' ENTERED AT 18:00:59 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Mar 2007  VOL 146 ISS 11
FILE LAST UPDATED: 6 Mar 2007  (20070306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L65
L63         1615 SEA FILE=CAPLUS ABB=ON  PLU=ON  WOO J?/AU
L64          393 SEA FILE=CAPLUS ABB=ON  PLU=ON  CHI M?/AU
L65            4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L63 AND L64


=> d stat que L122
```

```
L2            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3           90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5            3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8           17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18          18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20          91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21           4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22          53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23          19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27         167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L67       57253 SEA FILE=REGISTRY ABB=ON  PLU=ON  MEDLINE/LC
L70           6 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L67
L91        1020 SEA FILE=MEDLINE ABB=ON  PLU=ON  WOO J?/AU
L92         144 SEA FILE=MEDLINE ABB=ON  PLU=ON  CHI M?/AU
L94       18551 SEA FILE=MEDLINE ABB=ON  PLU=ON  L70
L95       19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96        1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97        4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98         713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L112        426 SEA FILE=MEDLINE ABB=ON  PLU=ON  (ADALAT/BI OR BAY-A-1040/BI
                OR BAY-1040/BI OR CORDIPIN/BI OR CORDIPINE/BI OR CORINFAR/BI
                OR FENIGIDIN/BI OR INFEDIPIN/BI OR KORINFAR/BI OR "MONOHYDROCHL
                ORIDE, NIFEDIPINE"/BI OR NIFANGIN/BI OR "NIFEDIPINE MONOHYDROCH
                LORIDE"/BI OR NIFEDIPINE-GTIS/BI OR PROCARDIA/BI OR "PROCARDIA
                XL"/BI)
L114      19161 SEA FILE=MEDLINE ABB=ON  PLU=ON  L95 OR L112
L115        382 SEA FILE=MEDLINE ABB=ON  PLU=ON  (DYNACIRC/BI OR "ISRADIPINE,
                (+-)-ISOMER"/BI OR "ISRADIPINE, (R)-ISOMER"/BI OR "ISRADIPINE,
                (S)-ISOMER"/BI OR LOMIR/BI OR "PN 200-110"/BI OR "PN 205
                033"/BI OR "PN 205 034"/BI OR "PN 205-033"/BI OR "PN 205-034"/B
                I OR "PN 205033"/BI OR "PN 205034"/BI OR PN-200-110/BI OR
                PN-205-033/BI OR PN-205-034/BI OR PN205033/BI OR PN205034/BI)
L116       1595 SEA FILE=MEDLINE ABB=ON  PLU=ON  L96 OR L115
L117        404 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("LOVASTATIN, (1 ALPHA(S*))-IS
                OMER"/BI OR "LOVASTATIN, 1 ALPHA-ISOMER (WITHOUT R*/S*
                NOTATION)"/BI OR "MK 803"/BI OR MK-803/BI OR MK803/BI OR
                MEVACOR/BI OR MEVINOLIN/BI OR "MONACOLIN K"/BI)
L118       4139 SEA FILE=MEDLINE ABB=ON  PLU=ON  L97 OR L117
L119         29 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("ALPHAPHARM BRAND OF
                GLIPIZIDE"/BI OR "GLIBENESE BRAND OF GLIPIZIDE"/BI OR GLIDIAZIN
                AMIDE/BI OR GLUCOTROL/BI OR GLUPITEL/BI OR GLYDIAZINAMIDE/BI
                OR GLYPIDIZINE/BI OR "K 4024"/BI OR K-4024/BI OR K4024/BI OR
                "KENFARMA BRAND OF GLIPIZIDE"/BI OR "LACER BRAND OF GLIPIZIDE"/
                BI OR "LILLY BRAND OF GLIPIZIDE"/BI OR MELIZIDE/BI OR MINDIAB/B
                I OR MINIDIAB/BI OR MINODIAB/BI OR OZIDIA/BI OR "PFIZER BRAND
                OF GLIPIZIDE"/BI OR "PHARMACIA BRAND OF GLIPIZIDE"/BI OR
                "PYRAZINECARBOXAMIDE, N-(2-(4-((((CYCLOHEXYLAMINO)CARBONYL)AMIN
                O)SULFONYL)PHENYL)ETHYL)-5-METHYL-"/BI)
L120        723 SEA FILE=MEDLINE ABB=ON  PLU=ON  L98 OR L119
L122          6 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L94 OR L114 OR L116 OR L118
                OR L120) AND (L91 OR L92)


=> file medline
FILE 'MEDLINE' ENTERED AT 18:01:17 ON 07 MAR 2007
```

FILE LAST UPDATED: 7 Mar 2007 (20070307/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d stat que L122
L2             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3            90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8            17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18           18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20           91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22           53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23           19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27          167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L67        57253 SEA FILE=REGISTRY ABB=ON  PLU=ON  MEDLINE/LC
L70            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L67
L91         1020 SEA FILE=MEDLINE ABB=ON  PLU=ON  WOO J?/AU
L92          144 SEA FILE=MEDLINE ABB=ON  PLU=ON  CHI M?/AU
L94        18551 SEA FILE=MEDLINE ABB=ON  PLU=ON  L70
L95        19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96         1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97         4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98          713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L112         426 SEA FILE=MEDLINE ABB=ON  PLU=ON  (ADALAT/BI OR BAY-A-1040/BI
                 OR BAY-1040/BI OR CORDIPIN/BI OR CORDIPINE/BI OR CORINFAR/BI
                 OR FENIGIDIN/BI OR INFEDIPIN/BI OR KORINFAR/BI OR "MONOHYDROCHL
                 ORIDE, NIFEDIPINE"/BI OR NIFANGIN/BI OR "NIFEDIPINE MONOHYDROCH
                 LORIDE"/BI OR NIFEDIPINE-GTIS/BI OR PROCARDIA/BI OR "PROCARDIA
                 XL"/BI)
L114       19161 SEA FILE=MEDLINE ABB=ON  PLU=ON  L95 OR L112
L115         382 SEA FILE=MEDLINE ABB=ON  PLU=ON  (DYNACIRC/BI OR "ISRADIPINE,
                 (+-)-ISOMER"/BI OR "ISRADIPINE, (R)-ISOMER"/BI OR "ISRADIPINE,
                 (S)-ISOMER"/BI OR LOMIR/BI OR "PN 200-110"/BI OR "PN 205
                 033"/BI OR "PN 205 034"/BI OR "PN 205-033"/BI OR "PN 205-034"/B
                 I OR "PN 205033"/BI OR "PN 205034"/BI OR PN-200-110/BI OR
                 PN-205-033/BI OR PN-205-034/BI OR PN205033/BI OR PN205034/BI)
L116        1595 SEA FILE=MEDLINE ABB=ON  PLU=ON  L96 OR L115
L117         404 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("LOVASTATIN, (1 ALPHA(S*))-IS
                 OMER"/BI OR "LOVASTATIN, 1 ALPHA-ISOMER (WITHOUT R*/S*
                 NOTATION)"/BI OR "MK 803"/BI OR MK-803/BI OR MK803/BI OR
                 MEVACOR/BI OR MEVINOLIN/BI OR "MONACOLIN K"/BI)
L118        4139 SEA FILE=MEDLINE ABB=ON  PLU=ON  L97 OR L117
L119          29 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("ALPHAPHARM BRAND OF
                 GLIPIZIDE"/BI OR "GLIBENESE BRAND OF GLIPIZIDE"/BI OR GLIDIAZIN
                 AMIDE/BI OR GLUCOTROL/BI OR GLUPITEL/BI OR GLYDIAZINAMIDE/BI
                 OR GLYPIDIZINE/BI OR "K 4024"/BI OR K-4024/BI OR K4024/BI OR
                 "KENFARMA BRAND OF GLIPIZIDE"/BI OR "LACER BRAND OF GLIPIZIDE"/
                 BI OR "LILLY BRAND OF GLIPIZIDE"/BI OR MELIZIDE/BI OR MINDIAB/B
```

```
                I OR MINIDIAB/BI OR MINODIAB/BI OR OZIDIA/BI OR "PFIZER BRAND
                OF GLIPIZIDE"/BI OR "PHARMACIA BRAND OF GLIPIZIDE"/BI OR
                "PYRAZINECARBOXAMIDE, N-(2-(4-((((CYCLOHEXYLAMINO)CARBONYL)AMIN
                O)SULFONYL)PHENYL)ETHYL)-5-METHYL-"/BI)
L120          723 SEA FILE=MEDLINE ABB=ON  PLU=ON  L98 OR L119
L122            6 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L94 OR L114 OR L116 OR L118
                OR L120) AND (L91 OR L92)


=> file embase
FILE 'EMBASE' ENTERED AT 18:01:22 ON 07 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

 FILE COVERS 1974 TO 7 Mar 2007 (20070307/ED)

 EMBASE is now updated daily.  SDI frequency remains weekly (default)
 and biweekly.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d stat que L153
L2              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3             90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5              3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7             37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8             17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18            18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20            91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21             4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22            53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23            19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27           167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L29             8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31           102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33            28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE?/CN
L36             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37           133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38           137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39            87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40           111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE/CN
L42           129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43           151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L68         30841 SEA FILE=REGISTRY ABB=ON  PLU=ON  EMBASE/LC
L71             6 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L68
L74             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND L68
L77             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L68
L80             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L43 AND L68
L95         19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96          1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97          4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98           713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L100          663 SEA FILE=MEDLINE ABB=ON  PLU=ON  SODIUM ALGINATE
```

```
L101       5653 SEA FILE=MEDLINE ABB=ON  PLU=ON  ALGINATE
L105       4774 SEA FILE=MEDLINE ABB=ON  PLU=ON  METHYLCELLULOSE
L106        458 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYDROXYPROPYLMETHYLCELLULOSE
L123      46607 SEA FILE=EMBASE ABB=ON  PLU=ON  (L71 OR (L95 OR L96 OR L97 OR
                L98))
L124       3286 SEA FILE=EMBASE ABB=ON  PLU=ON  (ADALAT/BI OR "ADALAT CRONO"/BI
                 OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR
                ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR
                "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR
                "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI
                OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/B
                I OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI
                 OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2
                NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR
                ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR
                INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR
                NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR
                NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR
                NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR
                NOVONIFEDIN/BI OR PHENYGIDINE/BI OR PIDILAT/BI OR "PIDILAT
                RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI
                OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR
                UNIDIPINE/BI OR ZENUSIN/BI)
L125       1049 SEA FILE=EMBASE ABB=ON  PLU=ON  (ISRODIPINE/BI OR LOMIR/BI OR
                "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN
                200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN
                205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR
                PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI)
L126       2955 SEA FILE=EMBASE ABB=ON  PLU=ON  (ALTOCOR/BI OR ALTOPREV/BI OR
                ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR
                LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR
                "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR
                "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI)
L127        524 SEA FILE=EMBASE ABB=ON  PLU=ON  ("CP 28,720"/BI OR "CP
                28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR
                GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/
                BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI
                OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K
                4024"/BI OR MINIDIAB/BI OR MINODIAB/BI)
L128      46760 SEA FILE=EMBASE ABB=ON  PLU=ON  (L123 OR L124 OR L125 OR L126
                OR L127)
L129      13985 SEA FILE=EMBASE ABB=ON  PLU=ON  (ALGIN/BI OR ALGINATE/BI OR
                "ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC
                ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST
                SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI
                 OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR
                ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR
                MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR
                "POLYMANNURONIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI
                OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR
                "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN
                GREEN"/BI OR "ZELGAN PINK"/BI)
L130       6223 SEA FILE=EMBASE ABB=ON  PLU=ON  L74 OR (L100 OR L101)
L131      15293 SEA FILE=EMBASE ABB=ON  PLU=ON  (L129 OR L130)
L132        649 SEA FILE=EMBASE ABB=ON  PLU=ON  L77 OR XANTHAN GUM
L133        699 SEA FILE=EMBASE ABB=ON  PLU=ON  XANTHAN OR KELTROL OR RHODIGEL
                23
L134        699 SEA FILE=EMBASE ABB=ON  PLU=ON  (L132 OR L133)
L135       6010 SEA FILE=EMBASE ABB=ON  PLU=ON  L80 OR (L105 OR L106)
L136       1239 SEA FILE=EMBASE ABB=ON  PLU=ON  (ADATOCEL/BI OR CONTACTOL/BI
```

```
                OR GONIOSOL/BI OR "HYDROXYPROPYL METHYL CELLULOSE"/BI OR
                "HYDROXYPROPYL METHYLCELLULOSE"/BI OR "HYDROXYPROPYLMETHYL
                CELLULOSE"/BI OR HYPROMELLOSE/BI OR "ISOPTO TEARS"/BI OR
                ISOPTONATURAL/BI OR ISOPTOPLAIN/BI OR ISOPTOTEARS/BI OR "K
                8515"/BI OR LUBAFAX/BI OR "METHOCEL E 15"/BI OR "METHOCEL
                EFK"/BI OR "METHOCEL K100M"/BI OR "METHOCEL K15M"/BI OR
                "METHOCEL K4M"/BI OR "METHOLOSE TC 5"/BI OR "METHYLHYDROXYPROPY
                L CELLULOSE"/BI OR METHYLHYDROXYPROPYLCELLULOSE/BI OR METOLOSE/
                BI OR OCCUCOAT/BI OR OCUCOAT/BI OR "PHARMACOAT 603"/BI OR
                "PHARMACOAT 606"/BI OR ULTRATEARS/BI)
L137        6060 SEA FILE=EMBASE ABB=ON  PLU=ON  (L135 OR L136)
L139          23 SEA FILE=EMBASE ABB=ON  PLU=ON  "ALGINIC ACID PROPYLENE GLYCOL
                ESTER"+UF/CT
L140          26 SEA FILE=EMBASE ABB=ON  PLU=ON  ("PROPYLENE GLYCOL ALGINATE"/BI
                 OR "PROPYLENEGLYCOL ALGINATE"/BI)
L141          34 SEA FILE=EMBASE ABB=ON  PLU=ON  (L139 OR L140)
L145        1034 SEA FILE=EMBASE ABB=ON  PLU=ON  WOO J?/AU
L146         165 SEA FILE=EMBASE ABB=ON  PLU=ON  CHI M?/AU
L147           0 SEA FILE=EMBASE ABB=ON  PLU=ON  L145 AND L146
L148           9 SEA FILE=EMBASE ABB=ON  PLU=ON  (L145 OR L146) AND L128
L149           4 SEA FILE=EMBASE ABB=ON  PLU=ON  (L145 OR L146) AND L131
L150           0 SEA FILE=EMBASE ABB=ON  PLU=ON  (L145 OR L146) AND L134
L151           3 SEA FILE=EMBASE ABB=ON  PLU=ON  (L145 OR L146) AND L137
L152           0 SEA FILE=EMBASE ABB=ON  PLU=ON  (L145 OR L146) AND L141
L153          16 SEA FILE=EMBASE ABB=ON  PLU=ON  (L147 OR L148 OR L149 OR L150
                OR L151 OR L152)


=> file biosis
FILE 'BIOSIS' ENTERED AT 18:01:31 ON 07 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 28 February 2007 (20070228/ED)


=> d stat que L169
L2             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3            90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8            17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18           18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20           91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22           53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23           19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27          167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L29            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31          102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L36            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37          133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38          137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
```

```
L39          87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40         111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L68       30841 SEA FILE=REGISTRY ABB=ON  PLU=ON  EMBASE/LC
L69      196582 SEA FILE=REGISTRY ABB=ON  PLU=ON  BIOSIS/LC
L72          11 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L69
L74           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND L68
L77           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L68
L78           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L69
L95       19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96        1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97        4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98         713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L100        663 SEA FILE=MEDLINE ABB=ON  PLU=ON  SODIUM ALGINATE
L101       5653 SEA FILE=MEDLINE ABB=ON  PLU=ON  ALGINATE
L125       1049 SEA FILE=EMBASE ABB=ON  PLU=ON  (ISRODIPINE/BI OR LOMIR/BI OR
                "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN
                200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN
                205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR
                PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI)
L126       2955 SEA FILE=EMBASE ABB=ON  PLU=ON  (ALTOCOR/BI OR ALTOPREV/BI OR
                ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR
                LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR
                "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR
                "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI)
L127        524 SEA FILE=EMBASE ABB=ON  PLU=ON  ("CP 28,720"/BI OR "CP
                28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR
                GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/
                BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI
                OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K
                4024"/BI OR MINIDIAB/BI OR MINODIAB/BI)
L129      13985 SEA FILE=EMBASE ABB=ON  PLU=ON  (ALGIN/BI OR ALGINATE/BI OR
                "ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC
                ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST
                SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI
                 OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR
                ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR
                MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR
                "POLYMANNURONIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI
                OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR
                "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN
                GREEN"/BI OR "ZELGAN PINK"/BI)
L130       6223 SEA FILE=EMBASE ABB=ON  PLU=ON  L74 OR (L100 OR L101)
L132        649 SEA FILE=EMBASE ABB=ON  PLU=ON  L77 OR XANTHAN GUM
L133        699 SEA FILE=EMBASE ABB=ON  PLU=ON  XANTHAN OR KELTROL OR RHODIGEL
                23
L154       1198 SEA FILE=BIOSIS ABB=ON  PLU=ON  WOO J?/AU
L155        244 SEA FILE=BIOSIS ABB=ON  PLU=ON  CHI M?/AU
L157      25683 SEA FILE=BIOSIS ABB=ON  PLU=ON  L72 OR (L95 OR L96 OR L97 OR
                L98)
L158        422 SEA FILE=BIOSIS ABB=ON  PLU=ON  (ADALAT/BI OR "ADALAT CRONO"/BI
                 OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR
                ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR
                "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR
                "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI
                OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/B
                I OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI
                 OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2
                NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR
                ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR
                INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR
```

```
                NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR
                NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR
                NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR
                NOVONIFEDIN/BI OR PHENYGIDINE/BI OR PIDILAT/BI OR "PIDILAT
                RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI
                OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR
                UNIDIPINE/BI OR ZENUSIN/BI)
L159        4086 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L125 OR L126 OR L127)
L160       26142 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L157 OR L158 OR L159)
L161       23308 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L129 OR L130)
L162        1552 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L132 OR L133)
L163        1071 SEA FILE=BIOSIS ABB=ON  PLU=ON  L78
L164        1552 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L162 OR L163)
L169           8 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L154 OR L155) AND (L157 OR
                L158 OR L159 OR L160 OR L161 OR L162 OR L163 OR L164)


=> file uspatfull
FILE 'USPATFULL' ENTERED AT 18:01:42 ON 07 MAR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Mar 2007 (20070306/PD)
FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)
HIGHEST GRANTED PATENT NUMBER: US7188369
HIGHEST APPLICATION PUBLICATION NUMBER: US2007050874
CA INDEXING IS CURRENT THROUGH 6 Mar 2007 (20070306/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Mar 2007 (20070306/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006


=> d stat que L170
L154        1198 SEA FILE=BIOSIS ABB=ON  PLU=ON  WOO J?/AU
L155         244 SEA FILE=BIOSIS ABB=ON  PLU=ON  CHI M?/AU
L170           1 SEA FILE=USPATFULL ABB=ON  PLU=ON  L154 AND L155


=> dup rem L65 L122 L153 L169 L170
FILE 'CAPLUS' ENTERED AT 18:02:04 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 18:02:04 ON 07 MAR 2007

FILE 'EMBASE' ENTERED AT 18:02:04 ON 07 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 18:02:04 ON 07 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 18:02:04 ON 07 MAR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L65
PROCESSING COMPLETED FOR L122
PROCESSING COMPLETED FOR L153
PROCESSING COMPLETED FOR L169
PROCESSING COMPLETED FOR L170
L185          23 DUP REM L65 L122 L153 L169 L170 (12 DUPLICATES REMOVED)
                ANSWERS '1-4' FROM FILE CAPLUS
```

ANSWERS '5-10' FROM FILE MEDLINE
ANSWERS '11-22' FROM FILE EMBASE
ANSWER '23' FROM FILE USPATFULL

=> d ibib abs hitind hitstr L185 1-4; d iall L185 5-22; d ibib abs L185 23

L185 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:655680 CAPLUS Full-text
DOCUMENT NUMBER: 145:110382
TITLE: Controlled release formulation for oral administration of pharmaceuticals for diabetes treatment
INVENTOR(S): ***Woo, Jong Soo***; Yi, Hong Gi; ***Chi, Moon Hyuk***; Kim, Young Hun
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006071078	A1	20060706	WO 2005-KR4609	20051228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KR 2006077812	A	20060705	KR 2004-117781	20041231
PRIORITY APPLN. INFO.:			KR 2004-117781 A	20041231

AB A controlled release combination formulation for oral administration comprises a controlled release portion containing metformin or a salt thereof as an active ingredient, and a combination of a polyethylene oxide and a natural gum as a carrier for controlled release; and a rapid-release portion containing a sulfonylurea-based drug for treating diabetes as an active ingredient coated on the controlled release portion and it is capable of maintaining an effective concentration of the drugs in blood at a constant level. Thus, a combination formulation contained metformin-HCl 46.11, and glimepiride 0.18%.
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L185 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:653417 CAPLUS Full-text
DOCUMENT NUMBER: 145:110367
TITLE: Pharmaceutical combination formulations comprising a 3-hydroxy-3-methylglutaryl CoA reductase inhibitor and an antihypertensive agent
INVENTOR(S): ***Woo, Jong Soo***; ***Chi, Moon Hyuk***; Kim, Yong Il
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006071077	A1	20060706	WO 2005-KR4607	20051228

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: KR 2004-116328 A 20041230

AB A complex formulation for oral administration comprises a sustained release formulation of an HMG-CoA reductase inhibitor (e.g., mevastatin, lovastatin, or pravastatin) and a film layer for rapid release of an anti-hypertensive, the film layer being coated on the sustained release formulation, can achieve improved therapeutic effects of the anti-hypertensive agent by promptly releasing it, while maintaining a constant drug level of the HMG-CoA reductase inhibitor in blood through a slow release. Accordingly, the complex formulation is useful for preventing and treating diseases such as hyperlipidemia, atherosclerosis, hypertension and cardiovascular disease. Combination formulations of amlodipine camsylate-simvastatin mixture exhibit dissoln. rates similar to those of the sustained release formulations of simvastatin.

CC 63-6 (Pharmaceuticals)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L185 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1123805 CAPLUS Full-text
DOCUMENT NUMBER: 143:411049
TITLE: Sustained-release formulation for oral administration of HMG-Co A reductase inhibitor and method for the preparation thereof
INVENTOR(S): ***Woo, Jong-Soo***; Yi, Hong-Gi; ***Chi, Moon-Hyuk***; Ryu, Jae-Kuk; Jung, Si-Young; Kim, Yong-Il
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097194	A1	20051020	WO 2005-KR1021	20050408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

KR 2005099583	A	20051013	KR 2004-24734	20040410
AU 2005230362	A1	20051020	AU 2005-230362	20050408
CA 2562418	A1	20051020	CA 2005-2562418	20050408
EP 1744782	A1	20070124	EP 2005-733408	20050408

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: KR 2004-24734 A 20040410
WO 2005-KR1021 W 20050408

AB The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 h. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels. A sustained-release tablet contained lovastatin 60, vitamin E TPGS 20, BHT 2, HPMC-2910 50, sodium alginate 36, xanthan gum 150, locust bean gum 50, propylene glycol ester alginate 30, HPMC-2208 110, kofovidone 35, light anhydrous silicic acid 10, and magnesium stearate 2 mg. Effects of tablets on lowering cholesterol and triglyceride levels in hyperlipidemic rats is shown.

IC ICM A61K047-00
ICS A61P009-10

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L185 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:347981 CAPLUS Full-text
DOCUMENT NUMBER: 140:344933
TITLE: Sustained-release composition for oral administration of drugs
INVENTOR(S): ***Woo, Jong-Soo; Chi, Moon-Hyuk***
PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea
SOURCE: Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1413295	A1	20040428	EP 2003-14596	20030708

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

KR 2004036130	A	20040430	KR 2002-64940	20021023
US 2004081693	A1	20040429	US 2003-650931	20030827
CA 2502731	A1	20040506	CA 2003-2502731	20031023
WO 2004037290	A1	20040506	WO 2003-KR2241	20031023

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG

AU 2003272118	A1	20040513	AU 2003-272118		20031023
JP 2004143175	A	20040520	JP 2003-362832		20031023
BR 2003015604	A	20050823	BR 2003-15604		20031023
CN 1741819	A	20060301	CN 2003-80101734		20031023
NZ 539192	A	20061130	NZ 2003-539192		20031023
PRIORITY APPLN. INFO.:			KR 2002-64940	A	20021023
			WO 2003-KR2241	W	20031023

AB A sustained-release composition for oral administration of a drug, comprises the drug, a mixture of sodium alginate and xanthan gum as a carrier for sustained release and a mixture of hydroxypropyl Me cellulose and propylene glycol alginate as a gel hydration accelerator, which is capable of maintaining a constant drug level in blood for 24 h or more owing to the fact that the drug release rate follows zero order kinetics and does not significantly vary with the degree of gastrointestinal motility due to rapid gel hydration without forming a non-gelated core. For example, sustained-release tablets were formulated containing nifedipine 33, Na alginate 500, xanthan gum 125, propylene glycol alginate 10, hydroxypropyl Me cellulose 45, Kollidon VA64 25, light anhydrous silicic acid 7, and Mg stearate 2 parts.

IC ICM A61K009-20
CC 63-6 (Pharmaceuticals)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L185 ANSWER 5 OF 23 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 2005041403 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 15588717
TITLE: Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
AUTHOR: ***Woo Je-Tae***; Nakagawa Hiroshi; Krecic Annette M; Nagai Kazuo; Hamilton Andrew D; Sebti Said M; Stern Paula H
CORPORATE SOURCE: Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Feinberg School of Medicine, 303 E. Chicago Avenue, Chicago, IL 60611, USA.
CONTRACT NUMBER: P60 AR30692 (NIAMS)
SOURCE: Biochemical pharmacology, (2005 Jan 1) Vol. 69, No. 1, pp. 87-95.
Journal code: 0101032. ISSN: 0006-2952.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200502
ENTRY DATE: Entered STN: 27 Jan 2005
Last Updated on STN: 16 Feb 2005

Entered Medline: 15 Feb 2005

ABSTRACT:
We have previously reported that the statin mevastatin (compactin) reversibly inhibits the fusion of TRAP-positive mononuclear preosteoclasts (pOCs) into multinucleated osteoclasts and disrupts the actin ring in mature osteoclasts through the inhibition of protein prenylation. Protein geranylgeranylation, specifically, is known to be required for pOC fusion and for the function and survival of mature osteoclasts. However, it has not been determined whether protein geranylgeranylation is involved in early differentiation of osteoclasts (pOC formation). The current study shows that statins and the geranylgeranyl transferase I inhibitor GGTI-2166 inhibit the pOC formation induced by RANKL or TNF-alpha in cultures of both mouse marrow-derived macrophage-colony-stimulating factor (M-CSF) dependent monocytes (MD cells) and the mouse monocyte cell line RAW 264.7 (RAW cells). Mevastatin, 0.1-0.6 microM, inhibited the formation of pOCs induced by receptor activator of nuclear factor-kappaB ligand (RANKL) or tumor necrosis factor (TNF-alpha) in both cell cultures. The inhibitory effects of mevastatin were overcome by the addition of mevalonate, farnesyl pyrophosphate or geranylgeranyl pyrophosphate. GGTI-2166 inhibited TRAP activity induced by RANKL or TNF-alpha in both cell cultures and prevented the incorporation of [3H]all-trans geranylgeraniol into prenylated proteins in RAW cells. However, the farnesyl transferase inhibitor FTI-2153 did not inhibit TRAP activity although FTI prevented the incorporation of [14C]mevalonate into farnesylated proteins in RAW cells. Clostridium difficile cytotoxin B (toxin B) inhibited pOC formation induced by RANKL or TNF-alpha in both cell cultures. The inhibitory effects of statins and GGTI-2166 on pOC formation may result from the inhibition of the geranylgeranylation of G-proteins, such as Rho or Rac, suggesting that the geranylgeranylation of these proteins is involved in the early differentiation of progenitor cells into pOCs.

CONTROLLED TERM:
*Alkyl and Aryl Transferases: AI, antagonists & inhibitors
Alkyl and Aryl Transferases: ME, metabolism
Animals
*Carrier Proteins: BI, biosynthesis
Cell Line
Enzyme Inhibitors: PD, pharmacology
*Leukocytes, Mononuclear: DE, drug effects
Leukocytes, Mononuclear: ME, metabolism
Lovastatin: AA, analogs & derivatives
Lovastatin: PD, pharmacology
*Membrane Glycoproteins: BI, biosynthesis
Mice
*Osteoclasts: DE, drug effects
Osteoclasts: ME, metabolism
RANK Ligand
Receptor Activator of Nuclear Factor-kappa B
*Tumor Necrosis Factor-alpha: BI, biosynthesis

CAS REGISTRY NO.: 73573-88-3 (compactin); ***75330-75-5 (Lovastatin)***

CHEMICAL NAME: 0 (Carrier Proteins); 0 (Enzyme Inhibitors); 0 (Membrane Glycoproteins); 0 (RANK Ligand); 0 (Receptor Activator of Nuclear Factor-kappa B); 0 (Tnfrsf11a protein, mouse); 0 (Tnfsf11 protein, mouse); 0 (Tumor Necrosis Factor-alpha); EC 2.5.- (Alkyl and Aryl Transferases); EC 2.5.1.- (geranylgeranyltransferase type-I)

L185 ANSWER 6 OF 23 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 2004255070 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 15153522
TITLE: Role of calcium in pancreatic islet cell death by IFN-gamma/TNF-alpha.
AUTHOR: Chang Inik; Cho Namjoo; Kim Sunshin; Kim Ja Young; Kim

Eunshil; ***Woo Ji-Eun***; Nam Joo Hyun; Kim Sung Joon;
Lee Myung-Shik
CORPORATE SOURCE: Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea.
SOURCE: Journal of immunology (Baltimore, Md. : 1950), (2004 Jun 1)
Vol. 172, No. 11, pp. 7008-14.
Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200408
ENTRY DATE: Entered STN: 22 May 2004
Last Updated on STN: 7 Aug 2004
Entered Medline: 6 Aug 2004

ABSTRACT:
We studied the intracellular events associated with pancreatic beta cell apoptosis by IFN-gamma/TNF-alpha synergism. IFN-gamma/TNF-alpha treatment of MIN6N8 insulinoma cells increased the amplitude of high voltage-activated Ca(2+) currents, while treatment with IFN-gamma or TNF-alpha alone did not. Cytosolic Ca(2+) concentration ([Ca(2+)](c)) was also increased by IFN-gamma/TNF-alpha treatment. Blockade of L-type Ca(2+) channel by ***nifedipine*** abrogated death of insulinoma cells by IFN-gamma/TNF-alpha. Diazoxide that attenuates voltage-activated Ca(2+) currents inhibited MIN6N8 cell death by IFN-gamma/TNF-alpha, while glibenclamide that accentuates voltage-activated Ca(2+) currents augmented insulinoma cell death. A protein kinase C inhibitor attenuated MIN6N8 cell death and the increase in [Ca(2+)](c) by IFN-gamma/TNF-alpha. Following the increase in [Ca(2+)](c), calpain was activated, and calpain inhibitors decreased insulinoma cell death by IFN-gamma/TNF-alpha. As a downstream of calpain, calcineurin was activated and the inhibition of calcineurin activation by FK506 diminished insulinoma cell death by IFN-gamma/TNF-alpha. BAD phosphorylation was decreased by IFN-gamma/TNF-alpha because of the increased calcineurin activity, which was reversed by FK506. IFN-gamma/TNF-alpha induced cytochrome c translocation from mitochondria to cytoplasm and activation of caspase-9. Effector caspases such as caspase-3 or -7 were also activated by IFN-gamma/TNF-alpha treatment. These results indicate that IFN-gamma/TNF-alpha synergism induces pancreatic beta cell apoptosis by Ca(2+) channel activation followed by downstream intracellular events such as mitochondrial events and caspase activation and also suggest the therapeutic potential of Ca(2+) modulation in type 1 diabetes.

CONTROLLED TERM: Animals
*Apoptosis
Calcineurin: PH, physiology
*Calcium: PH, physiology
Carrier Proteins: ME, metabolism
Caspases: ME, metabolism
Cytochromes c: ME, metabolism
*Interferon Type II: PD, pharmacology
*Islets of Langerhans: PA, pathology
Mice
Mice, Inbred NOD
Phosphorylation
Protein Transport
*Tumor Necrosis Factor-alpha: PD, pharmacology
bcl-Associated Death Protein
CAS REGISTRY NO.: 7440-70-2 (Calcium); 82115-62-6 (Interferon Type II);
9007-43-6 (Cytochromes c)
CHEMICAL NAME: 0 (Bad protein, mouse); 0 (Carrier Proteins); 0 (Tumor Necrosis Factor-alpha); 0 (bcl-Associated Death Protein);

EC 3.1.3.- (Calcineurin); EC 3.4.22.- (Caspases)

L185 ANSWER 7 OF 23 MEDLINE on STN DUPLICATE 6
ACCESSION NUMBER: 95032999 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 7946177
TITLE: Sustained-release ***isradipine*** compared with spirapril in the treatment of elderly patients with isolated systolic hypertension.
AUTHOR: Tomlinson B; ***Woo J***; Critchley J A; Or K K; Chan T Y; Sanderson J E
CORPORATE SOURCE: Department of Clinical Pharmacology, Chinese University of Hong Kong, Shatin, New Territories.
SOURCE: American journal of hypertension : journal of the American Society of Hypertension, (1994 Jul) Vol. 7, No. 7 Pt 2, pp. 35S-39S.
Journal code: 8803676. ISSN: 0895-7061.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199412
ENTRY DATE: Entered STN: 10 Jan 1995
Last Updated on STN: 3 Feb 1997
Entered Medline: 12 Dec 1994

ABSTRACT:
The benefits of treating isolated systolic hypertension (ISH) have been established, but the most appropriate choice of drug is still uncertain. For this reason, a sustained-release formulation of ***isradipine*** was compared with spirapril in a double-blind randomized study in elderly Chinese patients with ISH. The dosage was titrated if necessary after 4 weeks of treatment. The reduction in systolic/diastolic blood pressure after 8 weeks was similar for both treatments--20/10 mm Hg with ***isradipine*** versus 24/6 mm Hg with spirapril--measured in the supine position. There were no orthostatic symptoms and both treatments were well tolerated.

CONTROLLED TERM: Check Tags: Female; Male
Aged
Angiotensin-Converting Enzyme Inhibitors: TU, therapeutic use
Blood Pressure: DE, drug effects
Delayed-Action Preparations
Double-Blind Method
Enalapril: AE, adverse effects
*Enalapril: AA, analogs & derivatives
Enalapril: TU, therapeutic use
Heart Rate: DE, drug effects
Humans
*Hypertension: DT, drug therapy
Hypertension: PP, physiopathology
Isradipine: AE, adverse effects
****Isradipine: TU, therapeutic use***
Peak Expiratory Flow Rate: DE, drug effects
Systole
CAS REGISTRY NO.: ***75695-93-1 (Isradipine)***; 75847-73-3 (Enalapril); 83647-97-6 (spirapril)
CHEMICAL NAME: 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Delayed-Action Preparations)

L185 ANSWER 8 OF 23 MEDLINE on STN DUPLICATE 8
ACCESSION NUMBER: 93083264 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 1451544
TITLE: ***Isradipine*** treatment for hypertension in general practice in Hong Kong.
AUTHOR: Tomlinson B; ***Woo J***; Critchley J A; Teoh R
CORPORATE SOURCE: Department of Clinical Pharmacology, Prince of Wales Hospital, Shatin, Hong Kong.
SOURCE: Chinese medical journal, (1992 Jun) Vol. 105, No. 6, pp. 446-50.
Journal code: 7513795. ISSN: 0366-6999.
PUB. COUNTRY: China
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE) (RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199301
ENTRY DATE: Entered STN: 29 Jan 1993
Last Updated on STN: 29 Jan 1993
Entered Medline: 6 Jan 1993

ABSTRACT:
A 6-week open study of the introduction of ***isradipine*** treatment was conducted in general practice in Hong Kong. 303 Chinese patients with mild to moderate hypertension entered the study. Side effects were reported in 21% of patients and caused withdrawal from the study in 3 patients. The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with ***isradipine*** or with placebo. Supine blood pressure was reduced (P less than 0.01) from 170 +/- 20/102 +/- 6 mmHg to 153 +/- 19/92 +/- 8, 147 +/- 18/88 +/- 7 and 144 +/- 14/87 +/- 6 mmHg at 2, 4 and 6 weeks respectively in evaluable patients. Similar reductions occurred in standing blood pressure and there was no evidence of postural hypotension. Normalization and responder rates at 6 weeks were 86% and 69% respectively. Dosage was increased from 2.5 mg b.d. to 5 mg b.d. at 4 weeks in patients with diastolic blood pressure greater than 90 mmHg and their further response was greater than those remaining on 2.5 mg b.d.

CONTROLLED TERM: Antihypertensive Agents: AE, adverse effects
*Antihypertensive Agents: TU, therapeutic use
Dizziness: CI, chemically induced
Family Practice
Headache: CI, chemically induced
Hong Kong
Humans
*Hypertension: DT, drug therapy
Isradipine: AE, adverse effects
****Isradipine: TU, therapeutic use***
CAS REGISTRY NO.: ***75695-93-1 (Isradipine)***
CHEMICAL NAME: 0 (Antihypertensive Agents)

L185 ANSWER 9 OF 23 MEDLINE on STN DUPLICATE 9
ACCESSION NUMBER: 92215632 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 1666837
TITLE: A high incidence of cough associated with combination therapy of hypertension with ***isradipine*** and lisinopril in Chinese subjects.
AUTHOR: ***Woo J***; Chan T Y
CORPORATE SOURCE: Department of Medicine, Chinese University of Hong Kong.
SOURCE: The British journal of clinical practice, (1991 Autumn) Vol. 45, No. 3, pp. 178-80.
Journal code: 0372546. ISSN: 0007-0947.

PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199205
ENTRY DATE: Entered STN: 29 May 1992
Last Updated on STN: 29 May 1992
Entered Medline: 13 May 1992

ABSTRACT:
The efficacy and tolerability of combination therapy using Lisinopril (5-20 mg om) and ***Isradipine*** (1.25 mg-2.50 mg bd) was assessed in 29/50 Chinese subjects, whose blood pressures were not controlled on ***Isradipine*** alone. The addition of Lisinopril produced approximately two-fold reductions in blood pressure compared to ***Isradipine*** alone, increasing the responder rate of the original cohort of 50 subjects by 18% and normalization rate, by 32%. No significant changes in haematological or biochemical parameters, CXR or ECG, were observed. However, use of Lisinopril in our subjects was associated with a high incidence of cough (48%), possibly limiting its use in this population.

CONTROLLED TERM: Check Tags: Female; Male
Adult
Aged
Antihypertensive Agents: AE, adverse effects
Antihypertensive Agents: TU, therapeutic use
Cough: CI, chemically induced
*Dihydropyridines: TU, therapeutic use
Drug Therapy, Combination
Enalapril: AE, adverse effects
*Enalapril: AA, analogs & derivatives
Enalapril: TU, therapeutic use
Humans
*Hypertension: DT, drug therapy
Isradipine
Lisinopril
Middle Aged

CAS REGISTRY NO.: ***75695-93-1 (Isradipine)***; 75847-73-3 (Enalapril); 83915-83-7 (Lisinopril)
CHEMICAL NAME: 0 (Antihypertensive Agents); 0 (Dihydropyridines)

L185 ANSWER 10 OF 23 MEDLINE on STN
ACCESSION NUMBER: 2000241769 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 10780857
TITLE: Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
AUTHOR: ***Woo J T***; Kasai S; Stern P H; Nagai K
CORPORATE SOURCE: Department of Bioengineering, Tokyo Institute of Technology, Yokohama, Japan.
SOURCE: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, (2000 Apr) Vol. 15, No. 4, pp. 650-62.
Journal code: 8610640. ISSN: 0884-0431.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200007
ENTRY DATE: Entered STN: 10 Aug 2000

Last Updated on STN: 10 Aug 2000
Entered Medline: 25 Jul 2000

ABSTRACT:
Compactin (mevastatin), which inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and thus biosynthesis of cholesterol and the prenylation of proteins, inhibits osteoclastic bone resorption. Although it has been suggested that compactin inhibits bone resorption by inducing apoptosis of osteoclasts, the pathway by which compactin inhibits resorption has not been established. We investigated the effect of compactin on the differentiation of osteoclasts and the relationship between the morphological changes elicited by compactin and its inhibitory effect on bone resorption. Compactin inhibited the differentiation of osteoclasts, interfering with the fusion process by which prefusion osteoclasts (pOCs) develop into multinucleated osteoclast-like cells (OCLs), and also disrupted the actin ring of OCLs. The potency of compactin to inhibit fusion of pOCs and to disrupt the actin ring of OCLs corresponded to that of compactin to inhibit bone resorption. The effects of compactin were prevented by the addition of MVA lactone or its downstream products farnesylpyrophosphate (FPP) and geranylgeranyl-pyrophosphate (GGPP) but not by squalene. Apoptosis of OCLs was not induced by the concentration of compactin that inhibited fusion of pOCs and disrupted the actin ring. The normal process of pOC fusion and the integrity of the actin ring were restored by the withdrawal of compactin from the cultures after they had been treated with compactin for 24 h, but they were not restored by the addition of zVAD-fmk, a caspase inhibitor. Compactin also reversibly inhibited interleukin-1beta (IL-1beta)-, 1alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3)-, and parathyroid hormone (PTH)-stimulated 45Ca release in bone organ cultures. Our results indicate that the inhibitory effects of compactin on bone resorption result from the inhibition of fusion of pOCs into OCLs and disruption of actin ring in OCLs and that apoptosis of OCLs is not necessary for these inhibitory effects of compactin. These effects of compactin are likely to be a consequence of the inhibition of prenylation of proteins that play an important role in the fusion of pOCs and in maintaining actin ring integrity in OCLs.

CONTROLLED TERM: Check Tags: Male
*Actins: DE, drug effects
Actins: ME, metabolism
Animals
Apoptosis
*Bone Resorption: PP, physiopathology
Calcitriol: PD, pharmacology
Calcium: ME, metabolism
Coculture Techniques
Hydroxymethylglutaryl-CoA Reductase Inhibitors: ME, metabolism
*Hydroxymethylglutaryl-CoA Reductase Inhibitors: PD, pharmacology
Interleukin-1: PD, pharmacology
Lovastatin: AA, analogs & derivatives
Lovastatin: ME, metabolism
Lovastatin: PD, pharmacology
*Membrane Fusion: DE, drug effects
Mevalonic Acid: ME, metabolism
Mice
*Osteoclasts: DE, drug effects
Osteoclasts: ME, metabolism
Parathyroid Hormone: PD, pharmacology
Polyisoprenyl Phosphates: ME, metabolism

CAS REGISTRY NO.: 13058-04-3 (farnesyl pyrophosphate); 150-97-0 (Mevalonic Acid); 32222-06-3 (Calcitriol); 6699-20-3 (geranylgeranyl pyrophosphate); 73573-88-3 (compactin); 7440-70-2

(Calcium); ***75330-75-5 (Lovastatin)***

CHEMICAL NAME: 0 (Actins); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Interleukin-1); 0 (Parathyroid Hormone); 0 (Polyisoprenyl Phosphates)

L185 ANSWER 11 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 1

ACCESSION NUMBER: 2006613981 EMBASE Full-text

TITLE: Low-intensity ultrasound stimulates the viability and matrix gene expression of human articular chondrocytes in ***alginate*** bead culture.

AUTHOR: Choi B.H.; ***Woo J.-I.***; Min B.-H.; Park S.R.

CORPORATE SOURCE: S.R. Park, Department of Physiology, Inha University College of Medicine, Incheon, Korea, Republic of. srpark@inha.ac.kr

SOURCE: Journal of Biomedical Materials Research - Part A, (15 Dec 2006) Vol. 79, No. 4, pp. 858-864. .
Refs: 25
ISSN: 0021-9304 E-ISSN: 1552-4965 CODEN: JBMRCH

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 027 Biophysics, Bioengineering and Medical Instrumentation
029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 3 Jan 2007
Last Updated on STN: 3 Jan 2007

ABSTRACT: We investigated the effects of low-intensity ultrasound (LIUS) on the activity of human articular chondrocytes isolated from osteoarthritis patients and cultured in the three-dimensional ***alginate*** beads. LIUS was treated at 0, 100, 200, and 300 mW/cm(2) for 10 min everyday for 2, 7, or 15 days. LIUS induced the viability of cells only at day 15 but not until day 7 after treatment, when examined by trypan blue exclusion and LIVE/DEAD® assay kit. When examined at day 7, the proliferation of cells was not changed by LIUS in the (3)H-thymine incorporation. The expression of matrix producing proteins (type II collagen and proteoglycan) was clearly induced by 200-300 mW/cm(2) LIUS in the incorporation of radioactivity and Northern blot analysis. Although the expression of MMP-1, a matrix degrading protein, was decreased, that of TIMP-1, an inhibitor of MMPs, was not affected by LIUS. Histological analysis revealed an increase in the number and size of glycosaminoglycan-positive lacunae and cellular organelles, appearing as rough endoplasmic reticulum and mitochondria by LIUS. These results showed that the viability and metabolism of human articular chondrocytes in ***alginate*** culture was induced by LIUS treatment, suggesting that they could be a promising autologous source for cartilage tissue engineering. .COPYRGT. 2006 Wiley Periodicals, Inc.

CONTROLLED TERM: Medical Descriptors:
*ultrasound
*gene expression
*cartilage cell
*cell culture
*cell viability
cell stimulation
cell activity
cell proliferation
protein expression
Northern blotting
cell organelle

rough endoplasmic reticulum
cell size
cell metabolism
cell assay
collagen synthesis
human
controlled study
human tissue
human cell
aged
adult
article

CONTROLLED TERM: Drug Descriptors:
*alginic acid
trypan blue
thymine
collagen type 2: EC, endogenous compound
proteoglycan: EC, endogenous compound
interstitial collagenase: EC, endogenous compound
tissue inhibitor of metalloproteinase 1: EC, endogenous compound
glycosaminoglycan: EC, endogenous compound
matrix protein: EC, endogenous compound

CAS REGISTRY NO.: (alginic acid) 28961-37-7, 29894-36-8, 9005-32-7, ***9005-38-3***; (trypan blue) 72-57-1; (thymine) 65-71-4; (tissue inhibitor of metalloproteinase 1) 140208-24-8

NAME OF PRODUCT: (1) Noblelife; (2) LIVE/DEAD

COMPANY NAME: (1) Duplogen (Korea, Republic of) ; (2) Molecular Probes (United States)

L185 ANSWER 12 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 4

ACCESSION NUMBER: 1998276743 EMBASE Full-text

TITLE: Glucosamine-induced insulin resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP.

AUTHOR: Hresko R.C.; Heimberg H.; ***Chi M.M.-Y.***; Mueckler M.

CORPORATE SOURCE: M. Mueckler, Dept. of Cell Biology and Physiology, Washington Univ. School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110, United States. mike@cellbio.wustl.edu

SOURCE: Journal of Biological Chemistry, (7 Aug 1998) Vol. 273, No. 32, pp. 20658-20668. .
Refs: 42
ISSN: 0021-9258 CODEN: JBCHA3

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 003 Endocrinology
029 Clinical Biochemistry

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 17 Sep 1998
Last Updated on STN: 17 Sep 1998

ABSTRACT: Glucosamine, which enters the hexosamine pathway downstream of the rate- limiting step, has been routinely used to mimic the insulin resistance caused by high glucose and insulin. We investigated the effect of glucosamine on insulin-stimulated glucose transport in 3T3-L1 adipocytes. The Δ-insulin (insulin-stimulated ***minus*** basal) value for 2-deoxyglucose uptake was dramatically inhibited with increasing concentrations of glucosamine with an ED50 of 1.95 mM. Subcellular fractionation experiments

demonstrated that reduction in insulin-stimulated 2-deoxyglucose uptake by glucosamine was due to an inhibition of translocation of both Glut 1 and Glut 4 from the low density microsomes (LDM) to the plasma membrane. Analysis of the insulin signaling cascade revealed that glucosamine impaired insulin receptor autophosphorylation, insulin receptor substrate (IRS-1) phosphorylation, IRS-1-associated PI 3-kinase activity in the LDM, and AKT-1 activation by insulin. Measurement of intracellular ATP demonstrated that the effects of glucosamine were highly correlated with its ability to reduce ATP levels. Reduction of intracellular ATP using azide inhibited Glut 1 and Glut 4 translocation from the LDM to the plasma membrane, insulin receptor autophosphorylation, and IRS-1 tyrosine phosphorylation. Additionally, both the reduction in intracellular ATP and the effects on insulin action caused by glucosamine could be prevented by the addition of inosine, which served as an alternative energy source in the medium. We conclude that direct administration of glucosamine can rapidly lower cellular ATP levels and affect insulin action in fat cells by mechanisms independent of increased intracellular UDP-N-acetylhexosamines and that increased metabolism of glucose via the hexosamine pathway may not represent the mechanism of glucose toxicity in fat cells.

CONTROLLED TERM: Medical Descriptors:
*insulin resistance
glucose metabolism
protein phosphorylation
signal transduction
enzyme activity
enzyme activation
enzyme substrate complex
adipocyte
nonhuman
mouse
controlled study
animal cell
article
priority journal
Drug Descriptors:
*adenosine triphosphate: EC, endogenous compound
*insulin: EC, endogenous compound

CAS REGISTRY NO.: (adenosine triphosphate) 15237-44-2, 56-65-5, 987-65-5; (insulin) 9004-10-8

L185 ANSWER 13 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 5

ACCESSION NUMBER: 97329019 EMBASE Full-text
DOCUMENT NUMBER: 1997329019
TITLE: An estimate of chronic disease burden and some economic consequences among the elderly Hong Kong population.
AUTHOR: *Woo J.*; Ho S.C.; Chan S.G.; Yu A.L.M.; Yuen Y.K.; Lau J.
CORPORATE SOURCE: Prof. J. Woo, Department of Medicine, Prince of Wales Hospital, Shatin NT, Hong Kong
SOURCE: Journal of Epidemiology and Community Health, (1997) Vol. 51, No. 5, pp. 486-489. .
Refs: 16
ISSN: 0143-005X CODEN: JECHDR
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
020 Gerontology and Geriatrics
036 Health Policy, Economics and Management
LANGUAGE: English

SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 13 Nov 1997
Last Updated on STN: 13 Nov 1997

ABSTRACT: Objectives - To estimate the burden of chronic disease for an elderly Chinese population aged 70 years and over, and to illustrate the use of this information in estimating the economic consequences of disease burden using stroke as an example. Participants - A total of 1902 subjects recruited by random sampling of the old age and disability allowance schemes, which cover over 90% of the Hong Kong elderly population, stratified by sex and five year age groups from age 70 years onwards. Method - Information was collected on 10 medical conditions at baseline: arthritis, hypertension, cardiac disease, stroke, chronic obstructive airways disease, peptic ulcer, diabetes mellitus, osteoporotic fracture, malignancy, and dementia. A follow up survey was carried out after 18 months to determine the occurrence of new disease and the number with disease who had died. Disease burden is calculated as the number with disease at baseline plus the number developing new disease ***minus*** the number who had died. Results - Disease burden figures were highest for arthritis, hypertension, cardiac disease, and peptic ulcer, and were higher in the 70-79 age group than the 80+ age group for some diseases. For stroke, the economic cost based on a population projection for 2001 was estimated to be around HK$1,900,000,000, or US$250 million. Conclusion - Information on the burden of chronic disease is important. It enables the economic consequences to be estimated so that strategies can be developed to prevent diseases with high costs and known effective preventive methods.

CONTROLLED TERM: Medical Descriptors:
*chronic disease
*economic evaluation
*population research
aged
arthritis: EP, epidemiology
article
cost
dementia: EP, epidemiology
diabetes mellitus: EP, epidemiology
disease association
disease control
female
heart disease: EP, epidemiology
hong kong
human
hypertension: EP, epidemiology
major clinical study
male
malignant neoplastic disease: EP, epidemiology
obstructive airway disease: EP, epidemiology
osteoporosis: EP, epidemiology
peptic ulcer: EP, epidemiology
stroke: EP, epidemiology

 DUPLICATE 7
ACCESSION NUMBER: 92110257 EMBASE Full-text
DOCUMENT NUMBER: 1992110257
TITLE: Tolerability and efficacy of ***isradipine*** in Chinese hypertensives in general practice.
AUTHOR: Tomlinson B.; Critchley J.A.J.H.; ***Woo J.***; Teoh R.
CORPORATE SOURCE: Dept. of Clinical Pharmacology, Prince of Wales Hospital,Shatin, N.T., Hong Kong, Hong Kong
SOURCE: Current Therapeutic Research - Clinical and Experimental,

(1992) Vol. 51, No. 3, pp. 448-455.
ISSN: 0011-393X CODEN: CTCEA
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 006 Internal Medicine
018 Cardiovascular Diseases and Cardiovascular Surgery
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 8 May 1992
Last Updated on STN: 8 May 1992

ABSTRACT: A multicenter open study of ***isradipine*** in 449 Asian patients, mainly of Chinese extraction, with mild to moderate hypertension was conducted in general practice in Hong Kong and Singapore. The initial dosage was 2.5 mg BID and this was doubled or halved after four weeks, if necessary. Side effects were reported in 18.7% of patients and caused withdrawal from the study in 2.4%. Another 15% of patients were lost to follow-up. The incidence and pattern of side effects were similar to those reported in other studies with ***isradipine*** or with placebo. The overall reductions in blood pressure over six weeks in evaluable patients were 23/14 mmHg supine and 21/14 mmHg standing with normalization and responder rates of 82% and 74%, respectively. Patients responding less well showed further improvement with dosage increase from 2.5 mg BID to 5 mg BID, whereas those showing the greatest response maintained most of the effect when dosage was reduced to 1.25 mg BID.

CONTROLLED TERM: Medical Descriptors:
*drug efficacy
*drug tolerance
*hypertension: DT, drug therapy
article
chinese
dyspepsia: SI, side effect
flushing
headache
priority journal
vertigo: SI, side effect

L185 ANSWER 15 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DUPLICATE 10
ACCESSION NUMBER: 91044770 EMBASE Full-text
DOCUMENT NUMBER: 1991044770
TITLE: A clinical evaluation of the efficacy and tolerability of ***isradipine*** in the treatment of hypertension in a Chinese population.
AUTHOR: ***Woo J.***; Chan T.Y.K.; Critchley J.A.J.H.
CORPORATE SOURCE: Department of Medicine, The Prince of Wales Hospital, Shatin, N.T., Hong Kong
SOURCE: Advances in Therapy, (1990) Vol. 7, No. 6, pp. 362-368.
ISSN: 0741-238X CODEN: ADTHE7
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 006 Internal Medicine
017 Public Health, Social Medicine and Epidemiology
018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 16 Dec 1991
Last Updated on STN: 16 Dec 1991

ABSTRACT: The efficacy and tolerability of ***isradipine*** (1.25 and 2.5 mg BID) were assessed in a placebo-controlled open trial in 50 Chinese subjects of varying ages (mean ± SD age 64 ± 11 years, range 40 - 79 years). Significant reductions in blood pressure were achieved with both dosages of ***isradipine*** , and the overall responder and normalization rates were 68% and 40%, respectively. No age-related changes in efficacy were demonstrated. There were no changes in hematological or biochemical parameters, chest x-ray, or electrocardiographic findings. The incidence of side effects was not different from that on placebo. These findings are similar to those reported in Caucasian subjects.

CONTROLLED TERM: Medical Descriptors:
*blood pressure
*hypertension: DT, drug therapy
adult
aged
article
china
controlled study
female
flushing
headache: SI, side effect
heart palpitation: SI, side effect
human
major clinical study
male
side effect
Drug Descriptors:
isradipine: AE, adverse drug reaction
isradipine: DT, drug therapy
isradipine: DO, drug dose
isradipine: CT, clinical trial
placebo

CAS REGISTRY NO.: (***isradipine***) ***75695-93-1***, ***88977-22-4***

COMPANY NAME: Sandoz (United Kingdom)

L185 ANSWER 16 OF 23 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2007018332 EMBASE Full-text

TITLE: Optimization of tamsulosin hydrochloride controlled release pellets coated with Surelease and neutralized HPMCP.

AUTHOR: Kim M.-S.; Kim J.-S.; Lee S.; Jun S.W.; Park J.-S.; ***Woo J.-S.***; Hwang S.-J.

CORPORATE SOURCE: S.-J. Hwang, National Research Laboratory of Pharmaceutical Technology, College of Pharmacy, Chungnam National University, 220 Gung-dong, Yuseong-gu, Daejeon 305-764, Korea, Republic of. sjhwang@cnu.ac.kr

SOURCE: Journal of Pharmacy and Pharmacology, (2006) Vol. 58, No. 12, pp. 1611-1616. .
Refs: 19
ISSN: 0022-3573 CODEN: JPPMAB

COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 14 Feb 2007
Last Updated on STN: 14 Feb 2007

ABSTRACT: This study was to optimize the coating level in the development of controlled release pellets coated with Surelease and neutralized ***hydroxypropyl*** ***methylcellulose*** phthalate (HPMCP) by a computer optimization technique based on a response surface methodology utilizing polynomial equation. A full factorial 3(2) design was used for the optimization procedure with coating level (X(1)) and HPMCP content (X(2)) as the independent variables. The drug release percent at 2, 3 and 5 h were the target responses, which were restricted to 12-39% (Y(1)), 44-70% (Y(2)) and 70-100% (Y (3)), respectively. The quadratic model was well fitted to the data, and the resulting equation was used to predict the responses in the optimal region. It was shown that the optimized coating formulation was achieved at the ratio of 3:1 (Surelease: neutralized HPMCP) with 20% coating level. The optimized formulation showed release profiles and responses, which were close to predicted responses. Therefore, a full factorial 3(2) design and optimization technique can be successfully used in the development of optimized coating formulations based on Surelease and neutralized HPMCP to achieve a controlled release drug delivery system containing tamsulosin hydrochloride. .COPYRGT. 2006 The Authors.

CONTROLLED TERM: Medical Descriptors:
article
computer system
controlled release formulation
drug coating
drug delivery system
drug formulation
drug release
drug solubility

CONTROLLED TERM: Drug Descriptors:
*ethyl cellulose: PR, pharmaceutics
hydroxypropylmethylcellulose phthalate: PR, pharmaceutics
*tamsulosin: PR, pharmaceutics

CAS REGISTRY NO.: (ethyl cellulose) 9004-57-3; (***hydroxypropylmethylcellulose*** phthalate) ***9050-31-1***; (tamsulosin) 106133-20-4, 106138-88-9, 106463-17-6, 80223-99-0, 94666-07-6

CHEMICAL NAME: (1) Surelease

COMPANY NAME: (1) Colorcon (United States); Shinetsu (Japan); Youn sung fine chemicals (Kenya)

L185 ANSWER 17 OF 23 EMBASE

ACCESSION NUMBER: 2005559180 EMBASE Full-text

TITLE: Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids.

AUTHOR: Jun S.W.; Kim M.-S.; Jo G.H.; Lee S.; ***Woo J.S.***; Park J.-S.; Hwang S.-J.

CORPORATE SOURCE: S.-J. Hwang, National Research Laboratory Pharmaceutical Technology, College of Pharmacy, Chungnam National University, 220 Gung-dong, Yuseong-gu, Daejeon 305-764, Korea, Republic of. sjhwang@cnu.ac.kr

SOURCE: Journal of Pharmacy and Pharmacology, (2005) Vol. 57, No. 12, pp. 1529-1537. .
Refs: 38
ISSN: 0022-3573 CODEN: JPPMAB

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 12 Jan 2006
Last Updated on STN: 12 Jan 2006

ABSTRACT: Cefuroxime axetil (CA) solid dispersions with HPMC 2910/PVP K-30 were prepared using solution enhanced dispersion by supercritical fluids (SEDS) in an effort to increase the dissolution rate of poorly water-soluble drugs. Their physicochemical properties in solid state were characterized by differential scanning calorimeter (DSC), powder X-ray diffraction (PXRD), Fourier transform infrared spectrometry (FT-IR) and scanning electron microscopy. No endothermic and characteristic diffraction peaks corresponding to CA were observed for the solid dispersions in DSC and PXRD. FTIR analysis demonstrated the presence of intermolecular hydrogen bonds between CA and HPMC 2910/PVP K-30 in solid dispersions, resulting in the formation of amorphous or non-crystalline CA. Dissolution studies indicated that the dissolution rates were remarkably increased in solid dispersions compared with those in the physical mixture and drug alone. In conclusion, an amorphous or non-crystalline CA solid dispersion prepared using SEDS could be very useful for the formulation of solid dosage forms. .COPYRGT. 2005 The Authors.

CONTROLLED TERM: Medical Descriptors:
*dispersion
*supercritical fluid
drug solubility
differential scanning calorimetry
X ray diffraction
infrared spectroscopy
scanning electron microscopy
diffraction
hydrogen bond
solid
drug formulation
article
Drug Descriptors:
*cefuroxime axetil: PR, pharmaceutics
hydroxypropylmethylcellulose: PR, pharmaceutics
povidone derivative: PR, pharmaceutics
hpmc 2910
CAS REGISTRY NO.: (cefuroxime axetil) 64544-07-6; (***hydroxypropylmethylcellulose***) ***9004-65-3***
CHEMICAL NAME: (1) Hpmc 2910; (2) Pvp k 30
COMPANY NAME: (2) BASF (Germany); Hanni (Korea, Republic of)

L185 ANSWER 18 OF 23 EMBASE
ACCESSION NUMBER: 2003098727 EMBASE Full-text
TITLE: Contribution of Na(+)-Ca(2+) exchanger to pinacidil-induced relaxation in the rat mesenteric artery.
AUTHOR: Suk Y.T.; Yao X.; ***Chi M.W.***; Chak L.A.; Zhen Y.C.; Huang Y.
CORPORATE SOURCE: Y. Huang, Department of Physiology, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong Kong. yu-huang@cuhk.edu.hk
SOURCE: British Journal of Pharmacology, (2003) Vol. 138, No. 3, pp. 453-460. .
Refs: 28
ISSN: 0007-1188 CODEN: BJPCBM
COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 25 Mar 2003
Last Updated on STN: 25 Mar 2003

ABSTRACT: 1. Pinacidil relaxes blood vessels through opening the K(ATP) channels with a resultant membrane hyperpolarization and inhibition of Ca(2+) influx. The aim of this study was to examine the mechanisms thereby pinacidil induces K(+) channel-independent relaxation in isolated endothelium-denuded rat mesenteric artery. 2. Pinacidil-induced relaxation was inhibited by glibenclamide (1-10 μm) in phenylephrine-preconstricted rings, but was unaffected by glibenclamide after inhibition of K(+) channels and VGCCs. Pinacidil-induced K(+) channel-independent relaxation remained unchanged after treatment with cyclopiazonic acid (10 μm), thapsigargin (1 μm), ouabain (100 μM), propranolol (10 μm), Rp-cAMPS triethylamine (30 μM), L-NNA (100 μM), or ODQ (10 μm). 3. Pinacidil induced more relaxant effect in the presence of ***nifedipine*** than in the presence of 60 mM K(+) plus ***nifedipine.*** Pretreatment with Na(+)-Ca(2+) exchanger inhibitors, nickel (30-300 μm) or benzamil (20 μm) attenuated pinacidil-induced relaxation in normal or in ***nifedipine***-containing solution. Pinacidil (1 μM) produced less relaxant effect with decreasing extracellular Na(+) concentration. Na(+)-free condition abolished the inhibitory effect of benzamil. Both nickel and benzamil inhibited pinacidil-induced relaxation in the presence of glibenclamide (10 μm). Nickel (300 μm) did not affect the relaxant response to sodium nitroprusside. 4. Pinacidil relaxed the rings preconstricted by active phorbol and U46619 with similar potency. 5. The present results indicate that stimulation of the forward mode Na(+)-Ca(2+) exchange pathway is in part responsible for pinacidil-induced K(+) channel-independent vasorelaxation. Pinacidil also induces K(+) channel-dependent but VGCCs-independent relaxation. The PKC-mediated cellular pathway may be a target site for pinacidil only in higher concentrations.

CONTROLLED TERM: Medical Descriptors:
*artery dilatation
mesenteric artery
potassium channel
isolated artery
drug mechanism
concentration response
calcium channel
extracellular space
drug effect
drug potency
nonhuman
male
rat
controlled study
animal tissue
article
priority journal
Drug Descriptors:
*sodium calcium exchange protein: EC, endogenous compound
*pinacidil: PD, pharmacology
glibenclamide: PD, pharmacology
phenylephrine: PD, pharmacology
cyclopiazonic acid: PD, pharmacology
thapsigargin: PD, pharmacology

ouabain: PD, pharmacology
propranolol: PD, pharmacology
n(g) nitroarginine: PD, pharmacology
1h 1,2,4 oxadiazolo[4,3 a]quinoxalin 1 one: PD, pharmacology
nifedipine: CB, drug combination
nifedipine: PD, pharmacology
potassium ion: CB, drug combination
potassium ion: PD, pharmacology
protein inhibitor: PD, pharmacology
sodium calcium exchange protein inhibitor: PD, pharmacology
nickel: PD, pharmacology
benzamil: PD, pharmacology
sodium
nitroprusside sodium: PD, pharmacology
phorbol: PD, pharmacology
15 hydroxy 11alpha,9alpha epoxymethanoprosta 5,13 dienoic acid: PD, pharmacology
cyclic AMP derivative: PD, pharmacology
unclassified drug

CAS REGISTRY NO.: (pinacidil) 60560-33-0; (glibenclamide) 10238-21-8; (phenylephrine) 532-38-7, 59-42-7, 61-76-7; (cyclopiazonic acid) 18172-33-3, 83136-88-3; (thapsigargin) 67526-95-8; (ouabain) 11018-89-6, 630-60-4; (propranolol) 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (n(g) nitroarginine) 2149-70-4; (1h 1,2,4 oxadiazolo[4,3 a]quinoxalin 1 one) 41443-28-1; (***nifedipine***) ***21829-25-4***; (potassium ion) 24203-36-9; (nickel) 7440-02-0; (benzamil) 2898-76-2; (sodium) 7440-23-5; (nitroprusside sodium) 14402-89-2, 15078-28-1; (15 hydroxy 11alpha,9alpha epoxymethanoprosta 5,13 dienoic acid) 56985-40-1

CHEMICAL NAME: (1) U 46619

COMPANY NAME: (1) Sigma (United States); Merck (Germany)

L185 ANSWER 19 OF 23 EMBASE

ACCESSION NUMBER: 1998200312 EMBASE Full-text

TITLE: Effect of nimodipine on memory after cerebral infarction.

AUTHOR: Sze K.H.; Sim T.C.; Wong E.; Cheng S.; ***Woo J.***

CORPORATE SOURCE: Dr. K.H. Sze, Medical and Geriatric Unit, Shatin Hospital, 33A Kung Kok Street, Ma On Shah, N.T., Hong Kong

SOURCE: Acta Neurologica Scandinavica, (1998) Vol. 97, No. 6, pp. 386-392. .
Refs: 25
ISSN: 0001-6314 CODEN: ANRSAS

COUNTRY: Denmark

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 008 Neurology and Neurosurgery
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 14 Aug 1998
Last Updated on STN: 14 Aug 1998

ABSTRACT: Objectives - Epidemiological studies indicate widespread memory impairment in patients with stroke in the early post-ictal stage. Nimodipine may have psychopharmacological properties and may improve memory. We conducted a single-blind randomized controlled trial to determine whether nimodipine given 7-14 days after cerebral infarction improved memory. Material and methods - One hundred patients with acute cerebral infarction were

consecutively enrolled between D7 to D14. After stratification, patients were randomized to receive oral nimodipine 90 mg daily for 12 weeks, or no drug. Independent assessors administered Mini-Mental State Examination (MMSE) and Fuld Object-Memory Evaluation (FOME) at baseline, 6 weeks, and 12 weeks. Results - Patients receiving nimodipine showed greater improvement in FOME mean scores at 12 weeks (P=0.0334), and also in FOME score change across time (P=0.0283). Patients with severe disability who received nimodipine also showed greater MMSE score change across time (P=0.0495). Conclusion - Nimodipine given 7-14 days after cerebral infarction for 3 months results in memory improvement.

CONTROLLED TERM: Medical Descriptors:
*memory
*brain infarction: DT, drug therapy
*stroke: DT, drug therapy
*stroke: PC, prevention
drug effect
psychopharmacology
neuropsychological test
disability
secondary prevention
human
male
female
major clinical study
clinical trial
randomized controlled trial
single blind procedure
controlled study
aged
adult
oral drug administration
article
Drug Descriptors:
*nimodipine: CT, clinical trial
*nimodipine: DT, drug therapy
nifedipine: DT, drug therapy
acetylsalicylic acid: DT, drug therapy
warfarin: DT, drug therapy

CAS REGISTRY NO.: (nimodipine) 66085-59-4; (***nifedipine***) ***21829-25-4***; (acetylsalicylic acid) 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; (warfarin) 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2

L185 ANSWER 20 OF 23 EMBASE

ACCESSION NUMBER: 94229976 EMBASE Full-text
DOCUMENT NUMBER: 1994229976
TITLE: A model of nitrogen removal in waste-waters using ***alginate***-entrapped cyanobacteria Anabaena CH3.
AUTHOR: Lu C.; ***Chi Mei Lee***; Wei Ming Lu; Chen P.-C.
CORPORATE SOURCE: Dept. of Environmental Engineering, National Chung-Hsing University,Taichung 40227, Taiwan,Province of China
SOURCE: Environment International, (1994) Vol. 20, No. 4, pp. 529-540. .
ISSN: 0160-4120 CODEN: ENVIDV
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 046 Environmental Health and Pollution Control
LANGUAGE: English

SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 17 Aug 1994
Last Updated on STN: 17 Aug 1994

ABSTRACT: A mathematical model accounting for the mass transfer process and the growth kinetics of ***alginate***-entrapped cyanobacteria Anabaena CH3 in a batch reactor is presented to predict the removal of nitrogenous compounds in wastewaters. The governing equations were cast in dimensionless form and solved by the method of explicit finite difference. The mass transfer behaviour around a spherical bead and diffusion process within the cell-containing gel were drawn from the literature. The biological kinetic parameters of Anabaena CH3 in the nitrogenous medium were determined by a series of batch experiments. Good agreement between model predictions and experimental data was obtained by comparing dimensionless concentration profiles of ammonia and nitrate in the bulk liquid phase. The effects of dimensionless groups on the model performance were carried out in the sensitivity analysis. The Thiele modulus ($\phi 2$) and the total volume of the cell-containing gel beads available for liquid-phase mass transfer (α) were identified to strongly influence the ammonia removal rate in wastewaters.

CONTROLLED TERM: Medical Descriptors:
*waste water
anabaena
article
mathematical model
nitrogen fixation
priority journal
Drug Descriptors:
*ammonia
CAS REGISTRY NO.: (ammonia) 14798-03-9, 51847-23-5, 7664-41-7

L185 ANSWER 21 OF 23 EMBASE
ACCESSION NUMBER: 93117313 EMBASE Full-text
DOCUMENT NUMBER: 1993117313
TITLE: Phototherapeutic keratectomy in nine eyes with superficial corneal diseases.
AUTHOR: Tae Won Hahn; ***Woo Jin Sah***; Jae Ho Kim
CORPORATE SOURCE: Department of Ophthalmology, Kangnam St Mary's Hospital, Catholic University Medical College, 505, Banpo-dong,Seocho-ku, Seoul 137-040, Korea, Republic of
SOURCE: Refractive and Corneal Surgery, (1993) Vol. 9, No. 2 SUPPL., pp. S115-S118. .
ISSN: 0883-0444 CODEN: RCSUEH
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 012 Ophthalmology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 30 May 1993
Last Updated on STN: 30 May 1993
CONTROLLED TERM: Medical Descriptors:
*cornea dystrophy: SU, surgery
*cornea dystrophy: DI, diagnosis
*keratectomy
*keratopathy: SU, surgery
*keratopathy: DI, diagnosis
*scar: SU, surgery
*scar: DI, diagnosis
adult

article
astigmatism: CO, complication
clinical article
collagen synthesis
cornea disease: DI, diagnosis
cornea disease: SU, surgery
cornea epithelium
cornea opacity: DI, diagnosis
cornea opacity: ET, etiology
cornea opacity: CO, complication
cornea transplantation
excimer laser
eye photography
female
human
hypermetropia: DI, diagnosis
hypermetropia: CO, complication
laser surgery
male
pterygium: SU, surgery
slit lamp
surgical technique
topical drug administration
topography
visual acuity
Drug Descriptors:
methylcellulose
collagen: EC, endogenous compound
prednisolone acetate: AD, drug administration
prednisolone acetate: DO, drug dose

CAS REGISTRY NO.: (***methylcellulose***) 79484-92-7, 9004-67-5; (collagen) 9007-34-5; (prednisolone acetate) 52-21-1, 52628-64-5

L185 ANSWER 22 OF 23 EMBASE

ACCESSION NUMBER: 85125564 EMBASE Full-text
DOCUMENT NUMBER: 1985125564
TITLE: Intrauterine death from ergotamine overdosage.
AUTHOR: Au K.L.; ***Woo J.S.K.***; Wong V.C.W.
CORPORATE SOURCE: Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong, Hong Kong
SOURCE: European Journal of Obstetrics Gynecology and Reproductive Biology, (1985) Vol. 19, No. 5, pp. 313-315. .
CODEN: EOGRAL
COUNTRY: Netherlands
DOCUMENT TYPE: Journal
FILE SEGMENT: 038 Adverse Reactions Titles
037 Drug Literature Index
010 Obstetrics and Gynecology
052 Toxicology
021 Developmental Biology and Teratology
030 Pharmacology
LANGUAGE: English
ENTRY DATE: Entered STN: 10 Dec 1991
Last Updated on STN: 10 Dec 1991

ABSTRACT: Fetal death in a primigravid patient who had taken an overdose of ergotamine tartrate is presented. Non-stress cardiotocography performed shortly after admission was technically unsatisfactory for interpretation but revealed the presence of very frequent uterine contractions. The cause of

fetal death in this patient is discussed. Overdosage of ergotamine must be considered a serious threat to the well-being of the fetus in utero.

CONTROLLED TERM: Medical Descriptors:
*adverse drug reaction
*drug overdose
*fetus death
case report
intoxication
suicide attempt
priority journal
fetus
pregnancy
fatality
oral drug administration
human
Drug Descriptors:
*caffeine
*cyclizine
*ergotamine
*ergotamine tartrate
*migril
nifedipine

CAS REGISTRY NO.: (caffeine) 30388-07-9, 58-08-2; (cyclizine) 303-25-3, 5897-18-7, 82-92-8; (ergotamine) 113-15-5, 52949-35-6; (ergotamine tartrate) 379-79-3; (***nifedipine***) ***21829-25-4***

CHEMICAL NAME: Migril

L185 ANSWER 23 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:107294 USPATFULL Full-text
TITLE: Sustained release composition for oral administration of drugs
INVENTOR(S): ***Woo, Jong-Soo***, Suwon-si, KOREA, REPUBLIC OF
Chi, Moon-Hyuk, Suwon-Si, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004081693	A1	20040429
APPLICATION INFO.:	US 2003-650931	A1	20030827 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	KR 2002-64940	20021023

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: David A. Einhom, Esq., Anderson Kill & Olick, P.C., 1251 Avenue of the Americas, New York, NY, 10020
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sustained-release composition for oral administration of a drug, comprising the drug, a mixture of sodium alginate and xanthan gum as a carrier for sustained release and a mixture of hydroxypropyl methylcellulose and propylene glycol alginate as a gel hydration accelerator, which is

capable of maintaining a constant drug level in blood for 24 hours or more owing to the fact that the drug release rate follows zero order kinetics and does not significantly vary with the degree of gastrointestinal motility due to rapid gel hydration without forming a non-gelated core.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> file registry
FILE 'REGISTRY' ENTERED AT 18:03:14 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 MAR 2007  HIGHEST RN 925228-12-2
DICTIONARY FILE UPDATES:   6 MAR 2007  HIGHEST RN 925228-12-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> file caplus
FILE 'CAPLUS' ENTERED AT 18:03:17 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Mar 2007  VOL 146 ISS 11
FILE LAST UPDATED: 6 Mar 2007  (20070306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L55
L2             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3            90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
```

```
L7            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8            17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18           18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20           91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22           53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23           19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27          167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L28        12370 SEA FILE=CAPLUS ABB=ON  PLU=ON  L27
L29            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31          102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33           28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE?/CN
L34            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37          133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38          137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39           87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40          111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE/CN
L42          129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43          151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L44            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2
                  /CRN)
L45            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L46            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND (L40 OR L43 OR L45)
L47            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND (L43 OR L45)
L49           62 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L40 AND L43 AND L45
L50            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L43 AND L45
L51            0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L47 AND L45
L52            0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L47 AND L45
L53            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L45
L54            0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L47 AND L45
L55            4 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L49 OR L50 OR L51 OR L52 OR
                  L53 OR L54) AND L28


=> d stat que L60
L29            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31          102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33           28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE?/CN
L34            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37          133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38          137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39           87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40          111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE/CN
L42          129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43          151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L44            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2
                  /CRN)
```

```
L45             8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L46             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND (L40 OR L43 OR L45)
L47             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND (L43 OR L45)
L49            62 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L40 AND L43 AND L45
L50             1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L43 AND L45
L51             0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L47 AND L45
L52             0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L47 AND L45
L53             1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L45
L54             0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L47 AND L45
L56         14331 SEA FILE=CAPLUS ABB=ON  PLU=ON  NIFEDIPINE/BI
L57           908 SEA FILE=CAPLUS ABB=ON  PLU=ON  ISRADIPINE/BI
L58          3338 SEA FILE=CAPLUS ABB=ON  PLU=ON  LOVASTATIN/BI
L59          1072 SEA FILE=CAPLUS ABB=ON  PLU=ON  GLIPIZIDE/BI
L60             4 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L56 OR L57 OR L58 OR L59) AND
                  (L49 OR L50 OR L51 OR L52 OR L53 OR L54)


=> file medline
FILE 'MEDLINE' ENTERED AT 18:03:32 ON 07 MAR 2007

 FILE LAST UPDATED: 7 Mar 2007 (20070307/UP).  FILE COVERS 1950 TO DATE.

  All regular MEDLINE updates from November 15 to December 16 have been
  added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R))
  and 2007 tree numbers.

  The annual reload will be available in early 2007.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> d stat que L109
L2              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3             90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5              3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7             37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8             17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18            18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20            91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21             4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22            53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23            19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27           167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L29             8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31           102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33            28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE?/CN
L34             2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37           133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38           137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39            87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40           111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE/CN
```

```
L42          129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43          151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L44            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2
                 /CRN)
L45            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L67        57253 SEA FILE=REGISTRY ABB=ON  PLU=ON  MEDLINE/LC
L70            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L67
L73            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND L67
L76            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L67
L79            3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L43 AND L67
L82            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L45 AND L67
L94        18551 SEA FILE=MEDLINE ABB=ON  PLU=ON  L70
L95        19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96         1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97         4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98          713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L99           10 SEA FILE=MEDLINE ABB=ON  PLU=ON  L73
L100         663 SEA FILE=MEDLINE ABB=ON  PLU=ON  SODIUM ALGINATE
L101        5653 SEA FILE=MEDLINE ABB=ON  PLU=ON  ALGINATE
L102         263 SEA FILE=MEDLINE ABB=ON  PLU=ON  L76
L103         372 SEA FILE=MEDLINE ABB=ON  PLU=ON  XANTHAN GUM
L104         655 SEA FILE=MEDLINE ABB=ON  PLU=ON  L79
L105        4774 SEA FILE=MEDLINE ABB=ON  PLU=ON  METHYLCELLULOSE
L106         458 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYDROXYPROPYLMETHYLCELLULOSE
L107          13 SEA FILE=MEDLINE ABB=ON  PLU=ON  L82
L108        5243 SEA FILE=MEDLINE ABB=ON  PLU=ON  PROPYLENE GLYCOL
L109           0 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L94 OR L95 OR L96 OR L97 OR
                 L98) AND (L99 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR
                 L105 OR L106) AND (L107 OR L108)


=> d stat que L110
L2             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3            90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8            17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18           18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20           91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22           53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23           19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27          167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L29            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31          102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33           28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                 CELLULOSE?/CN
L36            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37          133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38          137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39           87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40          111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                 CELLULOSE/CN
L42          129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43          151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
```

```
L67        57253 SEA FILE=REGISTRY ABB=ON  PLU=ON  MEDLINE/LC
L70            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L67
L73            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND L67
L76            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L67
L79            3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L43 AND L67
L94        18551 SEA FILE=MEDLINE ABB=ON  PLU=ON  L70
L95        19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96         1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97         4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98          713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L99           10 SEA FILE=MEDLINE ABB=ON  PLU=ON  L73
L100         663 SEA FILE=MEDLINE ABB=ON  PLU=ON  SODIUM ALGINATE
L101        5653 SEA FILE=MEDLINE ABB=ON  PLU=ON  ALGINATE
L102         263 SEA FILE=MEDLINE ABB=ON  PLU=ON  L76
L103         372 SEA FILE=MEDLINE ABB=ON  PLU=ON  XANTHAN GUM
L104         655 SEA FILE=MEDLINE ABB=ON  PLU=ON  L79
L105        4774 SEA FILE=MEDLINE ABB=ON  PLU=ON  METHYLCELLULOSE
L106         458 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYDROXYPROPYLMETHYLCELLULOSE
L110           0 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L94 OR L95 OR L96 OR L97 OR
                 L98) AND (L99 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR
                 L105 OR L106)


=> d stat que L111
L29            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31          102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33           28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                 CELLULOSE?/CN
L34            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37          133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38          137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39           87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40          111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                 CELLULOSE/CN
L42          129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43          151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L44            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2
                 /CRN)
L45            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L67        57253 SEA FILE=REGISTRY ABB=ON  PLU=ON  MEDLINE/LC
L73            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND L67
L76            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L67
L79            3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L43 AND L67
L82            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L45 AND L67
L99           10 SEA FILE=MEDLINE ABB=ON  PLU=ON  L73
L100         663 SEA FILE=MEDLINE ABB=ON  PLU=ON  SODIUM ALGINATE
L101        5653 SEA FILE=MEDLINE ABB=ON  PLU=ON  ALGINATE
L102         263 SEA FILE=MEDLINE ABB=ON  PLU=ON  L76
L103         372 SEA FILE=MEDLINE ABB=ON  PLU=ON  XANTHAN GUM
L104         655 SEA FILE=MEDLINE ABB=ON  PLU=ON  L79
L105        4774 SEA FILE=MEDLINE ABB=ON  PLU=ON  METHYLCELLULOSE
L106         458 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYDROXYPROPYLMETHYLCELLULOSE
L107          13 SEA FILE=MEDLINE ABB=ON  PLU=ON  L82
L108        5243 SEA FILE=MEDLINE ABB=ON  PLU=ON  PROPYLENE GLYCOL
L111           0 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L99 OR L100 OR L101) AND
                 (L102 OR L103) AND (L104 OR L105 OR L106) AND (L107 OR L108)
```

```
=> d stat que L121
L2            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3           90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5            3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8           17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18          18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20          91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21           4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22          53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23          19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27         167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L29           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31         102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33          28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE?/CN
L34           2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37         133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38         137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39          87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40         111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE/CN
L42         129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43         151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L44           6 SEA FILE=REGISTRY ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2
                  /CRN)
L45           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L67       57253 SEA FILE=REGISTRY ABB=ON  PLU=ON  MEDLINE/LC
L70           6 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L67
L73           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND L67
L76           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L67
L79           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L43 AND L67
L82           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L45 AND L67
L94       18551 SEA FILE=MEDLINE ABB=ON  PLU=ON  L70
L95       19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96        1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97        4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98         713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L99          10 SEA FILE=MEDLINE ABB=ON  PLU=ON  L73
L100        663 SEA FILE=MEDLINE ABB=ON  PLU=ON  SODIUM ALGINATE
L101       5653 SEA FILE=MEDLINE ABB=ON  PLU=ON  ALGINATE
L102        263 SEA FILE=MEDLINE ABB=ON  PLU=ON  L76
L103        372 SEA FILE=MEDLINE ABB=ON  PLU=ON  XANTHAN GUM
L104        655 SEA FILE=MEDLINE ABB=ON  PLU=ON  L79
L105       4774 SEA FILE=MEDLINE ABB=ON  PLU=ON  METHYLCELLULOSE
L106        458 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYDROXYPROPYLMETHYLCELLULOSE
L107         13 SEA FILE=MEDLINE ABB=ON  PLU=ON  L82
L108       5243 SEA FILE=MEDLINE ABB=ON  PLU=ON  PROPYLENE GLYCOL
L112        426 SEA FILE=MEDLINE ABB=ON  PLU=ON  (ADALAT/BI OR BAY-A-1040/BI
                  OR BAY-1040/BI OR CORDIPIN/BI OR CORDIPINE/BI OR CORINFAR/BI
                  OR FENIGIDIN/BI OR INFEDIPIN/BI OR KORINFAR/BI OR "MONOHYDROCHL
```

```
                ORIDE, NIFEDIPINE"/BI OR NIFANGIN/BI OR "NIFEDIPINE MONOHYDROCH
                LORIDE"/BI OR NIFEDIPINE-GTIS/BI OR PROCARDIA/BI OR "PROCARDIA
                XL"/BI)
L114       19161 SEA FILE=MEDLINE ABB=ON  PLU=ON  L95 OR L112
L115         382 SEA FILE=MEDLINE ABB=ON  PLU=ON  (DYNACIRC/BI OR "ISRADIPINE,
                (+-)-ISOMER"/BI OR "ISRADIPINE, (R)-ISOMER"/BI OR "ISRADIPINE,
                (S)-ISOMER"/BI OR LOMIR/BI OR "PN 200-110"/BI OR "PN 205
                033"/BI OR "PN 205 034"/BI OR "PN 205-033"/BI OR "PN 205-034"/B
                I OR "PN 205033"/BI OR "PN 205034"/BI OR PN-200-110/BI OR
                PN-205-033/BI OR PN-205-034/BI OR PN205033/BI OR PN205034/BI)
L116        1595 SEA FILE=MEDLINE ABB=ON  PLU=ON  L96 OR L115
L117         404 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("LOVASTATIN, (1 ALPHA(S*))-IS
                OMER"/BI OR "LOVASTATIN, 1 ALPHA-ISOMER (WITHOUT R*/S*
                NOTATION)"/BI OR "MK 803"/BI OR MK-803/BI OR MK803/BI OR
                MEVACOR/BI OR MEVINOLIN/BI OR "MONACOLIN K"/BI)
L118        4139 SEA FILE=MEDLINE ABB=ON  PLU=ON  L97 OR L117
L119          29 SEA FILE=MEDLINE ABB=ON  PLU=ON  ("ALPHAPHARM BRAND OF
                GLIPIZIDE"/BI OR "GLIBENESE BRAND OF GLIPIZIDE"/BI OR GLIDIAZIN
                AMIDE/BI OR GLUCOTROL/BI OR GLUPITEL/BI OR GLYDIAZINAMIDE/BI
                OR GLYPIDIZINE/BI OR "K 4024"/BI OR K-4024/BI OR K4024/BI OR
                "KENFARMA BRAND OF GLIPIZIDE"/BI OR "LACER BRAND OF GLIPIZIDE"/
                BI OR "LILLY BRAND OF GLIPIZIDE"/BI OR MELIZIDE/BI OR MINDIAB/B
                I OR MINIDIAB/BI OR MINODIAB/BI OR OZIDIA/BI OR "PFIZER BRAND
                OF GLIPIZIDE"/BI OR "PHARMACIA BRAND OF GLIPIZIDE"/BI OR
                "PYRAZINECARBOXAMIDE, N-(2-(4-((((CYCLOHEXYLAMINO)CARBONYL)AMIN
                O)SULFONYL)PHENYL)ETHYL)-5-METHYL-"/BI)
L120         723 SEA FILE=MEDLINE ABB=ON  PLU=ON  L98 OR L119
L121           0 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L94 OR L114 OR L116 OR L118
                OR L120) AND (L99 OR L100 OR L101) AND (L102 OR L103) AND
                (L104 OR L105 OR L106) AND (L107 OR L108)

=> file embase
FILE 'EMBASE' ENTERED AT 18:03:59 ON 07 MAR 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

 FILE COVERS 1974 TO 7 Mar 2007 (20070307/ED)

 EMBASE is now updated daily.  SDI frequency remains weekly (default)
 and biweekly.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d stat que L143
L2             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3            90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8            17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18           18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20           91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22           53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23           19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27          167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L29            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
```

```
L30           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31         102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33          28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                CELLULOSE?/CN
L36           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37         133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38         137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39          87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40         111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                CELLULOSE/CN
L42         129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43         151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L68       30841 SEA FILE=REGISTRY ABB=ON  PLU=ON  EMBASE/LC
L71           6 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L68
L74           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND L68
L77           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L68
L80           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L43 AND L68
L95       19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96        1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97        4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98         713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L100        663 SEA FILE=MEDLINE ABB=ON  PLU=ON  SODIUM ALGINATE
L101       5653 SEA FILE=MEDLINE ABB=ON  PLU=ON  ALGINATE
L105       4774 SEA FILE=MEDLINE ABB=ON  PLU=ON  METHYLCELLULOSE
L106        458 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYDROXYPROPYLMETHYLCELLULOSE
L123      46607 SEA FILE=EMBASE ABB=ON  PLU=ON  (L71 OR (L95 OR L96 OR L97 OR
                L98))
L124       3286 SEA FILE=EMBASE ABB=ON  PLU=ON  (ADALAT/BI OR "ADALAT CRONO"/BI
                 OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR
                ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR
                "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR
                "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI
                OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/B
                I OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI
                 OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2
                NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR
                ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR
                INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR
                NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR
                NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR
                NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR
                NOVONIFEDIN/BI OR PHENYGIDINE/BI OR PIDILAT/BI OR "PIDILAT
                RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI
                OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR
                UNIDIPINE/BI OR ZENUSIN/BI)
L125       1049 SEA FILE=EMBASE ABB=ON  PLU=ON  (ISRODIPINE/BI OR LOMIR/BI OR
                "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN
                200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN
                205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR
                PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI)
L126       2955 SEA FILE=EMBASE ABB=ON  PLU=ON  (ALTOCOR/BI OR ALTOPREV/BI OR
                ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR
                LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR
                "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR
                "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI)
L127        524 SEA FILE=EMBASE ABB=ON  PLU=ON  ("CP 28,720"/BI OR "CP
                28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR
                GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/
                BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI
```

```
                OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K
                4024"/BI OR MINIDIAB/BI OR MINODIAB/BI)
L128       46760 SEA FILE=EMBASE ABB=ON  PLU=ON  (L123 OR L124 OR L125 OR L126
                OR L127)
L129       13985 SEA FILE=EMBASE ABB=ON  PLU=ON  (ALGIN/BI OR ALGINATE/BI OR
                "ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC
                ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST
                SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI
                 OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR
                ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR
                MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR
                "POLYMANNURONIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI
                OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR
                "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN
                GREEN"/BI OR "ZELGAN PINK"/BI)
L130        6223 SEA FILE=EMBASE ABB=ON  PLU=ON  L74 OR (L100 OR L101)
L131       15293 SEA FILE=EMBASE ABB=ON  PLU=ON  (L129 OR L130)
L132         649 SEA FILE=EMBASE ABB=ON  PLU=ON  L77 OR XANTHAN GUM
L133         699 SEA FILE=EMBASE ABB=ON  PLU=ON  XANTHAN OR KELTROL OR RHODIGEL
                23
L134         699 SEA FILE=EMBASE ABB=ON  PLU=ON  (L132 OR L133)
L135        6010 SEA FILE=EMBASE ABB=ON  PLU=ON  L80 OR (L105 OR L106)
L136        1239 SEA FILE=EMBASE ABB=ON  PLU=ON  (ADATOCEL/BI OR CONTACTOL/BI
                OR GONIOSOL/BI OR "HYDROXYPROPYL METHYL CELLULOSE"/BI OR
                "HYDROXYPROPYL METHYLCELLULOSE"/BI OR "HYDROXYPROPYLMETHYL
                CELLULOSE"/BI OR HYPROMELLOSE/BI OR "ISOPTO TEARS"/BI OR
                ISOPTONATURAL/BI OR ISOPTOPLAIN/BI OR ISOPTOTEARS/BI OR "K
                8515"/BI OR LUBAFAX/BI OR "METHOCEL E 15"/BI OR "METHOCEL
                EFK"/BI OR "METHOCEL K100M"/BI OR "METHOCEL K15M"/BI OR
                "METHOCEL K4M"/BI OR "METHOLOSE TC 5"/BI OR "METHYLHYDROXYPROPY
                L CELLULOSE"/BI OR METHYLHYDROXYPROPYLCELLULOSE/BI OR METOLOSE/
                BI OR OCCUCOAT/BI OR OCUCOAT/BI OR "PHARMACOAT 603"/BI OR
                "PHARMACOAT 606"/BI OR ULTRATEARS/BI)
L137        6060 SEA FILE=EMBASE ABB=ON  PLU=ON  (L135 OR L136)
L143           2 SEA FILE=EMBASE ABB=ON  PLU=ON  L128 AND L131 AND L134 AND
                L137


=> s L143 not L153
L186           2 L143 NOT L153

=> file biosis
FILE 'BIOSIS' ENTERED AT 18:04:37 ON 07 MAR 2007
Copyright (c) 2007 The Thomson Corporation

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 28 February 2007 (20070228/ED)


=> d stat que L167
L2             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3            90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5             3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8            17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
```

```
L17           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18          18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20          91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21           4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22          53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23          19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27         167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L29           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31         102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33          28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                CELLULOSE?/CN
L34           2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37         133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38         137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39          87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40         111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                CELLULOSE/CN
L42         129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43         151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L44           6 SEA FILE=REGISTRY ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2
                /CRN)
L45           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L68       30841 SEA FILE=REGISTRY ABB=ON  PLU=ON  EMBASE/LC
L69      196582 SEA FILE=REGISTRY ABB=ON  PLU=ON  BIOSIS/LC
L72          11 SEA FILE=REGISTRY ABB=ON  PLU=ON  L27 AND L69
L74           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND L68
L77           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L68
L78           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND L69
L80           3 SEA FILE=REGISTRY ABB=ON  PLU=ON  L43 AND L68
L81           5 SEA FILE=REGISTRY ABB=ON  PLU=ON  L43 AND L69
L84           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L45 AND L69
L95       19109 SEA FILE=MEDLINE ABB=ON  PLU=ON  NIFEDIPINE
L96        1475 SEA FILE=MEDLINE ABB=ON  PLU=ON  ISRADIPINE
L97        4043 SEA FILE=MEDLINE ABB=ON  PLU=ON  LOVASTATIN
L98         713 SEA FILE=MEDLINE ABB=ON  PLU=ON  GLIPIZIDE
L100        663 SEA FILE=MEDLINE ABB=ON  PLU=ON  SODIUM ALGINATE
L101       5653 SEA FILE=MEDLINE ABB=ON  PLU=ON  ALGINATE
L105       4774 SEA FILE=MEDLINE ABB=ON  PLU=ON  METHYLCELLULOSE
L106        458 SEA FILE=MEDLINE ABB=ON  PLU=ON  HYDROXYPROPYLMETHYLCELLULOSE
L125       1049 SEA FILE=EMBASE ABB=ON  PLU=ON  (ISRODIPINE/BI OR LOMIR/BI OR
                "PK 200110"/BI OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN
                200110"/BI OR "PN 200110 N"/BI OR "PN 205033"/BI OR "PN
                205034"/BI OR "PN200 110"/BI OR PN200-110/BI OR PN200110/BI OR
                PRESCAL/BI OR "SDZ 200 110"/BI OR VASCAL/BI)
L126       2955 SEA FILE=EMBASE ABB=ON  PLU=ON  (ALTOCOR/BI OR ALTOPREV/BI OR
                ARTEIN/BI OR "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR
                LOVASTATIN/BI OR MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR
                "MK 803"/BI OR MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR
                "MONAKOLIN K"/BI OR "MSD 803"/BI OR NEOLIPID/BI)
L127        524 SEA FILE=EMBASE ABB=ON  PLU=ON  ("CP 28,720"/BI OR "CP
                28720"/BI OR "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR
                GLIBINESE/BI OR GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/
                BI OR GLUCOTROL/BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI
                OR GLYDIAZIAMIDE/BI OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K
                4024"/BI OR MINIDIAB/BI OR MINODIAB/BI)
L129      13985 SEA FILE=EMBASE ABB=ON  PLU=ON  (ALGIN/BI OR ALGINATE/BI OR
```

"ALGINATE SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC ACID"/BI OR "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST SET"/BI OR "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI OR "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR ALGINATE"/BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR MINUS/BI OR NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR "POLYMANNURONIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI OR PROTANAL/BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR "SODIUM POLYMANNURONATE"/BI OR SORBALGON/BI OR "ZELGAN GREEN"/BI OR "ZELGAN PINK"/BI)

L130 6223 SEA FILE=EMBASE ABB=ON PLU=ON L74 OR (L100 OR L101)

L132 649 SEA FILE=EMBASE ABB=ON PLU=ON L77 OR XANTHAN GUM

L133 699 SEA FILE=EMBASE ABB=ON PLU=ON XANTHAN OR KELTROL OR RHODIGEL 23

L135 6010 SEA FILE=EMBASE ABB=ON PLU=ON L80 OR (L105 OR L106)

L136 1239 SEA FILE=EMBASE ABB=ON PLU=ON (ADATOCEL/BI OR CONTACTOL/BI OR GONIOSOL/BI OR "HYDROXYPROPYL METHYL CELLULOSE"/BI OR "HYDROXYPROPYL METHYLCELLULOSE"/BI OR "HYDROXYPROPYLMETHYL CELLULOSE"/BI OR HYPROMELLOSE/BI OR "ISOPTO TEARS"/BI OR ISOPTONATURAL/BI OR ISOPTOPLAIN/BI OR ISOPTOTEARS/BI OR "K 8515"/BI OR LUBAFAX/BI OR "METHOCEL E 15"/BI OR "METHOCEL EFK"/BI OR "METHOCEL K100M"/BI OR "METHOCEL K15M"/BI OR "METHOCEL K4M"/BI OR "METHOLOSE TC 5"/BI OR "METHYLHYDROXYPROPY L CELLULOSE"/BI OR METHYLHYDROXYPROPYLCELLULOSE/BI OR METOLOSE/ BI OR OCCUCOAT/BI OR OCUCOAT/BI OR "PHARMACOAT 603"/BI OR "PHARMACOAT 606"/BI OR ULTRATEARS/BI)

L137 6060 SEA FILE=EMBASE ABB=ON PLU=ON (L135 OR L136)

L139 23 SEA FILE=EMBASE ABB=ON PLU=ON "ALGINIC ACID PROPYLENE GLYCOL ESTER"+UF/CT

L140 26 SEA FILE=EMBASE ABB=ON PLU=ON ("PROPYLENE GLYCOL ALGINATE"/BI OR "PROPYLENEGLYCOL ALGINATE"/BI)

L141 34 SEA FILE=EMBASE ABB=ON PLU=ON (L139 OR L140)

L157 25683 SEA FILE=BIOSIS ABB=ON PLU=ON L72 OR (L95 OR L96 OR L97 OR L98)

L158 422 SEA FILE=BIOSIS ABB=ON PLU=ON (ADALAT/BI OR "ADALAT CRONO"/BI OR "ADALAT PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR ALDIPIN/BI OR ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR "APRICAL RETARD"/BI OR "BAY 1040"/BI OR "BAY A 1040"/BI OR "BAY A1040"/BI OR BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI OR CHRONADALATE/BI OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/B I OR CORDICANT/BI OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI OR DEPIN/BI OR "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) PYRIDINE 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR ECODIPIN/BI OR EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR INFEDIPINE/BI OR MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR NIFANGIN/BI OR NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR NIFEDINE/BI OR NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR NIFENSAR/BI OR NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR NOVONIFEDIN/BI OR PHENYGIDINE/BI OR PIDILAT/BI OR "PIDILAT RETARD"/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI OR SEPAMIT/BI OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR UNIDIPINE/BI OR ZENUSIN/BI)

L159 4086 SEA FILE=BIOSIS ABB=ON PLU=ON (L125 OR L126 OR L127)

L160 26142 SEA FILE=BIOSIS ABB=ON PLU=ON (L157 OR L158 OR L159)

L161 23308 SEA FILE=BIOSIS ABB=ON PLU=ON (L129 OR L130)

L162 1552 SEA FILE=BIOSIS ABB=ON PLU=ON (L132 OR L133)

L163 1071 SEA FILE=BIOSIS ABB=ON PLU=ON L78

L164 1552 SEA FILE=BIOSIS ABB=ON PLU=ON (L162 OR L163)

L165 4435 SEA FILE=BIOSIS ABB=ON PLU=ON L137 OR L81

L166 96 SEA FILE=BIOSIS ABB=ON PLU=ON L84 OR L141

```
L167            0 SEA FILE=BIOSIS ABB=ON  PLU=ON  L160 AND L161 AND L164 AND
                  L165 AND L166


=> file uspatfull
FILE 'USPATFULL' ENTERED AT 18:04:52 ON 07 MAR 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Mar 2007 (20070306/PD)
FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)
HIGHEST GRANTED PATENT NUMBER: US7188369
HIGHEST APPLICATION PUBLICATION NUMBER: US2007050874
CA INDEXING IS CURRENT THROUGH 6 Mar 2007 (20070306/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Mar 2007 (20070306/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006


=> d stat que L184
L173           67 SEA FILE=USPATFULL ABB=ON  PLU=ON  (WO2004037226/PN OR
                  EP331385/PN OR EP616508/PN OR EP782846/PN OR AU2003274655/PN
                  OR CA2054822/PN OR CA2411153/PN OR CA2503380/PN OR EP1150722/PN
                   OR EP1296656/PN OR EP1299499/PN OR EP1558222/PN OR EP241178/PN
                   OR EP484186/PN OR EP740528/PN OR EP812545/PN OR EP983326/PN
                  OR US2002012680/PN OR US2002032171/PN OR US2006057204/PN OR
                  US6267985/PN OR US6294192/PN OR US6451339/PN OR US6703044/PN
                  OR US6761903/PN OR WO2002000201/PN OR WO2002005620/PN OR
                  WO2002005660/PN OR WO2002005661/PN OR WO2003080056/PN OR
                  WO2003090693/PN OR WO2004113042/PN OR WO2005046363/PN OR
                  WO2005107713/PN OR WO9517104/PN OR AT103492/PN OR AT180170/PN
                  OR AT188118/PN OR AT203148/PN OR AT228776/PN OR AT235228/PN OR
                  AT254157/PN OR AT305802/PN OR AT334662/PN OR AT338800/PN OR
                  AU2000063445/PN OR AU2001013246/PN OR AU2003213020/PN OR
                  AU2003218058/PN OR AU2003230719/PN OR AU2003234240/PN OR
                  AU2003237944/PN OR AU2003297561/PN OR AU2004249662/PN OR
                  AU2004289248/PN OR AU2005230362/PN OR AU590403/PN OR AU618932/P
                  N OR AU657706/PN OR AU667471/PN OR AU683713/PN OR AU688837/PN
                  OR AU713127/PN OR AU725810/PN OR AU731072/PN OR AU740326/PN OR
                  AU753760/PN OR AU754917/PN OR AU772345/PN OR AU782828/PN OR
                  AU8172030/PN OR AU8770616/PN OR AU8770617/PN OR AU9176742/PN
                  OR AU9186961/PN OR AU9220020/PN OR AU9513020/PN OR AU9514318/PN
                   OR AU9673269/PN OR AU9724856/PN OR AU9856271/PN OR AU9879126/P
                  N OR AU9888405/PN OR AU9892840/PN OR AU9910043/PN OR AU9929241/
                  PN OR AU9956852/PN OR BG64100/PN OR BR2001008145/PN OR
                  BR2001012014/PN OR BR2004015741/PN OR BR9809674/PN OR BR9913227
                  /PN OR CA1164264/PN OR CA1300515/PN OR CA2069759/PN OR
                  CA2177713/PN OR CA2188331/PN OR CA2200620/PN OR CA2269769/PN
                  OR CA2291040/PN OR CA2309380/PN OR CA2338688/PN OR CA2361847/PN
                   OR CA2388610/PN OR CA2397832/PN OR CA2414161/PN OR CA2414166/P
                  N OR CA24141
L174         6797 SEA FILE=USPATFULL ABB=ON  PLU=ON  NIFEDIPINE
L175         1469 SEA FILE=USPATFULL ABB=ON  PLU=ON  ISRADIPINE
L176         5820 SEA FILE=USPATFULL ABB=ON  PLU=ON  LOVASTATIN
L177         2595 SEA FILE=USPATFULL ABB=ON  PLU=ON  GLIPIZIDE
L178           15 SEA FILE=USPATFULL ABB=ON  PLU=ON  L173 AND (L174 OR L175 OR
                  L176 OR L177)
L182            8 SEA FILE=REGISTRY ABB=ON  PLU=ON  (9005-38-3/BI OR 11138-66-2/B
                  I OR 9004-65-3/BI OR 9005-37-2/BI OR 9050-31-1/BI OR 71138-97-1
                  /BI OR 70535-77-2/BI OR 497236-18-7/BI)
L183         9847 SEA FILE=USPATFULL ABB=ON  PLU=ON  L182
```

```
L184          9 SEA FILE=USPATFULL ABB=ON  PLU=ON  L183 AND L178


=> s L184 not L170
L187          9 L184 NOT L170

=> => file caplus
FILE 'CAPLUS' ENTERED AT 18:05:40 ON 07 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 7 Mar 2007  VOL 146 ISS 11
FILE LAST UPDATED: 6 Mar 2007  (20070306/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L55
L2            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  NIFEDIPINE/CN
L3           90 SEA FILE=REGISTRY ABB=ON  PLU=ON  21829-25-4/CRN
L4            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  ISRADIPINE/CN
L5            3 SEA FILE=REGISTRY ABB=ON  PLU=ON  75695-93-1/CRN
L6            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN/CN
L7           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  75330-75-5/CRN
L8           17 SEA FILE=REGISTRY ABB=ON  PLU=ON  LOVASTATIN?/CN
L17           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  GLIPIZID?/CN
L18          18 SEA FILE=REGISTRY ABB=ON  PLU=ON  29094-61-9/CRN
L20          91 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L2 OR L3)
L21           4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L4 OR L5)
L22          53 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23          19 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L17 OR L18)
L27         167 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)
L28       12370 SEA FILE=CAPLUS ABB=ON  PLU=ON  L27
L29           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31         102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33          28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                  CELLULOSE?/CN
L34           2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37         133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38         137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39          87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40         111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
```

```
L41           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                CELLULOSE/CN
L42         129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43         151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L44           6 SEA FILE=REGISTRY ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2
                /CRN)
L45           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L46           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND (L40 OR L43 OR L45)
L47           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND (L43 OR L45)
L49          62 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L40 AND L43 AND L45
L50           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L43 AND L45
L51           0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L47 AND L45
L52           0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L47 AND L45
L53           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L45
L54           0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L47 AND L45
L55           4 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L49 OR L50 OR L51 OR L52 OR
                L53 OR L54) AND L28


=> d stat que L60
L29           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
L30           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM/CN
L31         102 SEA FILE=REGISTRY ABB=ON  PLU=ON  XANTHAN GUM?/CN
L33          28 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                CELLULOSE?/CN
L34           2 SEA FILE=REGISTRY ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN

L36           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  SODIUM ALGINATE/CN
L37         133 SEA FILE=REGISTRY ABB=ON  PLU=ON  9005-38-3/CRN
L38         137 SEA FILE=REGISTRY ABB=ON  PLU=ON  L29 OR L36 OR L37
L39          87 SEA FILE=REGISTRY ABB=ON  PLU=ON  11138-66-2/CRN
L40         111 SEA FILE=REGISTRY ABB=ON  PLU=ON  L30 OR L31 OR L39
L41           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  HYDROXYPROPYL METHYL
                CELLULOSE/CN
L42         129 SEA FILE=REGISTRY ABB=ON  PLU=ON  9004-65-3/CRN
L43         151 SEA FILE=REGISTRY ABB=ON  PLU=ON  L33 OR L41 OR L42
L44           6 SEA FILE=REGISTRY ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2
                /CRN)
L45           8 SEA FILE=REGISTRY ABB=ON  PLU=ON  L34 OR L44
L46           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L38 AND (L40 OR L43 OR L45)
L47           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L40 AND (L43 OR L45)
L49          62 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L40 AND L43 AND L45
L50           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L43 AND L45
L51           0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L38 AND L47 AND L45
L52           0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L47 AND L45
L53           1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 AND L45
L54           0 SEA FILE=CAPLUS ABB=ON  PLU=ON  L47 AND L45
L56       14331 SEA FILE=CAPLUS ABB=ON  PLU=ON  NIFEDIPINE/BI
L57         908 SEA FILE=CAPLUS ABB=ON  PLU=ON  ISRADIPINE/BI
L58        3338 SEA FILE=CAPLUS ABB=ON  PLU=ON  LOVASTATIN/BI
L59        1072 SEA FILE=CAPLUS ABB=ON  PLU=ON  GLIPIZIDE/BI
L60           4 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L56 OR L57 OR L58 OR L59) AND
                (L49 OR L50 OR L51 OR L52 OR L53 OR L54)


=> s L55 or L60
L188          4 L55 OR L60

=> dup rem L188 L186 L187
FILE 'CAPLUS' ENTERED AT 18:06:15 ON 07 MAR 2007
```

FILE 'EMBASE' ENTERED AT 18:06:15 ON 07 MAR 2007

FILE 'USPATFULL' ENTERED AT 18:06:15 ON 07 MAR 2007

PROCESSING COMPLETED FOR L188
PROCESSING COMPLETED FOR L186
PROCESSING COMPLETED FOR L187
L189 14 DUP REM L188 L186 L187 (1 DUPLICATE REMOVED)
ANSWERS '1-4' FROM FILE CAPLUS
ANSWERS '5-6' FROM FILE EMBASE
ANSWERS '7-14' FROM FILE USPATFULL

=> d ibib abs hitind hitstr L189 1-4; d iall L189 5-6; d ibib abs kwic hitstr L189 7-14

L189 ANSWER 1 OF 14 CAPLUS DUPLICATE 1
ACCESSION NUMBER: 2003:319266 CAPLUS Full-text
DOCUMENT NUMBER: 138:343857
TITLE: Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
INVENTOR(S): Chen, Feng-Jing; Venkateshwaran, Srinivasan; Krill, Steven L.; Patel, Mahesh V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 55 pp., Cont.-in-part of U.S. Ser. No. 898,553.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003077297	A1	20030424	US 2002-74687	20020211
US 6294192	B1	20010925	US 1999-258654	19990226
US 6267985	B1	20010731	US 1999-345615	19990630
US 6248363	B1	20010619	US 1999-447690	19991123
US 2003064097	A1	20030403	US 2001-800593	20010306
US 6569463	B2	20030527		
US 2002032171	A1	20020314	US 2001-877541	20010608
US 6761903	B2	20040713		
US 2002012680	A1	20020131	US 2001-898553	20010702
US 6451339	B2	20020917		
WO 2003068186	A1	20030821	WO 2003-US4195	20030211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003213020	A1	20030904	AU 2003-213020	20030211

PRIORITY APPLN. INFO.:

US 1999-258654	A1 19990226
US 1999-345615	A2 19990630
US 1999-447690	A3 19991123
US 2001-800593	A2 20010306
US 2001-877541	A2 20010608
US 2001-898553	A2 20010702
US 1999-375636	A2 19990817
US 2000-751968	A2 20001229
US 2002-74687	A 20020211
WO 2003-US4195	W 20030211

AB The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 weight % to about 80 weight % of the active agent and the second fraction representing about 20 weight % to about 95 weight % of the active agent. One or more addnl. active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different release profiles. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release. A pharmaceutical suspension contained isotretinoin 40, soybean oil 200, Maisine 35-1 100, and Lutrol F68 100 mg.

IC ICM A61K009-00

INCL 424400000

CC 63-6 (Pharmaceuticals)

IT 50-27-1, Estriol 50-28-2, 17β-Estradiol, biological studies 50-35-1, Thalidomide 50-50-0, 17β-Estradiol benzoate 51-98-9, Norethindrone acetate 52-76-6, Lynestrenol 53-16-7, Estrone, biological studies 54-11-5, Nicotine 57-63-6, Ethynylestradiol 57-83-0, Progesterone, biological studies 68-22-4, Norethindrone 68-23-5, Norethynodrel 68-96-2, Hydroxyprogesterone 71-58-9, Medroxyprogesterone acetate 72-33-3, Mestranol 79-10-7D, Acrylic acid, polymers 79-41-4D, Methacrylic acid, polymers 79-64-1, Dimethisterone 128-13-2, Ursodeoxycholic Acid 152-43-2, Quinestrol 297-76-7, Ethynodiol diacetate 302-22-7, Chlormadinone acetate 302-23-8, Hydroxyprogesterone acetate 313-06-4, 17β-Estradiol cypionate 427-51-0, Cyproterone acetate 432-60-0, Allylestrenol 434-03-7, Ethisterone 481-97-0, Estrone sulfate 514-61-4, Normethisterone 514-68-1, Estriol succinate 566-65-4 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate 637-07-0, Clofibrate 797-63-7, Levonorgestrel 848-21-5, Norgestrienone 882-09-7, Clofibric acid 901-93-9, Estrone acetate 977-79-7, Medrogestone 979-32-8, 17β-Estradiol valerate 1318-93-0, Montmorillonite, biological studies 1323-54-2, Acetoxypregnenolone 1327-43-1, Magnesium aluminum silicate 1335-30-4, Aluminum silicate 1343-88-0, Magnesium silicate 1405-86-3, Glycyrrhizin 1743-60-8 1951-25-3, Amiodarone 2098-66-0, Cyproterone 2529-45-5, Flurogestone acetate 2919-66-6, Melengestrol acetate 3137-73-3, Anagestone acetate 3434-88-6, 17β-Estradiol diacetate 3562-63-8, Megestrol 4759-48-2, Isotretinoin 4956-37-0 5779-47-5, Ethynylestradiol 3-acetate 5934-04-3, Ethynylestradiol 3-benzoate 6533-00-2, Norgestrel 7280-37-7, Piperazine estrone sulfate 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-40-2, Locust bean gum 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-18-0, Agar 9003-39-8, Polyvinyl pyrrolidone 9004-32-4, Sodium carboxymethylcellulose 9004-57-3, Ethylcellulose 9004-58-4, Ethyl hydroxyethylcellulose 9004-59-5, Ethyl methylcellulose 9004-64-2, Hydroxypropyl cellulose ***9004-65-3***, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies ***9005-37-2***

, Propylene glycol alginate ***9005-38-3***, Sodium alginate
9063-38-1, Sodium starch glycolate ***11138-66-2***, Xanthan gum
12173-47-6, Hectorite 12174-11-7, Attapulgite 14291-86-2 14929-11-4,
Simfibrate ***21829-25-4***, ***Nifedipine*** 23288-49-5,
Probucol 25189-83-7, Poly(N-vinyl caprolactam) 25322-68-3,
Polyethylene glycol 25812-30-0, Gemfibrozil 30299-08-2, Clinofibrate
31637-97-5, Etofibrate 31694-55-0 31980-29-7, Nicofibrate
35189-28-7, Norgestimate 39386-78-2, Tamarind gum 41859-67-0,
Bezafibrate 42017-89-0, Fenofibric acid 42408-82-2, Butorphanol
42597-57-9, Ronifibrate, biological studies 49562-28-9, Fenofibrate
52214-84-3, Ciprofibrate 53694-15-8, Polyoxyethylene sorbitol
54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 55285-45-5,
Pirifibrate 55937-99-0, Beclobrate 60282-87-3, Gestodene 61748-93-4
61931-73-5, Ethoxylated glucose 68693-11-8, Modafinil 69047-39-8,
Binifibrate 73963-72-1, Cilostazol 76547-98-3, Lisinopril
82626-48-0, Zolpidem 91161-71-6, Terbinafine 95233-18-4, Atovaquone
99614-02-5, Ondansetron 103062-96-0 107753-78-6, Zafirlukast
144034-80-0, Rizatriptan 151319-34-5, Zaleplon 159989-64-7, Nelfinavir
161814-49-9, Amprenavir 162011-90-7, Rofecoxib 163222-33-1, Ezetimibe
169590-42-5, Celecoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT ***9004-65-3***, Hydroxypropyl methylcellulose ***9005-37-2***,
Propylene glycol alginate ***9005-38-3***, Sodium alginate
11138-66-2, Xanthan gum ***21829-25-4***, ***Nifedipine***
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

RN 9004-65-3 CAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 CAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 CAPLUS
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 11138-66-2 CAPLUS
CN Xanthan gum (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 21829-25-4 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester (CA INDEX NAME)



L189 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1123805 CAPLUS Full-text
DOCUMENT NUMBER: 143:411049
TITLE: Sustained-release formulation for oral administration

of HMG-Co A reductase inhibitor and method for the preparation thereof

INVENTOR(S): Woo, Jong-Soo; Yi, Hong-Gi; Chi, Moon-Hyuk; Ryu, Jae-Kuk; Jung, Si-Young; Kim, Yong-Il

PATENT ASSIGNEE(S): Hanmi Pharm. Co., Ltd., S. Korea

SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097194	A1	20051020	WO 2005-KR1021	20050408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005099583	A	20051013	KR 2004-24734	20040410
AU 2005230362	A1	20051020	AU 2005-230362	20050408
CA 2562418	A1	20051020	CA 2005-2562418	20050408
EP 1744782	A1	20070124	EP 2005-733408	20050408
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: KR 2004-24734 A 20040410
WO 2005-KR1021 W 20050408

AB The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 h. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels. A sustained-release tablet contained ***lovastatin*** 60, vitamin E TPGS 20, BHT 2, HPMC-2910 50, sodium alginate 36, xanthan gum 150, locust bean gum 50, propylene glycol ester alginate 30, HPMC-2208 110, kofovidone 35, light anhydrous silicic acid 10, and magnesium stearate 2 mg. Effects of tablets on lowering cholesterol and triglyceride levels in hyperlipidemic rats is shown.

IC ICM A61K047-00
ICS A61P009-10

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

ST sustained release oral pharmaceutical HMGCo A reductase inhibitor; ***lovastatin*** sustained release oral pharmaceutical tablet

IT 73573-88-3, Mevastatin ***75330-75-5, Lovastatin*** 79902-63-9, Velostatin 81093-37-0, Pravastatin 81093-37-0D, Pravastatin, lactones 93957-54-1, Fluvastatin 134523-00-5, Atorvastatin 143201-11-0, Rivastatin 145599-86-6, Cerivastatin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release formulation for oral administration of hmg-coa reductase inhibitor and method for preparation thereof)

IT 50-81-7, Ascorbic acid, biological studies 89-65-6, Erythorbic acid

128-37-0, Butylated hydroxy toluene, biological studies 9000-40-2, Locust bean gum 9002-96-4 ***9004-65-3***, Hydroxypropyl methyl cellulose 9004-99-3, Polyoxyethylene stearic acid ester ***9005-37-2***, Propylene glycol alginate ***9005-38-3***, Sodium alginate ***11138-66-2***, Xanthan gum 25013-16-5, Butylatedhydroxyanisole 106392-12-5, Ethylene glycol propylene glycol block copolymer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release formulation for oral administration of hmg-coa reductase inhibitor and method for preparation thereof)

IT ***75330-75-5***, ***Lovastatin***
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release formulation for oral administration of hmg-coa reductase inhibitor and method for preparation thereof)

RN 75330-75-5 CAPLUS

CN Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT ***9004-65-3***, Hydroxypropyl methyl cellulose ***9005-37-2***, Propylene glycol alginate ***9005-38-3***, Sodium alginate ***11138-66-2***, Xanthan gum
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sustained-release formulation for oral administration of hmg-coa reductase inhibitor and method for preparation thereof)

RN 9004-65-3 CAPLUS

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O

CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 CAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 CAPLUS
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 11138-66-2 CAPLUS
CN Xanthan gum (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L189 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:757454 CAPLUS Full-text
DOCUMENT NUMBER: 139:250344
TITLE: Process for producing drug solid dispersion
INVENTOR(S): Nakano, Tomio; Izumi, Shogo
PATENT ASSIGNEE(S): Nippon Shinyaku Co., Ltd., Japan; Imoto Machinery Co., Ltd.

SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077827	A1	20030925	WO 2003-JP3226	20030318

W: CA, CN, JP, KR, RU, US
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR

PRIORITY APPLN. INFO.: JP 2002-75541 A 20020319

AB Disclosed is a process for producing a drug solid dispersion. In particular, a process for producing a drug solid dispersion, comprising effecting compression and shearing of a material to be kneaded by rotation of disk and further effecting spiral transfer of the material by rotation of spiral screw to thereby produce a kneaded material, wherein a drug solid dispersion composed of at least a pharmaceutically acceptable polymer carrier and a drug is produced by kneading extruder that is so constructed that, in a valley portion between rotary disk and a stationary disk, the material is extruded toward the periphery by a boundary portion of the two disks and fed outward through the interstice provided between the circumference of the rotary disk and an internal surface of cylinder. A solid dispersion of the present invention was prepared from ***nifedipine*** 20 g and hydroxypropyl Me cellulose acetate succinate (AQOAT) 100 g.

IC ICM A61J003-06
CC 63-6 (Pharmaceuticals)
IT 53-86-1, Indomethacine 57-41-0, Phenytoin 79-41-4D, Methacrylic acid, copolymers 126-07-8, Griseofulvin 1508-65-2, Oxybutynin hydrochloride 7585-39-9, β-Cyclodextrin 9000-01-5, Gum arabic 9000-65-1, Tragacanth 9002-18-0, Agar 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinyl pyrrolidone 9004-32-4, Carboxymethyl cellulose sodium salt 9004-38-0, Cellulose Acetate phthalate 9004-53-9, Dextrin 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose ***9004-65-3***, TC-5R 9004-67-5, Methyl cellulose 9005-25-8, α-Starch, biological studies ***9005-37-2***, Propylene glycol alginate ***9005-38-3***, Sodium alginate 9032-42-2, Hydroxyethyl methyl cellulose ***9050-31-1***, Hydroxypropyl methyl cellulose phthalate 9057-02-7, Pullulan 9063-38-1, Sodium Carboxymethyl starch 10016-20-3, α-Cyclodextrin ***11138-66-2***, Xanthan gum 17465-86-0, γ-Cyclodextrin ***21829-25-4***, ***Nifedipine*** 25086-89-9, N-Vinyl pyrrolidone vinyl acetate copolymer 25212-88-8, Eudragit L100-55 25322-68-3, Macrogol 37353-59-6, Hydroxymethyl cellulose 54527-84-3, Nicardipine hydrochloride ***71138-97-1***, AQOAT
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(process for producing drug solid dispersion with polymer carriers)

IT ***9004-65-3***, TC-5R ***9005-37-2***, Propylene glycol alginate ***9005-38-3***, Sodium alginate ***9050-31-1***, Hydroxypropyl methyl cellulose phthalate ***11138-66-2***, Xanthan gum ***21829-25-4***, ***Nifedipine*** ***71138-97-1***, AQOAT
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(process for producing drug solid dispersion with polymer carriers)

RN 9004-65-3 CAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 CAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 CAPLUS
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9050-31-1 CAPLUS

CN Cellulose, hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 88-99-3
CMF C8 H6 O4



CM 3

CRN 67-56-1
CMF C H4 O



CM 4

CRN 57-55-6
CMF C3 H8 O2



RN 11138-66-2 CAPLUS
CN Xanthan gum (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 21829-25-4 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester (CA INDEX NAME)



RN 71138-97-1 CAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether, acetate hydrogen butanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 110-15-6
CMF C4 H6 O4



CM 2

CRN 64-19-7
CMF C2 H4 O2



CM 3

CRN 9004-65-3
CMF C3 H8 O2 . x C H4 O . x Unspecified

CM 4

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 5

CRN 67-56-1
CMF C H4 O



CM 6

CRN 57-55-6
CMF C3 H8 O2



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L189 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:319681 CAPLUS Full-text
DOCUMENT NUMBER: 134:331629
TITLE: Oral transmucosal drug dosage using solid solution
INVENTOR(S): Zhang, Hao; Croft, Jed
PATENT ASSIGNEE(S): Anesta Corp., USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030288	A1	20010503	WO 2000-US28113	20001012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6264981	B1	20010724	US 1999-428071	19991027
CA 2388610	A1	20010503	CA 2000-2388610	20001012
EP 1242013	A1	20020925	EP 2000-972083	20001012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003512402	T	20030402	JP 2001-532709	20001012

PRIORITY APPLN. INFO.:
US 1999-428071 A 19991027
WO 2000-US28113 W 20001012

AB The present invention is directed toward formulation and method for oral transmucosal delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in solid solution with a dissoln. agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by absorption through a patient's oral

mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent. Oral transmucosal formulation containing piroxicam 2, mannitol 10, Emdex 86.7, sodium hydroxide 0.24, and magnesium stearate 1% was prepared Th Cmax and AUC of the drug was two fold of the wet granulation formulation and it was absorbed into the blood stream faster.

IC ICM A61F013-02
ICS A61K009-20; A61K009-68

CC 63-6 (Pharmaceuticals)

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 50-99-7, Dextrose, biological studies 51-30-9, Isoproterenol hydrochloride 51-43-4, Epinephrine 51-61-6, Dopamine, biological studies 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-83-0, Progestron, biological studies 58-22-0, Testosterone 58-38-8, Prochlorperazine 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological studies 60-79-7, Ergonovine 63-12-7, Benzquinamide 63-42-3, Lactose 67-52-7, 2,4,6(1H,3H,5H)-Pyrimidinetrione 69-65-8, Mannitol 71-50-1, Acetate, biological studies 76-74-4, Pentobarbital 76-75-5, Thiopental 77-10-1, Phencyclidine 77-27-0, Thiamylal 77-86-1, Tris 87-99-0, Xylitol 94-24-6, Tetracaine 97-53-0, Eugenol 107-43-7, Trimethylglycine 110-16-7, Maleic acid, biological studies 113-15-5, Ergotamine 129-51-1, Oxytocic 134-03-2, Sodium ascorbate 137-58-6, Lidocaine 138-56-7, Trimethobenzamide 151-83-7, Methohexital 317-34-0, Aminophylline 361-37-5, Methysergide 364-62-5, Metoclopramide 437-38-7, Fentanyl 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5, Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 585-86-4, Lactitol 586-06-1, Metaproterenol 604-75-1, Oxazepam 652-67-5, Isosorbide 721-50-6, Prilocaine 846-49-1, Lorazepam 1400-61-9, Nystatin 1406-18-4, Vitamin E 1421-14-3, Propanidid 2078-54-8, Propofol 3385-03-3, Flunisolide 3715-17-1, Tartrate, biological studies 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 6740-88-1, Ketamine 7440-70-2, Calcium, biological studies 9000-30-0, Guar gum 9000-65-1, Tragacanth 9002-60-2, Adrenocorticotropic hormone, biological studies 9002-64-6, Parathyroid hormone 9002-72-6, Growth hormone 9002-89-5, Polyvinyl alcohol 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-53-9, Dextrin 9004-57-3, Ethylcellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose ***9004-65-3***, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid ***9005-37-2***, Propylene glycolalginate ***9005-38-3***, Sodium alginate 9005-49-6, Heparin), biological studies 9007-12-9, Calcitonin 9041-90-1, Angiotensin I 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 11000-17-2, Vasopressin 11103-57-4, Vitamin A ***11138-66-2***, Xanthan gum 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 16679-58-6, Desmopressin 17560-51-9, Metolazone 18559-94-9, Albuterol ***21829-25-4***, ***Nifedipine*** 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 25322-68-3, Polyethylene glycol 25322-68-3D, alkyl ethers 28860-95-9, Carbidopa 28911-01-5, Triazolam 33125-97-2, Etomidate 36322-90-4, Piroxicam 36894-69-6, Labetalol 38396-39-3, Bupivacaine 39404-33-6, Dextrates 42200-33-9, Nadolol 51384-51-1, Metoprolol 54182-58-0, Sucralfate 54767-75-8, Suloctidil 56030-54-7, Sufentanil 59467-70-8, Midazolam 59708-52-0, Carfentanil 60617-12-1, β-Endorphin 61380-40-3, Lofentanil 62571-86-2, Captopril

71195-58-9, Alfentanil 75847-73-3, Enalapril 81147-92-4, Esmolol
103628-46-2, Sumatriptan 106392-12-5, Poloxamer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral transmucosal drug dosage using solid solution)

IT ***9004-65-3***, Hydroxypropyl methylcellulose ***9005-37-2***, Propylene glycolalginate ***9005-38-3***, Sodium alginate ***11138-66-2***, Xanthan gum ***21829-25-4***, ***Nifedipine***
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral transmucosal drug dosage using solid solution)

RN 9004-65-3 CAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 CAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI,. 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 CAPLUS
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 11138-66-2 CAPLUS
CN Xanthan gum (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 21829-25-4 CAPLUS
CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, 3,5-dimethyl ester (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L189 ANSWER 5 OF 14 EMBASE

ACCESSION NUMBER: 2006359876 EMBASE Full-text
TITLE: Buccal bioadhesive drug delivery - A promising option for orally less efficient drugs.
AUTHOR: Sudhakar Y.; Kuotsu K.; Bandyopadhyay A.K.
CORPORATE SOURCE: A.K. Bandyopadhyay, Buccal Adhesive Research Laboratory, Division of Pharmaceutics, Department of Pharmaceutical Technology, Kolkata, 700032, India. akbju@yahoo.com
SOURCE: Journal of Controlled Release, (10 Aug 2006) Vol. 114, No. 1, pp. 15-40. .
Refs: 208
ISSN: 0168-3659 CODEN: JCREEC
PUBLISHER IDENT.: S 0168-3659(06)00202-1
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 23 Aug 2006

Last Updated on STN: 23 Aug 2006

ABSTRACT: Rapid developments in the field of molecular biology and gene technology resulted in generation of many macromolecular drugs including peptides, proteins, polysaccharides and nucleic acids in great number possessing superior pharmacological efficacy with site specificity and devoid of untoward and toxic effects. However, the main impediment for the oral delivery of these drugs as potential therapeutic agents is their extensive presystemic metabolism, instability in acidic environment resulting into inadequate and erratic oral absorption. Parentral route of administration is the only established route that overcomes all these drawbacks associated with these orally less/inefficient drugs. But, these formulations are costly, have least patient compliance, require repeated administration, in addition to the other hazardous effects associated with this route. Over the last few decades' pharmaceutical scientists throughout the world are trying to explore transdermal and transmucosal routes as an alternative to injections. Among the various transmucosal sites available, mucosa of the buccal cavity was found to be the most convenient and easily accessible site for the delivery of therapeutic agents for both local and systemic delivery as retentive dosage forms, because it has expanse of smooth muscle which is relatively immobile, abundant vascularization, rapid recovery time after exposure to stress and the near absence of langerhans cells. Direct access to the systemic circulation through the internal jugular vein bypasses drugs from the hepatic first pass metabolism leading to high bioavailability. Further, these dosage forms are self-administrable, cheap and have superior patient compliance. Developing a dosage form with the optimum pharmacokinetics is a promising area for continued research as it is enormously important and intellectually challenging. With the right dosage form design, local environment of the mucosa can be controlled and manipulated in order to optimize the rate of drug dissolution and permeation. A rational approach to dosage form design requires a complete understanding of the physicochemical and biopharmaceutical properties of the drug and excipients. Advances in experimental and computational methodologies will be helpful in shortening the processing time from formulation design to clinical use. This paper aims to review the developments in the buccal adhesive drug delivery systems to provide basic principles to the young scientists, which will be useful to circumvent the difficulties associated with the formulation design.

CONTROLLED TERM: Medical Descriptors:
*drug delivery system
cheek mucosa
mucus
saliva
drug absorption
hydrogen bond
disulfide bond
electricity
hydrophobicity
covalent bond
quantitative analysis
qualitative analysis
drug formulation
basement membrane
biocompatibility
physical chemistry
drug release
thermodynamics
drug penetration
drug transport
drug bioavailability
human

nonhuman
review
priority journal

CONTROLLED TERM: Drug Descriptors:
*penetration enhancing agent: PR, pharmaceutics
*drug carrier: PR, pharmaceutics
polycarbophil: PR, pharmaceutics
carboxymethylcellulose: PR, pharmaceutics
hydroxypropylcellulose: PR, pharmaceutics
hydroxypropylmethylcellulose: PR, pharmaceutics
hydroxyethylcellulose: PR, pharmaceutics
xanthan: PR, pharmaceutics
guar gum: PR, pharmaceutics
chitosan: PR, pharmaceutics
carrageenan: PR, pharmaceutics
alginic acid: PR, pharmaceutics
polycaprolactone: PR, pharmaceutics
polystyrene: PR, pharmaceutics
edetic acid: PR, pharmaceutics
citric acid: PR, pharmaceutics
salicylate sodium: PR, pharmaceutics
dodecyl sulfate sodium: PR, pharmaceutics
polyoxyethylene: PR, pharmaceutics
glycocholate sodium: PR, pharmaceutics
taurodeoxycholic acid: PR, pharmaceutics
glycodeoxycholic acid: PR, pharmaceutics
ketoprofen: BD, buccal drug administration
ketoprofen: PR, pharmaceutics
nifedipine: BD, buccal drug administration
nifedipine: PR, pharmaceutics
propranolol derivative: BD, buccal drug administration
propranolol derivative: PR, pharmaceutics
diltiazem: BD, buccal drug administration
diltiazem: PR, pharmaceutics
miconazole: BD, buccal drug administration
miconazole: PR, pharmaceutics
ergotamine: BD, buccal drug administration
ergotamine: PR, pharmaceutics
polymer: PR, pharmaceutics
unindexed drug

CAS REGISTRY NO.: (polycarbophil) 9003-97-8; (carboxymethylcellulose) 8050-38-2, 9000-11-7, 9004-32-4, 9050-04-8; (hydroxypropylcellulose) 9004-64-2; (***hydroxypropylmethylcellulose***) ***9004-65-3***; (hydroxyethylcellulose) 9004-62-0; (***xanthan***) ***11138-66-2***; (guar gum) 9000-30-0; (chitosan) 9012-76-4; (carrageenan) 9000-07-1, 9049-05-2, 9061-82-9, 9064-57-7; (alginic acid) 28961-37-7, 29894-36-8, 9005-32-7, ***9005-38-3***; (polycaprolactone) 24980-41-4, 25248-42-4; (polystyrene) 9003-53-6; (edetic acid) 150-43-6, 60-00-4; (citric acid) 126-44-3, 5949-29-1, 77-92-9, 8002-14-0; (salicylate sodium) 54-21-7; (dodecyl sulfate sodium) 151-21-3; (glycocholate sodium) 863-57-0; (taurodeoxycholic acid) 1180-95-6, 516-50-7; (glycodeoxycholic acid) 16409-34-0, 360-65-6; (ketoprofen) 22071-15-4, 57495-14-4; (***nifedipine***) ***21829-25-4***; (diltiazem) 33286-22-5, 42399-41-7; (miconazole) 22916-47-8; (ergotamine) 113-15-5, 52949-35-6

reserved on STN

ACCESSION NUMBER: 97171083 EMBASE Full-text
DOCUMENT NUMBER: 1997171083
TITLE: Mucoadhesive drug delivery systems.
AUTHOR: Ahuja A.; Khar R.K.; Ali J.
CORPORATE SOURCE: A. Ahuja, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India
SOURCE: Drug Development and Industrial Pharmacy, (1997) Vol. 23, No. 5, pp. 489-515. .
Refs: 144
ISSN: 0363-9045 CODEN: DDIPD8
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index
039 Pharmacy
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 10 Jul 1997
Last Updated on STN: 10 Jul 1997

ABSTRACT: Mucoadhesion in drug delivery systems has recently gained interest among pharmaceutical scientists as a means of promoting dosage form residence time as well as improving intimacy of contact with various absorptive membranes of the biological system. Besides acting as platforms for sustained-release dosage forms, bioadhesive polymers can themselves exert some control over the rate and amount of drug release, and thus contribute to the therapeutic advantage of such systems. This paper describes some aspects of bioadhesion such as mucus layer, mucoadhesion, and theories of bioadhesion to explain the adhesion mechanism. The factors important to mucoadhesion, the methods used to study bioadhesion, and bioadhesive polymers are described. The methods that evaluate the mucoadhesive dosage forms and finally the bioadhesive drug delivery systems designed for several therapeutic purposes are presented.

CONTROLLED TERM: Medical Descriptors:
*drug adsorption
*membrane binding
*mucosa
bioavailability
drug delivery system
drug design
drug release
human
review
theory
Drug Descriptors:
*alginic acid
*carbopol 934
*carbopol 940
*carboxymethylcellulose
*chitosan
*gelatin
*guar gum
*hydroxyethylcellulose
*hydroxypropylcellulose
hydroxypropylmethylcellulose
*pectin
*polyacrylic acid
*polycarbophil
*polymer
*starch

xanthan
beclometasone dipropionate: PR, pharmaceutics
beclometasone dipropionate: PK, pharmacokinetics
budesonide
buprenorphine: PR, pharmaceutics
buprenorphine: PK, pharmacokinetics
cetylpyridinium salt: PR, pharmaceutics
cetylpyridinium salt: PK, pharmacokinetics
diltiazem: PK, pharmacokinetics
diltiazem: PR, pharmaceutics
fluoride sodium: PK, pharmacokinetics
fluoride sodium: PR, pharmaceutics
glyceryl trinitrate: PK, pharmacokinetics
glyceryl trinitrate: PR, pharmaceutics
insulin: PR, pharmaceutics
insulin: PK, pharmacokinetics
isosorbide dinitrate: PR, pharmaceutics
isosorbide dinitrate: PK, pharmacokinetics
ketoprofen: PK, pharmacokinetics
ketoprofen: PR, pharmaceutics
lidocaine: PR, pharmaceutics
lidocaine: PK, pharmacokinetics
metoclopramide: PK, pharmacokinetics
metoclopramide: PR, pharmaceutics
metronidazole: PR, pharmaceutics
metronidazole: PK, pharmacokinetics
nifedipine: PK, pharmacokinetics
nifedipine: PR, pharmaceutics
prochlorperazine: PR, pharmaceutics
prochlorperazine: PK, pharmacokinetics
propranolol: PR, pharmaceutics
propranolol: PK, pharmacokinetics
replens
retinoic acid: PK, pharmacokinetics
retinoic acid: PR, pharmaceutics
triamcinolone acetonide: PR, pharmaceutics
triamcinolone acetonide: PK, pharmacokinetics
unindexed drug
verapamil: PK, pharmacokinetics
verapamil: PR, pharmaceutics
unclassified drug

CAS REGISTRY NO.: (alginic acid) 28961-37-7, 29894-36-8, 9005-32-7, ***9005-38-3***; (carbopol 934) 9007-16-3; (carbopol 940) 76050-42-5; (carboxymethylcellulose) 8050-38-2, 9000-11-7, 9004-32-4, 9050-04-8; (chitosan) 9012-76-4; (gelatin) 9000-70-8; (guar gum) 9000-30-0; (hydroxyethylcellulose) 9004-62-0; (hydroxypropylcellulose) 9004-64-2; (***hydroxypropylmethylcellulose***) ***9004-65-3***; (pectin) 9000-69-5; (polyacrylic acid) 74350-43-9, 87003-46-1, 9003-01-4, 9003-04-7; (polycarbophil) 9003-97-8; (starch) 9005-25-8, 9005-84-9; (***xanthan***) ***11138-66-2***; (beclometasone dipropionate) 5534-09-8; (budesonide) 51333-22-3; (buprenorphine) 52485-79-7, 53152-21-9; (cetylpyridinium salt) 123-03-5, 140-72-7, 2349-55-5, 7773-52-6; (diltiazem) 33286-22-5, 42399-41-7; (fluoride sodium) 51668-54-3, 7681-49-4, 79933-27-0; (glyceryl trinitrate) 55-63-0; (insulin) 9004-10-8; (isosorbide dinitrate) 87-33-2; (ketoprofen) 22071-15-4, 57495-14-4; (lidocaine) 137-58-6, 24847-67-4, 56934-02-2, 73-78-9; (metoclopramide) 12707-59-4,

2576-84-3, 364-62-5, 7232-21-5; (metronidazole) 39322-38-8, 443-48-1; (***nifedipine***) ***21829-25-4***; (prochlorperazine) 58-38-8; (propranolol) 13013-17-7, 318-98-9, 3506-09-0, 4199-09-1, 525-66-6; (retinoic acid) 302-79-4; (triamcinolone acetonide) 76-25-5; (verapamil) 152-11-4, 52-53-9

CHEMICAL NAME: Rhinocort; Replens

L189 ANSWER 7 OF 14 USPATFULL on STN

ACCESSION NUMBER: 2003:152382 USPATFULL Full-text

TITLE: Pharmaceutical dosage forms for highly hydrophilic materials

INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Krill, Steven L., Danbury, CT, UNITED STATES
Venkateshvaran, Srinivasan, Salt Lake City, UT, UNITED STATES

PATENT ASSIGNEE(S): LIPOCINE, INC. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003104048	A1	20030605	<--
APPLICATION INFO.:	US 2002-158206	A1	20020529 (10)	

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, GRANTED, Pat. No. US 6451339
Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192
Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: THORPE NORTH WESTERN, 8180 SOUTH 700 EAST, SUITE 200, P.O. BOX 1219, SANDY, UT, 84070

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 2976

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical dosage forms having a highly hydrophilic fill material and a shell encapsulating the fill material are disclosed and described. Generally, the shell has at least one plasticizing agent therein in order to provide the shell with an effective plasticity. In one aspect, the shell may have included therein an amount of plasticizing agent that is sufficient to provide the shell with an effective plasticity upon migration of a portion of the plasticizing agent into the fill material. In another aspect, the plasticizing agent may have a solubility in the fill material of less than about 10% w/w. In yet another aspect, a combination of a plasticizing agent, and a plasticizing agent having a solubility in the fill material of less than about 10% w/w, may be presented in a total amount sufficient to provide the shell with an effective plasticity upon migration of plasticizing agent into the fill material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003104048 A1 20030605 <--

DETD [0129] Lipid-regulating agents that are generally classified as hydrophobic include HMG CoA reductase inhibitors such as atorvastatin, simvastatin, fluvastatin, pravastatin, ***lovastatin***, cerivastatin, rosuvastatin, and pitavastatin, as well as other lipid-lowering ("antihyperlipidemic") agents such as bezafibrate, beclobrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, clofibric. . .

DETD . . . amlodipine, benazepril, benidipine, candesartan, captopril, carvedilol, darodipine, dilitazem, diazoxide, doxazosin, enalapril, epleronone, eposartan, felodipine, fenoldopam, fosinopril, guanabenz, iloprost, imidapril, irbesartan, ***isradipine***, lercardinipine, lisinopril, losartan, mibefradil, minoxidil, nebivolol, nicardipine, ***nifedipine***, nimodipine, nisoldipine, olmesartan, omapatrilat, phenoxybenzamine, pindolol, prazosin, quinapril, reserpine, semotiadil, sitaxsentan, terazosin, telmisartan, trandolapril, and valsartan.

DETD [0133] Anti-diabetic agents include, by way of example, acetohexamide, chlorpropamide, ciglitazone, farglitazar, glibenclamide, gliclazide, ***glipizide***, glucagon, glyburide, glymepiride, miglitol, pioglitazone, nateglinide, pimagedine, repaglinide, rosiglitazone, tolazamide, tolbutamide, triampterine, and troglitazone.

DETD [0149] Anti-diabetics, such as acetohexamide, chlorpropamide, farglitazar, glibenclamide, gliclazide, ***glipizide***, glimepiride, miglitol, nateglinide, pimagedine, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone, and voglibose;

DETD . . . and cardiac inotropes such as amrinone, digoxin, digitoxin, enoximone, lanatoside C, medigoxin, and milrinone; calcium channel blockers such as verapamil, ***nifedipine***, nicardipene, felodipine, ***isradipine***, nimodipine, amlodipine and diltiazem; beta-blockers such as acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxyprenolol, pindolol, propafenone, propranolol, esmolol, sotalol, timolol,. . .

DETD . . . acid sources, esomeprazole, estradiol, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide*** , glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, lisinopril, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megestrol acetate, methadone, methoxsalen, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, ***nifedipine***, nisoldipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, oxaprozin, paclitaxel, pantoprazole, paracalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudoephedrine, pyridostigmine,. . .

DETD . . . of lipid-regulating agents, e.g., (a) a fibrate and a statin, such as fenofibrate and atorvastatin, fenofibrate and simvastatin, fenofibrate and ***lovastatin***, or fenofibrate and pravastatin; (b) a fibrate and nicotinic acid, such fenofibrate and niacin; and (c) a statin and a nicotinic acid, such as ***lovastatin*** and niacin;

DETD . . . and rosiglitazone, (b) a fibrate and an insulin stimulant such as a sulfonylurea, e.g., fenofibrate and glimepiride, or fenofibrate and ***glipizide***, a statin and and insulin sensitizer such as a thiazolidinedione, e.g., ***lovastatin*** and pioglitazone, simvastatin and rosiglitazone, pravastatin and pioglitazone, or the like;

DETD . . . as glyburide combined with acarbose, (ii) acarbose and a meglitinide such as repaglinide, (iii) miglitol and a sulfonylurea such as ***glipizide***, or (iv) acarbose and a thiazolidinedione such as pioglitazone;

DETD . . . a diuretic agent such as losartan and hydrochlorothiazide; a combination of a calcium channel blocker and a β-blocker such as ***nifedipine*** and atenolol; and a combination of a calcium channel blocker and an ACE inhibitor such as felodipine and ramipril;

DETD . . . combinations of an antihypertensive agent and an antidiabetic agent, such as an ACE inhibitor and a sulfonylurea, e.g., irbesartan and ***glipizide***;

DETD [0193] combinations of a lipid-regulating agent and a drug for treating coronary artery disease, e.g., fenofibrate and ezetimibe, or ***lovastatin*** and ezetimibe; and

COMMAND INTERRUPTED
REENTER FILE 'CAPLUS, EMBASE, USPATFULL'
AND TRY AGAIN, OR ENTER '?' FOR MORE INFORMATION.

Your command did not complete due to a temporary system problem. To recover, reenter the file you are in now. Then, any command that is normally available to you may be used. No cost summary for the current file will be displayed. After reentering the current file you may retry your command. Also, you may wish to SAVE your search query. This can be done in any file. If you cannot access your current file, or if your command fails a second time, notify the Help Desk. Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or by using the SEND command in STNMAIL file.

=> d ibib abs kwic hitstr L189 7-14
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> => d ibib abs kwic hitstr L189 7-14
YOU HAVE REQUESTED DATA FROM FILE 'EMBASE, USPATFULL, CAPLUS' - CONTINUE? (Y)/N:y

DETD [0193] combinations of a lipid-regulating agent and a drug for treating coronary artery disease, e.g., fenofibrate and ezetimibe, or ***lovastatin*** and ezetimibe; and

L189 ANSWER 7 OF 14 USPATFULL on STN

ACCESSION NUMBER:	2003:152382 USPATFULL Full-text			
TITLE:	Pharmaceutical dosage forms for highly hydrophilic materials			
INVENTOR(S):	Patel, Mahesh V., Salt Lake City, UT, UNITED STATES Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES Krill, Steven L., Danbury, CT, UNITED STATES Venkateshvaran, Srinivasan, Salt Lake City, UT, UNITED STATES			
PATENT ASSIGNEE(S):	LIPOCINE, INC. (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003104048	A1	20030605	<--
APPLICATION INFO.:	US 2002-158206	A1	20020529	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-898553, filed on 2 Jul 2001, GRANTED, Pat. No. US 6451339			

Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192
Continuation-in-part of Ser. No. US 2001-877541, filed on 8 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THORPE NORTH WESTERN, 8180 SOUTH 700 EAST, SUITE 200, P.O. BOX 1219, SANDY, UT, 84070
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2976
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical dosage forms having a highly hydrophilic fill material and a shell encapsulating the fill material are disclosed and described. Generally, the shell has at least one plasticizing agent therein in order to provide the shell with an effective plasticity. In one aspect, the shell may have included therein an amount of plasticizing agent that is sufficient to provide the shell with an effective plasticity upon migration of a portion of the plasticizing agent into the fill material. In another aspect, the plasticizing agent may have a solubility in the fill material of less than about 10% w/w. In yet another aspect, a combination of a plasticizing agent, and a plasticizing agent having a solubility in the fill material of less than about 10% w/w, may be presented in a total amount sufficient to provide the shell with an effective plasticity upon migration of plasticizing agent into the fill material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003104048 A1 20030605 <--

DETD [0129] Lipid-regulating agents that are generally classified as hydrophobic include HMG CoA reductase inhibitors such as atorvastatin, simvastatin, fluvastatin, pravastatin, ***lovastatin***, cerivastatin, rosuvastatin, and pitavastatin, as well as other lipid-lowering ("antihyperlipidemic") agents such as bezafibrate, beclobrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, clofibric. . .

DETD . . . amlodipine, benazepril, benidipine, candesartan, captopril, carvedilol, darodipine, dilitazem, diazoxide, doxazosin, enalapril, epleronone, eposartan, felodipine, fenoldopam, fosinopril, guanabenz, iloprost, imidapril, irbesartan, ***isradipine***, lercardinipine, lisinopril, losartan, mibefradil, minoxidil, nebivolol, nicardipine, ***nifedipine***, nimodipine, nisoldipine, olmesartan, omapatrilat, phenoxybenzamine, pindolol, prazosin, quinapril, reserpine, semotiadil, sitaxsentan, terazosin, telmisartan, trandolapril, and valsartan.

DETD [0133] Anti-diabetic agents include, by way of example, acetohexamide, chlorpropamide, ciglitazone, farglitazar, glibenclamide, gliclazide, ***glipizide***, glucagon, glyburide, glymepiride, miglitol, pioglitazone, nateglinide, pimagedine, repaglinide, rosiglitazone, tolazamide, tolbutamide, triampterine, and troglitazone.

DETD [0149] Anti-diabetics, such as acetohexamide, chlorpropamide, farglitazar, glibenclamide, gliclazide, ***glipizide***, glimepiride, miglitol, nateglinide, pimagedine, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone, and voglibose;

DETD . . . and cardiac inotropes such as amrinone, digoxin, digitoxin, enoximone, lanatoside C, medigoxin, and milrinone; calcium channel blockers such as verapamil, ***nifedipine***, nicardipene,

felodipine, ***isradipine***, nimodipine, amlodipine and diltiazem; beta-blockers such as acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxyprenolol, pindolol, propafenone, propranolol, esmolol, sotalol, timolol,. . .

DETD . . . acid sources, esomeprazole, estradiol, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide*** , glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, lisinopril, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megestrol acetate, methadone, methoxsalen, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, ***nifedipine***, nisoldipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, oxaprozin, paclitaxel, pantoprazole, paracalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudoephedrine, pyridostigmine,. . .

DETD . . . of lipid-regulating agents, e.g., (a) a fibrate and a statin, such as fenofibrate and atorvastatin, fenofibrate and simvastatin, fenofibrate and ***lovastatin***, or fenofibrate and pravastatin; (b) a fibrate and nicotinic acid, such fenofibrate and niacin; and (c) a statin and a nicotinic acid, such as ***lovastatin*** and niacin;

DETD . . . and rosiglitazone, (b) a fibrate and an insulin stimulant such as a sulfonylurea, e.g., fenofibrate and glimepiride, or fenofibrate and ***glipizide***, a statin and and insulin sensitizer such as a thiazolidinedione, e.g., ***lovastatin*** and pioglitazone, simvastatin and rosiglitazone, pravastatin and pioglitazone, or the like;

DETD . . . as glyburide combined with acarbose, (ii) acarbose and a meglitinide such as repaglinide, (iii) miglitol and a sulfonylurea such as ***glipizide***, or (iv) acarbose and a thiazolidinedione such as pioglitazone;

DETD . . . a diuretic agent such as losartan and hydrochlorothiazide; a combination of a calcium channel blocker and a β-blocker such as ***nifedipine*** and atenolol; and a combination of a calcium channel blocker and an ACE inhibitor such as felodipine and ramipril;

DETD . . . combinations of an antihypertensive agent and an antidiabetic agent, such as an ACE inhibitor and a sulfonylurea, e.g., irbesartan and ***glipizide***;

DETD [0193] combinations of a lipid-regulating agent and a drug for treating coronary artery disease, e.g., fenofibrate and ezetimibe, or ***lovastatin*** and ezetimibe; and

IT 56-81-5, Glycerin, biological studies 57-48-7, D-Fructose, biological studies 57-83-0, Progesterone, biological studies 59-02-9, α-Tocopherol 69-65-8, D-Mannitol 102-76-1, Triacetin 1318-93-0, Montmorillonite, biological studies 1327-43-1, Magnesium aluminum silicate 1335-30-4, Aluminum silicate 1343-88-0, Magnesium silicate 1405-86-3, Glycyrrhizin 9000-01-5, Acacia gum 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-40-2, Locust bean gum 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-18-0, Agar 9002-96-4, TPGS 9003-39-8, Povidone 9004-32-4, Sodium carboxymethyl cellulose 9004-57-3, Ethyl cellulose 9004-58-4, Ethyl hydroxyethyl cellulose 9004-59-5, Ethyl methyl cellulose 9004-64-2, Hydroxypropyl cellulose ***9004-65-3***, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9005-25-8D, Starch, hydrolyzates, hydrogenated ***9005-37-2***, Propylene glycol alginate

9005-38-3, Sodium alginate 9063-38-1, Sodium starch glycolate *11138-66-2*, Xanthan gum 12173-47-6, Hectorite 12174-11-7, Attapulgite 25322-68-3, PEG 400 25618-55-7, Polyglycerol 39386-78-2, Tamarind gum 49562-28-9, Fenofibrate 82626-48-0, Zolpidem 96081-19-5, Anidrisorb 35/70 99614-02-5, Ondansetron 103628-46-2, Sumatriptan 106392-12-5, Lutrol F68 151319-34-5, Zaleplon 156259-68-6, Capmul MCM
(encapsulation of fill material containing drug and carrier of hydrophilic surfactant)

IT *9004-65-3*, Hydroxypropyl methyl cellulose *9005-37-2*, Propylene glycol alginate *9005-38-3*, Sodium alginate *11138-66-2*, Xanthan gum
(encapsulation of fill material containing drug and carrier of hydrophilic surfactant)

RN 9004-65-3 USPATFULL
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 USPATFULL
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

RN 11138-66-2 USPATFULL
CN Xanthan gum (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L189 ANSWER 8 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2003:92739 USPATFULL Full-text
TITLE: SOLID CARRIERS FOR IMPROVED DELIVERY OF HYDROPHOBIC ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003064097	A1	20030403	<--
	US 6569463	B2	20030527	
APPLICATION INFO.:	US 2001-800593	A1	20010306 (9)	

RELATED APPLN. INFO.: Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 91
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 3863
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2003064097 A1 20030403 <--
US 6569463 B2 20030527

DETD . . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide***, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, lisinopril, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mefepristone, mefloquine, megesterol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratiptan, nelfinavir, ***nifedipine***, nilsolidipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, osteradiol, oxaprozin, paclitaxel, paricalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudo-ephedrine, pyridostigmine,. . .

DETD . . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furzolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide***, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, mefepristone, mefloquine, megesterol acetate, methdone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, mmedroxyprogestrone, montelukast, nabumetone, nalbuphine, naratiptan,. . .

DETD . . . dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, flucanazole, flurbiprofen, fosphenytion, frovatriptan, furzolidone, glibenclamide, ***glipizide***, glyburide, glymepride, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mefepristone, megesterol acetate, methoxsalen, metronidazole, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratiptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine,. . .

DETD . . . active ingredients include: amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporine, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lanosprazole, loratadine, ***lovastatin***, megesterol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paricalcitol, pioglitazone, pranlukast, progesterone, pseudo-ephedrine, rabeprazole, rapamycin, refocoxib, repaglinide, rimexolone, ritanovir, rosiglitazone,. . .

DETD [0313]

EXAMPLE 19

Component	Amount (g)
Lovastatin	20

Coenzyme Q10	50
PEG-40 stearate	150
Glycerol monolaurate	50
Non-pareil seed (25/30 mesh)	200

CLM What is claimed is:

. . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide***, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, lisinopril, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mefepristone, mefloquine, megesterol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratiptan, nelfinavir, ***nifedipine***, nilsolidipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, osteradiol, oxaprozin, paclitaxel, paricalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudo-ephedrine, pyridostigmine,. . .

. . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furzolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide***, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, mefepristone, mefloquine, megesterol acetate, methdone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, mmedroxyprogesterone, montelukast, nabumetone, nalbuphine, naratiptan,. . .

. . . dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, flucanazole, flurbiprofen, fosphenytion, frovatriptan, furzolidone, glibenclamide, ***glipizide***, glyburide, glymepride, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mefepristone, megesterol acetate, methoxsalen, metronidazole, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratiptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine,. . .

. . . group consisting of amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporine, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lanosprazole, loratadine, ***lovastatin***, megesterol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paricalcitol, pioglitazone, pranlukast, progesterone, pseudo-ephedrine, rabeprazole, rapamycin, refocoxib, repaglinide, rimexolone, ritanovir, rosiglitazone,. . .

. . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide***, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide,

lisinopril, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mefepristone, mefloquine, megesterol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratiptan, nelfinavir, ***nifedipine***, nilsolidipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, osteradiol, oxaprozin, paclitaxel, paricalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudo-ephedrine, pyridostigmine,. . .

. . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furzolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide***, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, mefepristone, mefloquine, megesterol acetate, methdone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, mmedroxyprogesterone, montelukast, nabumetone, nalbuphine, naratiptan,. . .

. . . dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, flucanazole, flurbiprofen, fosphenytion, frovatriptan, furzolidone, glibenclamide, ***glipizide***, glyburide, glymepride, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mefepristone, megesterol acetate, methoxsalen, metronidazole, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratiptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine,. . .

. . . group consisting of amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporine, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lanosprazole, loratadine, ***lovastatin***, megesterol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paricalcitol, pioglitazone, pranlukast, progesterone, pseudo-ephedrine, rabeprazole, rapamycin, refocoxib, repaglinide, rimexolone, ritanovir, rosiglitazone,. . .

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides,

biological studies 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4, Benzonatate 105-37-3, EThyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone 542-28-9, δ-Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, β-Butyrolactone 3445-11-2 4419-39-0, BeclomethAsone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D, Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4, Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8, Polyvinylpyrrolidone ***9004-65-3***, Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic acid, salts ***9005-37-2***, Propylene glycol alginate 9005-63-4D, Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLOLEIQUECC497 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4, Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D, Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 23288-49-5, Probucol 25168-73-4, Sucrose monostearate 25265-75-2,

Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D, Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs. 27195-16-0, Sucrose distearate 27203-92-5, TRamadol 27638-00-2, Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquistearate 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8, Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5, Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 65271-80-9, Mitoxantrone
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

IT ***9004-65-3***, Hydroxypropyl methylcellulose ***9005-37-2***, Propylene glycol alginate
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1
CMF C H4 O

$H_3C—OH$

CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



L189 ANSWER 9 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2002:55008 USPATFULL Full-text
TITLE: Clear oil-containing pharmaceutical compositions containing a therapeutic agent
INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES
Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Fikstad, David T., Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002032171	A1	20020314	<--
	US 6761903	B2	20040713	
APPLICATION INFO.:	US 2001-877541	A1	20010608	(9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-345615, filed on 30 Jun 1999, GRANTED, Pat. No. US 6267985 Continuation-in-part of Ser. No. US 2000-751968, filed on 29 Dec 2000, PENDING Continuation-in-part of Ser. No. US 1999-375636, filed on 17 Aug 1999, GRANTED, Pat. No. US 6309663
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Mark A. Wilson, REED & ASSOCIATES, 3282 Alpine Road, Portola Valley, CA, 94028
NUMBER OF CLAIMS: 205
EXEMPLARY CLAIM: 1
LINE COUNT: 4418
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a carrier,

where the carrier is formed from a combination of a triglyceride and at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous medium, the carrier forms a clear, aqueous dispersion of the triglyceride and surfactants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2002032171 A1 20020314 <--
US 6761903 B2 20040713

DETD . . . propionate, fluvastatin, foscarnet sodium, fosinopril, fosphenytoin, fosphenytoin sodium, frovatriptan, frusemide, fumagillin, furazolidone, furosemide, furzolidone, gabapentin, gancyclovir, gemfibrozil, gentamycin, glibenclamide, gliclazide, ***glipizide***, glucagon, glybenclamide, glyburide, glyceryl trinitrate, glymepiride, glymepride, granisetron, granulocyte stimulating factor, grepafloxacin, griseofulvin, guanabenz, guanabenz acetate, halofantrine, halofantrine HCl, haloperidol, hydrocortisone, hyoscyamine, ibufenac, ibuprofen, imipenem, indinavir, indivir, indomethacin, insulin, interleukin-3, irbesartan, irinotecan, isosorbide dinitrate, isosorbide mononitrate, isotretinoin, isoxazole, ***isradipine***, itraconazole, ivermectin, ketoconazole, ketoprofen, ketorolac, ketotifen, labetalol, lamivudine, lamotrigine, lanatoside C, lanosprazole, leflunomide, levofloxacin, levothyroxine, lisinopril, lomefloxacin, lomustine, loperamide, loratadine, lorazepam, lorefloxacin, lormetazepam, losartan, ***lovastatin***, L-thryroxine, lysuride, lysuride maleate, maprotiline, maprotiline HCl, mazindol, mebendazole, meclofenamic acid, meclozine, meclozine HCl, medazepam, medigoxin, medroxyprogesterone acetate, mefenamic acid, . . . nalbuphine, nalidixic acid, naproxen, naratriptan, naratriptan HCl, natamycin, nedocromil sodium, nefazodone, nelfinavir, nerteporfin, neutontin, nevirapine, nicardipine, nicardipine HCl, nicotine, nicoumalone, ***nifedipine***, nilutamide, nimesulide, nimodipine, nimorazole, nisoldipine, nitrazepam, nitro furantoin, nitrofurazone, nizatidine, non-essential fatty acids, norethisterone, norfloxacin, norgestrel, nortriptyline HCl, nystatin, oestradiol, . . .

IT 50-70-4, Sorbitol, biological studies 50-70-4D, Sorbitol, esters 50-78-2, Aspirin 56-81-5, Glycerol, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-55-6, Propylene glycol, biological studies 57-55-6D, 1,2-Propanediol, cyclodextrin ethers 58-32-2, Dipyridamole 58-95-7, α-Tocopherol acetate 59-02-9, α-Tocopherol 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 67-63-0, Isopropanol, biological studies 77-89-4, Acetyl triethyl citrate 77-90-7, Acetyl tributyl citrate 77-93-0, Triethyl citrate 77-94-1, Tributyl citrate 81-24-3 81-25-4 81-81-2, Warfarin 83-44-3 87-69-4D, Tartaric acid, esters 87-78-5, Mannitol 100-51-6, Benzyl alcohol, biological studies 102-76-1, Triacetin 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2, ε-Caprolactam, biological studies 105-60-2D, ε-Caprolactam, derivs. 106-32-1, Ethyl caprylate 107-21-1, Ethylene glycol, biological studies 107-21-1D, Ethylene glycol, esters 107-88-0, 1,3-Butanediol 110-27-0, Isopropyl myristate 111-62-6, Ethyl oleate 111-90-0, Transcutol 112-80-1, Oleic acid, biological studies 115-77-5, Pentaerythritol, biological studies 115-77-5D, Pentaerythritol, esters 115-83-3, Pentaerythritol tetrastearate 118-71-8, Maltol 119-13-1, δ-Tocopherol 122-32-7, Glyceryl trioleate 124-07-2, Octanoic acid, biological studies 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Lauric

acid, biological studies 148-03-8, β-Tocopherol 151-41-7, Lauryl sulfate 334-48-5, Decanoic acid 360-65-6 434-13-9 463-40-1 474-25-9 475-31-0 490-23-3, β-Tocotrienol 502-44-3, ε-Caprolactone 516-35-8 516-50-7 537-40-6, Glyceryl trilinoleate 538-23-8, Glyceryl tricaprylate 538-24-9, Glyceryl trilaurate 541-15-1D, Carnitine, esters with fatty acids, salts 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 555-43-1, Glyceryl tristearate 577-11-7, Sodium docusate 616-45-5, 2-Pyrrolidone 616-45-5D, 2-Pyrrolidone, derivs. 621-70-5, Glyceryl tricaproate 621-71-6, Glyceryl tricaprate 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7, 2-Piperidone 675-20-7D, 2-Piperidone, derivs. 823-22-3, δ-Caprolactone 872-50-4, N-Methylpyrrolidone, biological studies 1331-12-0, Propylene glycol monoacetate 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1338-43-8, Sorbitan monooleate 1398-61-4, Chitin 1406-18-4, Vitamin E 1721-51-3, α-Tocotrienol 1935-18-8, Palmitoylcarnitine 2466-77-5, Lauroylcarnitine 2687-91-4, N-Ethylpyrrolidone 2687-94-7, N-Octylpyrrolidone 2687-96-9, N-Lauryl-2-pyrrolidone 3068-88-0, β-Butyrolactone 3416-24-8, Glucosamine 3445-11-2 4345-03-3, α-Tocopherol succinate 5306-85-4, Dimethyl isosorbide 6493-05-6, Pentoxifylline 6990-06-3, Fusidic acid 7616-22-0, γ-Tocopherol 7664-93-9D, Sulfuric acid, alkyl esters, salts 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Polyethylene glycol lauryl ether 9002-96-4 9003-39-8, Polyvinylpyrrolidone 9003-39-8D, PVP, conjugates with phosphatidylethanolamines 9004-34-6D, Cellulose, derivs. 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-61-9, Hyaluronic acid ***9004-65-3***, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyethylene glycol monolaurate 9004-95-9, Polyethylene glycol cetyl ether 9004-96-0, Polyethylene glycol oleate 9004-98-2, Polyethylene glycol oleyl ether 9004-99-3, Polyethylene glycol monostearate 9005-00-9, Polyethylene glycol stearyl ether 9005-02-1, Polyethylene glycol dilaurate 9005-07-6, Polyethylene glycol dioleate 9005-08-7, Polyethylene glycol distearate 9005-25-8, Starch, biological studies 9005-32-7D, Alginic acid, salts ***9005-37-2***, Propylene glycol alginate 9005-49-6, Heparin, biological studies 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-27-6, Chondroitin 9007-48-1, Polyglyceryl oleate 9009-32-9, Polyglyceryl stearate 9014-63-5, Xylan 9016-45-9, Polyethylene glycol nonyl phenyl ether 9041-08-1, Heparin sodium 9050-30-0, Heparan sulfate 9050-36-6, Maltodextrin 9062-73-1, Polyethylene glycol sorbitan laurate 9062-90-2, Polyethylene glycol sorbitan oleate 10041-19-7 11140-04-8, Imwitor 988 12619-70-4, Cyclodextrin 12619-70-4D, Cyclodextrin, hydroxypropyl ethers 12772-47-3, Pentaerythritol oleate 13027-26-4, δ-Tocopherol acetate 13081-97-5, Pentaerythritol distearate 13552-80-2, Glyceryl triundecanoate 14101-61-2, γ-Tocotrienol 14440-80-3, Stearoyl-2 Lactylate 14465-68-0, Glyceryl trilinolenate 14605-22-2 22373-05-3, β-Tocopherol acetate 22373-06-4, γ-Tocopherol acetate 22882-95-7, Isopropyl linoleate 25168-73-4, Sucrose monostearate 25249-06-3, Polygalacturonic acid 25322-68-3D, ethers or esters 25322-69-4D, Polypropylene glycol, esters 25339-99-5, Sucrose monolaurate 25612-59-3, δ-Tocotrienol 25618-55-7D, Polyglycerol, esters with fatty acids 25637-97-2, Sucrose dipalmitate 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26446-38-8, Sucrose monopalmitate 26658-19-5, Sorbitan tristearate 27195-16-0, Sucrose distearate 27321-96-6, Polyethylene glycol

cholesteryl ether 29874-09-7, Myristoylcarnitine 29894-36-8, Polymannuronic acid 31692-85-0, Glycofurol 31694-55-0D, AMD triesters with fatty acids 35296-72-1, Butanol 36291-32-4, Citric acid monoglyceride 37270-89-6, Nadroparin calcium 51938-44-4, Sorbitan sesquistearate 53168-42-6, Myvacet 9-45 54392-26-6, Sorbitan monoisostearate 55142-85-3, Ticlid 56451-84-4 57307-93-4, Pentaerythritol caprylate 61725-93-7, Polyglyceryl distearate 61752-68-9, Sorbitan tetrastearate 64480-66-6, Glycoursodeoxycholic acid 68818-37-1, Pentaerythritol decanoate 68958-64-5, Polyethylene glycol glyceryl trioleate 69070-98-0 70226-44-7, Heparan 73963-72-1, Cilostazol 74504-64-6, Polyglyceryl laurate 75634-40-1, Dermatan 83138-62-9, Polyglyceryl isostearate 88662-03-7 93790-70-6, Cholylsarcosine 93790-72-8, N-Methyltaurocholic acid 98913-68-9, Pentaerythritol isostearate 106392-12-5, Polyethylene glycol-polypropylene glycol block copolymer 110540-43-7, Polyglyceryl pentaoleate 113665-84-2, Clopidogrel 128254-89-7 128254-90-0 128286-20-4 146478-45-7, Polyglyceryl dioleate 148796-42-3 150372-93-3, Polyoxyethylene glyceryl laurate 162011-90-7, Rofecoxib 181695-72-7, Valdecoxib 198470-84-7, Parecoxib 208666-87-9, Captex 810D 256923-73-6, γ-Tocotrienol acetate 300583-65-7 300583-68-0 403815-06-5 403815-07-6 403815-12-3 403821-12-5, Polyglyceryl trioleate 403838-29-9
(clear oil-containing pharmaceutical compns. containing therapeutic agent)

IT ***9004-65-3***, Hydroxypropyl methyl cellulose ***9005-37-2***, Propylene glycol alginate
(clear oil-containing pharmaceutical compns. containing therapeutic agent)

RN 9004-65-3 USPATFULL
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



L189 ANSWER 10 OF 14 USPATFULL on STN

ACCESSION NUMBER:	2002:21845 USPATFULL Full-text
TITLE:	Compositions and methods for improved delivery of lipid regulating agents
INVENTOR(S):	Patel, Mahesh V., Salt Lake City, UT, UNITED STATES Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002012680	A1	20020131	<--
	US 6451339	B2	20020917	
APPLICATION INFO.:	US 2001-898553	A1	20010702 (9)	

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS:	140
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Page(s)
LINE COUNT:	3604

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 2002012680 A1 20020131 <--
US 6451339 B2 20020917

DETD [0092] anti-diabetics, such as acetohexamide, chlorpropamide, glibenclamide, gliclazide, ***glipizide***, glymepride, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide and troglitazone;

DETD . . . benidipine, benezepril, candesartan, captopril, darodipine, dilitazem HCl, diazoxide, doxazosin HCl, elanapril, eposartan losartan, mesylate, felodipine, fenolclopam, fosinopril, guanabenz acetate, irbesartan, ***isradipine***, lisinopril, minoxidil, nicardipine HCl, ***nifedipine***, nimodipine, nisolidipine, phenoxybenzamine HCl, prazosin HCl, quinapril, reserpine, terazosin HCl, telmisartan, and valsartan;

CLM What is claimed is:

. . . nelfinavir, efavirenz, dicoumarol, tirofibran, cilostazol, ticlidopine, clopidrogel, oprevelkin, paroxetine, sertraline, venlafaxine, bupropion, clomipramine, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide*** , glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraçonazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, lisinopril, benezepril, ***nifedipine***, nilsolidipine, telmisartan, irbesartan, eposartan, valsartan, candesartan, minoxidil, terzosin, halofantrine, mefloquine, dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratiptan, rizatriptan, aminogluthemide, busulphan,. .

. . . montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide***, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, halofantrine,. . .

. . . amiodarone, zileuton, zafirlukast, albuterol, montelukast, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide***, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, terbenafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, nitrofurantoin, dihydroergotamine, ergotamine, frovatriptan, pizofetin, zolmitriptan, pseudo-ephedrine,. . .

. . . nelfinavir, efavirenz, dicoumarol, tirofibran, cilostazol, ticlidopine, clopidrogel, oprevelkin, paroxetine, sertraline, venlafaxine, bupropion, clomipramine, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide*** , glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, lisinopril, benezepril, ***nifedipine***, nilsolidipine, telmisartan, irbesartan, eposartan, valsartan, candesartan, minoxidil, terzosin, halofantrine, mefloquine, dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratiptan, rizatriptan, aminogluthemide, busulphan,. .

. . . montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen,

ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide***, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, halofantrine,. . .

. . . amiodarone, zileuton, zafirlukast, albuterol, montelukast, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide***, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, terbenafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, nitrofurantoin, dihydroergotamine, ergotamine, frovatriptan, pizofetin, zolmitriptan, pseudo-ephedrine,. . .

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides, biological studies 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4, Benzonatate 105-37-3, EThyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone 542-28-9, δ-Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7,

2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, β-Butyrolactone 3445-11-2 4419-39-0, BeclomethAsone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D, Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4, Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8, Polyvinylpyrrolidone ***9004-65-3***, Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic acid, salts ***9005-37-2***, Propylene glycol alginate 9005-63-4D, Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLOLEIQUECC497 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4, Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D, Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 23288-49-5, Probucol 25168-73-4, Sucrose monostearate 25265-75-2, Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D, Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs. 27195-16-0, Sucrose distearate 27203-92-5, TRamadol 27638-00-2, Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquistearate 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8, Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5, Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 65271-80-9, Mitoxantrone

(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

IT *9004-65-3*, Hydroxypropyl methylcellulose *9005-37-2*,
Propylene glycol alginate
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



L189 ANSWER 11 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:162866 USPATFULL Full-text
TITLE: Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6294192	B1	20010925	<--
APPLICATION INFO.:	US 1999-258654		19990226	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Channavajjala, Lakshmi
LEGAL REPRESENTATIVE: Reed, Dianne E.Reed & Associates
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 3094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 6294192 B1 20010925 <--
DETD anti-diabetics, such as acetohexamide, chlorpropamide, glibenclamide, gliclazide, ***glipizide***, glimepiride, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide and troglitazone;
DETD . . . benidipine, benezepril, candesartan, captopril, darodipine, dilitazem HCl, diazoxide, doxazosin HCl, enalapril, eposartan, losartan mesylate, felodipine, fenoldopam, fosenopril, guanabenz acetate, irbesartan, ***isradipine***, lisinopril, minoxidil, nicardipine HCl, ***nifedipine***, nimodipine, nisoldipine, phenoxybenzamine HCl, prazosin HCl, quinapril, reserpine, terazosin HCl, telmisartan, and valsartan;
CLM What is claimed is:
. . . nelfinavir, efavirenz, dicournarol, tirofibran, cilostazol, ticlidopine, clopidrogel, oprevelkin, paroxetine, sertraline, venlafaxine, bupropion, clomipramine, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide*** , glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, lisinopril, benezepril, ***nifedipine***, nilsolidipine, telmisartan, irbesartan, eposartan, valsartan, candesartan, minnoxidil, terzosin, halofantrine, mefloquine,

dihydroergotamine, ergotamine, frovatriptan, pizofetin, sumatriptan, zolmitriptan, naratiptan, rizatriptan, aminogluthemide, busulphan, . . .

. . . montelukast, azithromycin, ciprofloxacin, clarithromycin, dirithromycin, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide***, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, amphotericin B, butenafine, terbinafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, griseofulvin, nitrofurantoin, spironolactone, halofantrine, . . .

. . . amiodarone, zileuton, zafirlukast, albuterol, montelukast, rifabutine, rifapentine, trovafloxacin, baclofen, ritanovir, saquinavir, nelfinavir, efavirenz, miglitol, repaglinide, glymepride, pioglitazone, rosigiltazone, troglitazone, glyburide, ***glipizide***, glibenclamide, carbamezepine, fosphenytion, tiagabine, topiramate, lamotrigine, vigabatrin, terbenafine, itraconazole, flucanazole, miconazole, ketoconazole, metronidazole, nitrofurantoin, dihydroergotamine, ergotamine, frovatriptan, pizofetin, zolmitriptan, pseudo-ephedrine, . . .

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4, Benzonatate 105-37-3, EThyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7

520-85-4, Medroxyprogesterone 542-28-9, δ-Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, β-Butyrolactone 3445-11-2 4419-39-0, BeclomethAsone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D, Sulfuric acid, salts alkyl derivs. 7689-03-4, Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8, Polyvinylpyrrolidone ***9004-65-3***, Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic acid, salts ***9005-37-2***, Propylene glycol alginate 9005-63-4D, Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLOLEIQUECC497 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4, Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D, Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 23288-49-5, Probucol 25168-73-4, Sucrose monostearate 25265-75-2, Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D, Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs. 27195-16-0, Sucrose distearate 27203-92-5, TRamadol 27638-00-2, Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquistearate 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8, Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5,

Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3
63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine
65271-80-9, Mitoxantrone
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

IT ***9004-65-3***, Hydroxypropyl methylcellulose ***9005-37-2***, Propylene glycol alginate
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



L189 ANSWER 12 OF 14 USPATFULL on STN

ACCESSION NUMBER:	2001:121093 USPATFULL Full-text
TITLE:	Clear oil-containing pharmaceutical compositions
INVENTOR(S):	Chen, Feng-Jing, Salt Lake City, UT, United States Patel, Mahesh V., Salt Lake City, UT, United States
PATENT ASSIGNEE(S):	Lipocine Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6267985	B1	20010731	<--
APPLICATION INFO.:	US 1999-345615		19990630	(9)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Spear, James M.
LEGAL REPRESENTATIVE:	Reed, Dianne E.Reed & Associates
NUMBER OF CLAIMS:	184
EXEMPLARY CLAIM:	1
LINE COUNT:	3767

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a triglyceride and a carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the triglyceride and surfactants. An optional therapeutic agent can be incorporated into the composition, or can be co-administered with the composition. The invention also provides methods of enhancing triglyceride solubility and methods of treatment with therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6267985 B1 20010731 <--

SUMM . . . propionate, fluvastatin, foscamet sodium, fosinopril, fosphenytoin, fosphenytoin sodium, frovatriptan, frusemide, fumagillin, furazolidone, furosemide, furzolidone, gabapentin, gancyclovir, gemfibrozil, gentamycin, glibenclamide, gliclazide, ***glipizide***, glucagon, glybenclamide, glyburide, glyceryl trinitrate, glymepiride, glymepride, granisetron, granulocyte stimulating factor, grepafloxacin, griseofulvin, guanabenz, guanabenz acetate, halofantrine, halofantrine HCl, haloperidol, hydrocortisone, hyoscyamine, ibufenac, ibuprofen, imipenem, indinavir, indivir, indomethacin, insulin, interleukin-3, irbesartan, irinotecan, isosorbide dinitrate, isosorbide mononitrate, isotretinoin, isoxazole, ***isradipine***, itraconazole, ivermectin, ketoconazole, ketoprofen, ketorolac, ketotifen, labetalol, lamivudine, lamotrigine, lanatoside C, lanosprazole, leflunomide, levofloxacin, levothyroxine, lisinopril, lomefloxacin, lomustine, loperamide, loratadine, lorazepam, lorefloxacin, lormetazepam, losartan, ***lovastatin***, L-thryroxine, lysuride, lysuride maleate, maprotiline, maprotiline HCl, mazindol, mebendazole, meclofenamic acid,

meclozine, meclozine HCl, medazepam, medigoxin. medroxyprogesterone acetate, mefenamic acid,. . . nalbuphine, nalidixic acid, naproxen, naratriptan, naratriptan HCl, natamycin, nedocromil sodium, nefazodone, nelfinavir, nerteporfin, neutontin, nevirapine, nicardipine, nicardipine HCl, nicotine, nicoumalone, ***nifedipine***, nilutamide, nimesulide, nimodipine, nimorazole, nisoldipine, nitrazepam, nitrofurantoin, nitrofurazone, nizatidine, non-essential fatty acids, norethisterone, norfloxacin, norgestrel, nortriptyline HCl, nystatin, oestradiol, ofloxacin,. . .

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides, biological studies 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4, Benzonatate 105-37-3, EThyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone 542-28-9, δ-Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, β-Butyrolactone 3445-11-2 4419-39-0, BeclomethAsone 4759-48-2,

Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D, Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4, Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8, Polyvinylpyrrolidone ***9004-65-3***, Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic acid, salts ***9005-37-2***, Propylene glycol alginate 9005-63-4D, Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLOLEIQUECC497 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4, Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D, Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 23288-49-5, Probucol 25168-73-4, Sucrose monostearate 25265-75-2, Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D, Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs. 27195-16-0, Sucrose distearate 27203-92-5, TRamadol 27638-00-2, Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide 31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil 41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone 49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide 51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquistearate 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8, Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5, Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine 65271-80-9, Mitoxantrone
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

IT ***9004-65-3***, Hydroxypropyl methylcellulose ***9005-37-2***, Propylene glycol alginate
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



L189 ANSWER 13 OF 14 USPATFULL on STN
ACCESSION NUMBER: 2001:116589 USPATFULL Full-text
TITLE: Oral transmucosal drug dosage using solid solution

INVENTOR(S): Zhang, Hao, Salt Lake City, UT, United States
Croft, Jed, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Anesta Corporation, Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6264981	B1	20010724	<-- duplicate
APPLICATION INFO.:	US 1999-428071		19991027 (9)	

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Azpuru, Carlos
LEGAL REPRESENTATIVE: Kirton & McConkie, Krieger, Michael F.
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed toward formulation and method for oral transmucosal delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in solid solution with a dissolution agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by absorption through a patient's oral mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PI US 6264981 B1 20010724 <--

DETD . . .	diuretic	20-100	mg
isosorbide	angina	2.5-40	mg
labetalol	antihypertensive	100-400	mg
lidocaine	antiarrhythmic	20-250	mg
metolazone	diuretic	5-50	mg
metoprolol	antihypertensive	25-100	mg
nadolol	antihypertensive	40-160	mg
nifedipine	antihypertensive	10-40	mg
nitroglycerin	antihypertensive/angina	0.4-1.0	mg
nitroprusside	hypotensive	10-50	mg
propranolol	antihypertensive/angina	0.1-50	mg

CLM What is claimed is:
. . . triazolam, droperidol, propanidid, etomidate, propofol, ketamine, diprivan, bretylium, captopril, clonidine, dopamine, enalapril, esmolol, furosemide, isosorbide, labetalol, lidocaine, metolazone, metoprolol, nadolol, ***nifedipine***, nitroglycerin, nitroprusside, propranolol, benzquinamide, meclizine, metoclopramide, prochlorperazine, trimethobenzamide, clotrimazole, nystatin, carbidopa, levodopa, sucralfate, albuterol, amninophylline, beclomethasone, dyphylline, epinephrine, flunisolide, isoetharine,. . .
. . . triazolam, droperidol, propanidid, etomidate, propofol, ketamine, diprivan, bretylium, captopril, clonidine, dopamine, enalapril, esmolol, furosemide, isosorbide, labetalol, lidocaine, metolazone, metoprolol, nadolol, ***nifedipine***, nitroglycerin, nitroprusside, propranolol, benzquinamide, meclizine, metoclopramide, prochlorperazine, trimethobenzamide, clotrimazole, nystatin, carbidopa, levodopa, sucralfate, albuterol, aminophylline, beclomethasone, dyphylline, epinephrine, flunisolide, isoetharine,. . .

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies

50-99-7, Dextrose, biological studies 51-30-9, Isoproterenol hydrochloride 51-43-4, Epinephrine 51-61-6, Dopamine, biological studies 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-83-0, Progestron, biological studies 58-22-0, Testosterone 58-38-8, Prochlorperazine 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological studies 60-79-7, Ergonovine 63-12-7, Benzquinamide 63-42-3, Lactose 67-52-7, 2,4,6(1H,3H,5H)-Pyrimidinetrione 69-65-8, Mannitol 71-50-1, Acetate, biological studies 76-74-4, Pentobarbital 76-75-5, Thiopental 77-10-1, Phencyclidine 77-27-0, Thiamylal 77-86-1, Tris 87-99-0, Xylitol 94-24-6, Tetracaine 97-53-0, Eugenol 107-43-7, Trimethylglycine 110-16-7, Maleic acid, biological studies 113-15-5, Ergotamine 129-51-1, Oxytocic 134-03-2, Sodium ascorbate 137-58-6, Lidocaine 138-56-7, Trimethobenzamide 151-83-7, Methohexital 317-34-0, Aminophylline 361-37-5, Methysergide 364-62-5, Metoclopramide 437-38-7, Fentanyl 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5, Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 585-86-4, Lactitol 586-06-1, Metaproterenol 604-75-1, Oxazepam 652-67-5, Isosorbide 721-50-6, Prilocaine 846-49-1, Lorazepam 1400-61-9, Nystatin 1406-18-4, Vitamin E 1421-14-3, Propanidid 2078-54-8, Propofol 3385-03-3, Flunisolide 3715-17-1, Tartrate 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 6740-88-1, Ketamine 7440-70-2, Calcium, biological studies 9000-30-0, Guar gum 9000-65-1, Tragacanth 9002-60-2, Adrenocorticotropic hormone, biological studies 9002-64-6, Parathyroid hormone 9002-72-6, Growth hormone 9002-89-5, Polyvinyl alcohol 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-53-9, Dextrin 9004-57-3, Ethylcellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose ***9004-65-3***, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid ***9005-37-2***, Propylene glycolalginate ***9005-38-3***, Sodium alginate 9005-49-6, Heparin), biological studies 9007-12-9, Calcitonin 9041-90-1, Angiotensin I 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 11000-17-2, Vasopressin 11103-57-4, Vitamin A ***11138-66-2***, Xanthan gum 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 16679-58-6, Desmopressin 17560-51-9, Metolazone 18559-94-9, Albuterol 21829-25-4, Nifedipine 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 25322-68-3, Polyethylene glycol 25322-68-3D, alkyl ethers 28860-95-9, Carbidopa 28911-01-5, Triazolam 33125-97-2, Etomidate 36322-90-4, Piroxicam 36894-69-6, Labetalol 38396-39-3, Bupivacaine 39404-33-6, Dextrates 42200-33-9, Nadolol 51384-51-1, Metoprolol 54182-58-0, Sucralfate 54767-75-8, Suloctidil 56030-54-7, Sufentanil 59467-70-8, Midazolam 59708-52-0, Carfentanil 60617-12-1, β-Endorphin 61380-40-3, Lofentanil 62571-86-2, Captopril 71195-58-9, Alfentanil 75847-73-3, Enalapril 81147-92-4, Esmolol 103628-46-2, Sumatriptan 106392-12-5, Poloxamer
(oral transmucosal drug dosage using solid solution)

IT ***9004-65-3***, Hydroxypropyl methylcellulose ***9005-37-2***, Propylene glycolalginate ***9005-38-3***, Sodium alginate ***11138-66-2***, Xanthan gum
(oral transmucosal drug dosage using solid solution)

RN 9004-65-3 USPATFULL

CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-38-3 USPATFULL
CN Alginic acid, sodium salt (8CI, 9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

RN 11138-66-2 USPATFULL

CN Xanthan gum (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

L189 ANSWER 14 OF 14 USPATFULL on STN

ACCESSION NUMBER:	2001:93131 USPATFULL Full-text
TITLE:	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S):	Patel, Mahesh V., Salt Lake City, UT, United States Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S):	Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6248363	B1	20010619	<--
APPLICATION INFO.:	US 1999-447690		19991123	(9)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Spear, James M.
LEGAL REPRESENTATIVE:	Reed, Dianne E.Reed & Associates
NUMBER OF CLAIMS:	57
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT:	3302

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PI US 6248363 B1 20010619 <--

DETD . . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide***, glyburide, glymepride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, lisinopril, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mefepristone, mefloquine, megesterol acetate, methadone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratiptan, nelfinavir, ***nifedipine***, nilsolidipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, osteradiol, oxaprozin, paclitaxel, paricalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudo-ephedrine,

pyridostigmine,. . .

DETD . . . essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, flucanazole, flurbiprofen, fluvastatin, fosphenytion, frovatriptan, furzolidone, gabapentin, gemfibrozil, glibenclamide, ***glipizide***, glyburide. glymepride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, mefepristone, mefloquine, megesterol acetate, methdone, methoxsalen, metronidazole, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, mmedroxyprogesterone, montelukast, nabumetone, nalbuphine, naratiptan,. . .

DETD . . . dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, flucanazole, flurbiprofen, fosphenytion, frovatriptan, furzolidone, glibenclamide, ***glipizide***, glyburide, glymepride, ibuprofen, irinotecan, isotreinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lanosprazole, leflunomide, loperamide, loratadine, ***lovastatin***, L-thryroxine, lutein, lycopene, medroxyprogesterone, mefepristone, megesterol acetate, methoxsalen, metronidazole, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratiptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine,. . .

DETD . . . active ingredients include: amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporine, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lanosprazole, loratadine, ***lovastatin***, megesterol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paricalcitol, pioglitazone, pranlukast, progesterone, pseudo-ephedrine, rabeprazole, rapamycin, refocoxib, repaglinide, rimexolone, ritanovir, rosiglitazone,. . .

DETD

Component	Amount (g)
Lovastatin	20
Coenzyme Q10	50
PBG-40 stearate	150
Glycerol monolaurate	50
Non-pareil seed (25/30 mesh)	200

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8, Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides, biological studies 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4,

Benzonatate 105-37-3, EThyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone 542-28-9, δ-Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, β-Butyrolactone 3445-11-2 4419-39-0, BeclomethAsone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide 7261-97-4, Dantrolene 7488-99-5, α Carotene 7664-93-9D, Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4, Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8, Polyvinylpyrrolidone ***9004-65-3***, Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic acid, salts ***9005-37-2***, Propylene glycol alginate 9005-63-4D, Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLOLEIQUECC497 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4, Cyclodextrin 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D, Cyclodextrin, hydroxypropyl ethers 13081-97-5, Pentaerythrityl di stearate 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 23288-49-5, Probucol 25168-73-4, Sucrose monostearate 25265-75-2, Butanediol 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D,

Polyglycerol, fatty acid esters 25637-84-7, Glyceryl dioleate
25637-97-2, Sucrose dipalmitate 25812-30-0, Gemfibrozil 26266-57-9,
Sorbitan monopalmitate 26266-58-0, Sorbitan Trioleate 26402-22-2,
Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8,
Sucrose monopalmitate 27154-43-4D, Piperidone, N-Alkyl derivs.
27195-16-0, Sucrose distearate 27203-92-5, TRamadol 27638-00-2,
Glyceryl dilaurate 29094-61-9, Glipizide 29767-20-2, Teniposide
31692-85-0, Glycofurol 32222-06-3, Calcitriol 33069-62-4, Paclitaxel
33419-42-0, Etoposide 34911-55-2, Bupropion 36354-80-0, Glyceryl
dicaprylate 37321-62-3, Lauroglycol 38304-91-5, Minoxidil
41340-25-4, Etodolac 42924-53-8, Nabumetone 43200-80-2, Zopiclone
49562-28-9, Fenofibrate 49697-38-3, Rimexolone 51333-22-3, Budesonide
51481-61-9, Cimetidine 51938-44-4, Sorbitan sesquistearate
52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6, Myvacet 9-45
53179-11-6, Loperamide 53230-10-7, Mefloquine 53988-07-1, Glyceryl
dicaprate 54392-26-6, Sorbitan monoisostearate 54965-21-8,
Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine
57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam
59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5,
Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3
63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine
65271-80-9, Mitoxantrone
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

IT ***9004-65-3***, Hydroxypropyl methylcellulose ***9005-37-2***, Propylene glycol alginate
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)

RN 9004-65-3 USPATFULL
CN Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 67-56-1
CMF C H4 O



CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 9005-37-2 USPATFULL
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

STRUCTURE DIAGRAM IS NOT AVAILABLE

CM 2

CRN 57-55-6
CMF C3 H8 O2



```
=> d his full

     (FILE 'HOME' ENTERED AT 09:05:03 ON 07 MAR 2007)

     FILE 'STNGUIDE' ENTERED AT 09:05:37 ON 07 MAR 2007

     FILE 'CAPLUS' ENTERED AT 09:12:51 ON 07 MAR 2007
                E US2003-650931 /APPS
L1            1 SEA ABB=ON  PLU=ON  US2003-650931 /AP
                D SCA

     FILE 'REGISTRY' ENTERED AT 09:14:08 ON 07 MAR 2007
L2            1 SEA ABB=ON  PLU=ON  NIFEDIPINE/CN
                D SCA
                SEL RN
L3           90 SEA ABB=ON  PLU=ON  21829-25-4/CRN
L4            1 SEA ABB=ON  PLU=ON  ISRADIPINE/CN
                D SCA
                SEL RN
L5            3 SEA ABB=ON  PLU=ON  75695-93-1/CRN
                D SCA
                E LOVASTATIN/CN
L6            1 SEA ABB=ON  PLU=ON  LOVASTATIN/CN
                SEL RN
L7           37 SEA ABB=ON  PLU=ON  75330-75-5/CRN
                D SCA L6
L8           17 SEA ABB=ON  PLU=ON  LOVASTATIN?/CN
L9           16 SEA ABB=ON  PLU=ON  L8 NOT L7
L10           2 SEA ABB=ON  PLU=ON  L8 AND (L6 OR L7)
                D SCA
L11          15 SEA ABB=ON  PLU=ON  L8 NOT L10
                D SCA
                E NIFEDIPINE/CN
L12          22 SEA ABB=ON  PLU=ON  NIFEDIPINE?/CN
L13           5 SEA ABB=ON  PLU=ON  L12 NOT (L2 OR L3)
                D SCA
L14          91 SEA ABB=ON  PLU=ON  (L2 OR L3)
L15           4 SEA ABB=ON  PLU=ON  (L4 OR L5)
L16          53 SEA ABB=ON  PLU=ON  (L6 OR L7 OR L8)
                E ISRADIPINE/CN
                E GLIPIZIDE/CN
L17           1 SEA ABB=ON  PLU=ON  GLIPIZID?/CN
                D SCA
                SEL RN
L18          18 SEA ABB=ON  PLU=ON  29094-61-9/CRN
L19          19 SEA ABB=ON  PLU=ON  (L17 OR L18)
L20          91 SEA ABB=ON  PLU=ON  (L2 OR L3)
L21           4 SEA ABB=ON  PLU=ON  (L4 OR L5)
L22          53 SEA ABB=ON  PLU=ON  (L6 OR L7 OR L8)
L23          19 SEA ABB=ON  PLU=ON  (L17 OR L18)
L24           0 SEA ABB=ON  PLU=ON  L20 AND (L21 OR L22 OR L23)
L25           0 SEA ABB=ON  PLU=ON  L21 AND (L22 OR L23)
L26           0 SEA ABB=ON  PLU=ON  L22 AND L23
L27         167 SEA ABB=ON  PLU=ON  (L20 OR L21 OR L22 OR L23)

     FILE 'CAPLUS' ENTERED AT 09:28:52 ON 07 MAR 2007
L28       12370 SEA ABB=ON  PLU=ON  L27
```

```
     FILE 'REGISTRY' ENTERED AT 09:29:01 ON 07 MAR 2007
                E SODIUM ALGINATE/CN
L29             8 SEA ABB=ON  PLU=ON  SODIUM ALGINAT?/CN
                D SCA
                E ALGINATE/CN
                E XANTHAN GUM/CN
L30             1 SEA ABB=ON  PLU=ON  XANTHAN GUM/CN
                D SCA
L31           102 SEA ABB=ON  PLU=ON  XANTHAN GUM?/CN
L32           102 SEA ABB=ON  PLU=ON  (L30 OR L31)
                E HYDROXYPROPYL METHYL CELLULOSE/CN
L33            28 SEA ABB=ON  PLU=ON  HYDROXYPROPYL METHYL CELLULOSE?/CN
                E PROPYLENE GLYCOL ALGINATE/CN
L34             2 SEA ABB=ON  PLU=ON  PROPYLENE GLYCOL ALGINATE?/CN
                SEL RN L29
L35           134 SEA ABB=ON  PLU=ON  (205256-12-8/CRN OR 205256-14-0/CRN OR
                225931-01-1/CRN OR 791635-67-1/CRN OR 887259-75-8/CRN OR
                9005-38-3/CRN OR 9010-06-4/CRN OR 9061-96-5/CRN)
                E SODIUM ALGINATE/CN
L36             1 SEA ABB=ON  PLU=ON  SODIUM ALGINATE/CN
                SEL RN
L37           133 SEA ABB=ON  PLU=ON  9005-38-3/CRN
L38           137 SEA ABB=ON  PLU=ON  L29 OR L36 OR L37
                SEL RN L30
L39            87 SEA ABB=ON  PLU=ON  11138-66-2/CRN
L40           111 SEA ABB=ON  PLU=ON  L30 OR L31 OR L39
L41             1 SEA ABB=ON  PLU=ON  HYDROXYPROPYL METHYL CELLULOSE/CN
                SEL RN
L42           129 SEA ABB=ON  PLU=ON  9004-65-3/CRN
L43           151 SEA ABB=ON  PLU=ON  L33 OR L41 OR L42
                SEL RN L34
                D SCA L34
                SEL RN L34
L44             6 SEA ABB=ON  PLU=ON  (130392-34-6/CRN OR 9005-37-2/CRN)
                D SCA
L45             8 SEA ABB=ON  PLU=ON  L34 OR L44
L46             1 SEA ABB=ON  PLU=ON  L38 AND (L40 OR L43 OR L45)
                D SCA
L47             1 SEA ABB=ON  PLU=ON  L40 AND (L43 OR L45)
                D SCA
L48             0 SEA ABB=ON  PLU=ON  L43 AND L45
                D COST

     FILE 'CAPLUS' ENTERED AT 09:55:20 ON 07 MAR 2007
L49            62 SEA ABB=ON  PLU=ON  L38 AND L40 AND L43 AND L45
L50             1 SEA ABB=ON  PLU=ON  L46 AND L43 AND L45
L51             0 SEA ABB=ON  PLU=ON  L38 AND L47 AND L45
L52             0 SEA ABB=ON  PLU=ON  L46 AND L47 AND L45
L53             1 SEA ABB=ON  PLU=ON  L46 AND L45
L54             0 SEA ABB=ON  PLU=ON  L47 AND L45
L55             4 SEA ABB=ON  PLU=ON  (L49 OR L50 OR L51 OR L52 OR L53 OR L54)
                AND L28
                D SCA
L56         14331 SEA ABB=ON  PLU=ON  NIFEDIPINE/BI
L57           908 SEA ABB=ON  PLU=ON  ISRADIPINE/BI
L58          3338 SEA ABB=ON  PLU=ON  LOVASTATIN/BI
L59          1072 SEA ABB=ON  PLU=ON  GLIPIZIDE/BI
L*** DEL        0 S L56-L59 AND L49_L54
L60             4 SEA ABB=ON  PLU=ON  (L56 OR L57 OR L58 OR L59) AND (L49 OR L50
                OR L51 OR L52 OR L53 OR L54)
```

```
L61      684024 SEA ABB=ON  PLU=ON  RELEAS?/BI
L62           2 SEA ABB=ON  PLU=ON  L60 AND L61
                D SCA

     FILE 'STNGUIDE' ENTERED AT 10:05:26 ON 07 MAR 2007

     FILE 'CAPLUS' ENTERED AT 10:11:05 ON 07 MAR 2007
L63        1615 SEA ABB=ON  PLU=ON  WOO J?/AU
L64         393 SEA ABB=ON  PLU=ON  CHI M?/AU
L65           4 SEA ABB=ON  PLU=ON  L63 AND L64
L66           1 SEA ABB=ON  PLU=ON  L65 AND L55

     FILE 'REGISTRY' ENTERED AT 10:12:11 ON 07 MAR 2007
L67       57253 SEA ABB=ON  PLU=ON  MEDLINE/LC
L68       30841 SEA ABB=ON  PLU=ON  EMBASE/LC
L69      196582 SEA ABB=ON  PLU=ON  BIOSIS/LC
L70           6 SEA ABB=ON  PLU=ON  L27 AND L67
L71           6 SEA ABB=ON  PLU=ON  L27 AND L68
L72          11 SEA ABB=ON  PLU=ON  L27 AND L69
L73           1 SEA ABB=ON  PLU=ON  L38 AND L67
L74           3 SEA ABB=ON  PLU=ON  L38 AND L68
L75           6 SEA ABB=ON  PLU=ON  L38 AND L69
L76           1 SEA ABB=ON  PLU=ON  L40 AND L67
L77           1 SEA ABB=ON  PLU=ON  L40 AND L68
L78           3 SEA ABB=ON  PLU=ON  L40 AND L69
L79           3 SEA ABB=ON  PLU=ON  L43 AND L67
L80           3 SEA ABB=ON  PLU=ON  L43 AND L68
L81           5 SEA ABB=ON  PLU=ON  L43 AND L69
L82           1 SEA ABB=ON  PLU=ON  L45 AND L67
L83           0 SEA ABB=ON  PLU=ON  L45 AND L68
L84           1 SEA ABB=ON  PLU=ON  L45 AND L69
L85           0 SEA ABB=ON  PLU=ON  L46 AND L67
L86           0 SEA ABB=ON  PLU=ON  L46 AND L68
L87           0 SEA ABB=ON  PLU=ON  L46 AND L69
L88           0 SEA ABB=ON  PLU=ON  L47 AND L67
L89           0 SEA ABB=ON  PLU=ON  L47 AND L68
L90           0 SEA ABB=ON  PLU=ON  L47 AND L69
                D COST

     FILE 'MEDLINE' ENTERED AT 10:41:19 ON 07 MAR 2007
L91        1020 SEA ABB=ON  PLU=ON  WOO J?/AU
L92         144 SEA ABB=ON  PLU=ON  CHI M?/AU
L93           0 SEA ABB=ON  PLU=ON  L91 AND L92
L94       18551 SEA ABB=ON  PLU=ON  L70
L95       19109 SEA ABB=ON  PLU=ON  NIFEDIPINE
L96        1475 SEA ABB=ON  PLU=ON  ISRADIPINE
L97        4043 SEA ABB=ON  PLU=ON  LOVASTATIN
L98         713 SEA ABB=ON  PLU=ON  GLIPIZIDE
L99          10 SEA ABB=ON  PLU=ON  L73
L100        663 SEA ABB=ON  PLU=ON  SODIUM ALGINATE
                D TRIAL 1
                D TRIAL 5-10
                D TRIAL 100
                D TRIAL 101
L101       5653 SEA ABB=ON  PLU=ON  ALGINATE
L102        263 SEA ABB=ON  PLU=ON  L76
L103        372 SEA ABB=ON  PLU=ON  XANTHAN GUM
                D TRIAL 50-55
L104        655 SEA ABB=ON  PLU=ON  L79
                D TRIAL 50-53
```

```
L105        4774 SEA ABB=ON  PLU=ON  METHYLCELLULOSE
L106         458 SEA ABB=ON  PLU=ON  HYDROXYPROPYLMETHYLCELLULOSE
L107          13 SEA ABB=ON  PLU=ON  L82
                 D TRIAL 1-13
L108        5243 SEA ABB=ON  PLU=ON  PROPYLENE GLYCOL
L109           0 SEA ABB=ON  PLU=ON  (L94 OR L95 OR L96 OR L97 OR L98) AND (L99
                 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR L106)
                 AND (L107 OR L108)
L110           0 SEA ABB=ON  PLU=ON  (L94 OR L95 OR L96 OR L97 OR L98) AND (L99
                 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR L106)
L111           0 SEA ABB=ON  PLU=ON  (L99 OR L100 OR L101) AND (L102 OR L103)
                 AND (L104 OR L105 OR L106) AND (L107 OR L108)
                 D COST
                 E NIFEDIPINE/CT
                 E NIFEDIPINE+ALL/CT
L112         426 SEA ABB=ON  PLU=ON  (ADALAT/BI OR BAY-A-1040/BI OR BAY-1040/BI
                 OR CORDIPIN/BI OR CORDIPINE/BI OR CORINFAR/BI OR FENIGIDIN/BI
                 OR INFEDIPIN/BI OR KORINFAR/BI OR "MONOHYDROCHLORIDE, NIFEDIPIN
                 E"/BI OR NIFANGIN/BI OR "NIFEDIPINE MONOHYDROCHLORIDE"/BI OR
                 NIFEDIPINE-GTIS/BI OR PROCARDIA/BI OR "PROCARDIA XL"/BI)
L113          52 SEA ABB=ON  PLU=ON  L112 NOT L95
L114       19161 SEA ABB=ON  PLU=ON  L95 OR L112
                 E ISRADIPINE+ALL/CT
L115         382 SEA ABB=ON  PLU=ON  (DYNACIRC/BI OR "ISRADIPINE, (+-)-ISOMER"/B
                 I OR "ISRADIPINE, (R)-ISOMER"/BI OR "ISRADIPINE, (S)-ISOMER"/BI
                  OR LOMIR/BI OR "PN 200-110"/BI OR "PN 205 033"/BI OR "PN 205
                 034"/BI OR "PN 205-033"/BI OR "PN 205-034"/BI OR "PN 205033"/BI
                  OR "PN 205034"/BI OR PN-200-110/BI OR PN-205-033/BI OR
                 PN-205-034/BI OR PN205033/BI OR PN205034/BI)
L116        1595 SEA ABB=ON  PLU=ON  L96 OR L115
                 E LOVASTATIN+ALL/CT
L*** DEL    4236 S E57-E65/BI
L117         404 SEA ABB=ON  PLU=ON  ("LOVASTATIN, (1 ALPHA(S*))-ISOMER"/BI OR
                 "LOVASTATIN, 1 ALPHA-ISOMER (WITHOUT R*/S* NOTATION)"/BI OR
                 "MK 803"/BI OR MK-803/BI OR MK803/BI OR MEVACOR/BI OR MEVINOLIN
                 /BI OR "MONACOLIN K"/BI)
L118        4139 SEA ABB=ON  PLU=ON  L97 OR L117
                 E GLIPIZIDE+ALL/CT
L119          29 SEA ABB=ON  PLU=ON  ("ALPHAPHARM BRAND OF GLIPIZIDE"/BI OR
                 "GLIBENESE BRAND OF GLIPIZIDE"/BI OR GLIDIAZINAMIDE/BI OR
                 GLUCOTROL/BI OR GLUPITEL/BI OR GLYDIAZINAMIDE/BI OR GLYPIDIZINE
                 /BI OR "K 4024"/BI OR K-4024/BI OR K4024/BI OR "KENFARMA BRAND
                 OF GLIPIZIDE"/BI OR "LACER BRAND OF GLIPIZIDE"/BI OR "LILLY
                 BRAND OF GLIPIZIDE"/BI OR MELIZIDE/BI OR MINDIAB/BI OR
                 MINIDIAB/BI OR MINODIAB/BI OR OZIDIA/BI OR "PFIZER BRAND OF
                 GLIPIZIDE"/BI OR "PHARMACIA BRAND OF GLIPIZIDE"/BI OR "PYRAZINE
                 CARBOXAMIDE, N-(2-(4-((((CYCLOHEXYLAMINO)CARBONYL)AMINO)SULFONY
                 L)PHENYL)ETHYL)-5-METHYL-"/BI)
L120         723 SEA ABB=ON  PLU=ON  L98 OR L119
L121           0 SEA ABB=ON  PLU=ON  (L94 OR L114 OR L116 OR L118 OR L120) AND
                 (L99 OR L100 OR L101) AND (L102 OR L103) AND (L104 OR L105 OR
                 L106) AND (L107 OR L108)
L122           6 SEA ABB=ON  PLU=ON  (L94 OR L114 OR L116 OR L118 OR L120) AND
                 (L91 OR L92)
                 D TRIAL 1-6

     FILE 'EMBASE' ENTERED AT 11:02:57 ON 07 MAR 2007
L123       46607 SEA ABB=ON  PLU=ON  (L71 OR (L95 OR L96 OR L97 OR L98))
                 D TRIAL 1-5
                 E NIFEDIPINE+ALL/CT
```

```
L124        3286 SEA ABB=ON  PLU=ON  (ADALAT/BI OR "ADALAT CRONO"/BI OR "ADALAT
                 PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR ALDIPIN/BI OR
                 ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR "APRICAL RETARD"/BI
                  OR "BAY 1040"/BI OR "BAY A 1040"/BI OR "BAY A1040"/BI OR
                 BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI OR CHRONADALATE/BI
                  OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/BI OR CORDICANT/BI
                 OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI OR DEPIN/BI OR
                 "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) PYRIDINE
                 3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR ECODIPIN/BI OR
                 EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR INFEDIPINE/BI OR
                 MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR NIFANGIN/BI OR
                 NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR NIFEDINE/BI OR
                 NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR NIFENSAR/BI OR
                 NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR NOVONIFEDIN/BI
                 OR PHENYGIDINE/BI OR PIDILAT/BI OR "PIDILAT RETARD"/BI OR
                 PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI OR SEPAMIT/BI
                 OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR UNIDIPINE/BI OR
                 ZENUSIN/BI)
                 E ISRADIPINE+ALL/CT
L125        1049 SEA ABB=ON  PLU=ON  (ISRODIPINE/BI OR LOMIR/BI OR "PK 200110"/B
                 I OR "PN 200 110"/BI OR "PN 200-110"/BI OR "PN 200110"/BI OR
                 "PN 200110 N"/BI OR "PN 205033"/BI OR "PN 205034"/BI OR "PN200
                 110"/BI OR PN200-110/BI OR PN200110/BI OR PRESCAL/BI OR "SDZ
                 200 110"/BI OR VASCAL/BI)
                 E LOVASTATIN+ALL/CT
                 E E2+ALL/CT
L126        2955 SEA ABB=ON  PLU=ON  (ALTOCOR/BI OR ALTOPREV/BI OR ARTEIN/BI OR
                 "L 654969"/BI OR LIPIVAS/BI OR LOVACOL/BI OR LOVASTATIN/BI OR
                 MEVACOR/BI OR MEVINACOR/BI OR "MK 0803"/BI OR "MK 803"/BI OR
                 MK0803/BI OR MK803/BI OR "MONACOLIN K"/BI OR "MONAKOLIN K"/BI
                 OR "MSD 803"/BI OR NEOLIPID/BI)
                 E GLIPIZIDE+ALL/CT
L127         524 SEA ABB=ON  PLU=ON  ("CP 28,720"/BI OR "CP 28720"/BI OR
                 "CP28,720"/BI OR CP28720/BI OR GLIBENESE/BI OR GLIBINESE/BI OR
                 GLIBIZIDE/BI OR GLIDIAZINAMIDE/BI OR GLUCATROL/BI OR GLUCOTROL/
                 BI OR "GLUCOTROL XL"/BI OR GLYDIAZENAMIDE/BI OR GLYDIAZIAMIDE/B
                 I OR GLYDIAZINAMIDE/BI OR GLYPIZIDE/BI OR "K 4024"/BI OR
                 MINIDIAB/BI OR MINODIAB/BI)
L128       46760 SEA ABB=ON  PLU=ON  (L123 OR L124 OR L125 OR L126 OR L127)
                 E SODIUM ALGINATE+ALL/CT
                 E E2+ALL/CT
L129       13985 SEA ABB=ON  PLU=ON  (ALGIN/BI OR ALGINATE/BI OR "ALGINATE
                 SODIUM"/BI OR ALGINATES/BI OR "ALGINIC GULURONIC ACID"/BI OR
                 "BLUEPRINT RAPID"/BI OR COLOURGEL/BI OR "G-C FAST SET"/BI OR
                 "G-C VERICOL AROMA"/BI OR KALGINATE/BI OR KELACID/BI OR
                 "KELCOGEL LV"/BI OR KELGIN/BI OR KELTONE/BI OR "KERR ALGINATE"/
                 BI OR "MANUGEL DJX"/BI OR "MANUGEL DMB"/BI OR MINUS/BI OR
                 NORALGIN/BI OR NORGINE/BI OR POLYMANNURONATE/BI OR "POLYMANNURO
                 NIC ACID"/BI OR "POLYMANNURONIC GULURONIC ACID"/BI OR PROTANAL/
                 BI OR PSOTHANOL/BI OR "SODIUM ALGINATE"/BI OR "SODIUM POLYMANNU
                 RONATE"/BI OR SORBALGON/BI OR "ZELGAN GREEN"/BI OR "ZELGAN
                 PINK"/BI)
L130        6223 SEA ABB=ON  PLU=ON  L74 OR (L100 OR L101)
L131       15293 SEA ABB=ON  PLU=ON  (L129 OR L130)
L132         649 SEA ABB=ON  PLU=ON  L77 OR XANTHAN GUM
                 E XANTHAN GUM+ALL/CT
                 E E2+ALL/CT
L133         699 SEA ABB=ON  PLU=ON  XANTHAN OR KELTROL OR RHODIGEL 23
L134         699 SEA ABB=ON  PLU=ON  (L132 OR L133)
L135        6010 SEA ABB=ON  PLU=ON  L80 OR (L105 OR L106)
```

```
                E HYDROXYPROPYLMETHYLCELLULOSE/CT
                E E3+ALL/CT
L136        1239 SEA ABB=ON  PLU=ON  (ADATOCEL/BI OR CONTACTOL/BI OR GONIOSOL/BI
                 OR "HYDROXYPROPYL METHYL CELLULOSE"/BI OR "HYDROXYPROPYL
                METHYLCELLULOSE"/BI OR "HYDROXYPROPYLMETHYL CELLULOSE"/BI OR
                HYPROMELLOSE/BI OR "ISOPTO TEARS"/BI OR ISOPTONATURAL/BI OR
                ISOPTOPLAIN/BI OR ISOPTOTEARS/BI OR "K 8515"/BI OR LUBAFAX/BI
                OR "METHOCEL E 15"/BI OR "METHOCEL EFK"/BI OR "METHOCEL
                K100M"/BI OR "METHOCEL K15M"/BI OR "METHOCEL K4M"/BI OR
                "METHOLOSE TC 5"/BI OR "METHYLHYDROXYPROPYL CELLULOSE"/BI OR
                METHYLHYDROXYPROPYLCELLULOSE/BI OR METOLOSE/BI OR OCCUCOAT/BI
                OR OCUCOAT/BI OR "PHARMACOAT 603"/BI OR "PHARMACOAT 606"/BI OR
                ULTRATEARS/BI)
L137        6060 SEA ABB=ON  PLU=ON  (L135 OR L136)
                D COST
L138           0 SEA ABB=ON  PLU=ON  L83
                E PROPYLENE GLYCOL ALGINATE+ALL/CT
                E E2+ALL
L139          23 SEA ABB=ON  PLU=ON  "ALGINIC ACID PROPYLENE GLYCOL ESTER"+UF/CT

L140          26 SEA ABB=ON  PLU=ON  ("PROPYLENE GLYCOL ALGINATE"/BI OR
                "PROPYLENEGLYCOL ALGINATE"/BI)
L141          34 SEA ABB=ON  PLU=ON  (L139 OR L140)
L142           0 SEA ABB=ON  PLU=ON  L128 AND L131 AND L134 AND L137 AND L141
L143           2 SEA ABB=ON  PLU=ON  L128 AND L131 AND L134 AND L137
                D TRIAL 1-2
L144           0 SEA ABB=ON  PLU=ON  L131 AND L134 AND L137 AND L141
L145        1034 SEA ABB=ON  PLU=ON  WOO J?/AU
L146         165 SEA ABB=ON  PLU=ON  CHI M?/AU
L147           0 SEA ABB=ON  PLU=ON  L145 AND L146
L148           9 SEA ABB=ON  PLU=ON  (L145 OR L146) AND L128
L149           4 SEA ABB=ON  PLU=ON  (L145 OR L146) AND L131
L150           0 SEA ABB=ON  PLU=ON  (L145 OR L146) AND L134
L151           3 SEA ABB=ON  PLU=ON  (L145 OR L146) AND L137
L152           0 SEA ABB=ON  PLU=ON  (L145 OR L146) AND L141
L153          16 SEA ABB=ON  PLU=ON  (L147 OR L148 OR L149 OR L150 OR L151 OR
                L152)
                D TRIAL 1-5

     FILE 'STNGUIDE' ENTERED AT 11:22:20 ON 07 MAR 2007
                D COST

     FILE 'BIOSIS' ENTERED AT 17:16:06 ON 07 MAR 2007
L154        1198 SEA ABB=ON  PLU=ON  WOO J?/AU
L155         244 SEA ABB=ON  PLU=ON  CHI M?/AU
L156           0 SEA ABB=ON  PLU=ON  L154 AND L155
L157       25683 SEA ABB=ON  PLU=ON  L72 OR (L95 OR L96 OR L97 OR L98)
L158         422 SEA ABB=ON  PLU=ON  (ADALAT/BI OR "ADALAT CRONO"/BI OR "ADALAT
                PA"/BI OR "ADALAT RETARD"/BI OR ADALATE/BI OR ALDIPIN/BI OR
                ANGIBLOC/BI OR APONIFED/BI OR APRICAL/BI OR "APRICAL RETARD"/BI
                 OR "BAY 1040"/BI OR "BAY A 1040"/BI OR "BAY A1040"/BI OR
                BAY1040/BI OR CALCIGARD/BI OR CHRONADALAT/BI OR CHRONADALATE/BI
                 OR CORACTEN/BI OR CORDAFEN/BI OR CORDAFLEX/BI OR CORDICANT/BI
                OR CORDIPIN/BI OR CORINFAR/BI OR COROTREND/BI OR DEPIN/BI OR
                "DIMETHYL 1,4 DIHYDRO 2,6 DIMETHYL 4 (2 NITROPHENYL) PYRIDINE
                3,5 DICARBOXYLATE"/BI OR DURANIFIN/BI OR ECODIPIN/BI OR
                EMABERIN/BI OR FENIGIDIN/BI OR HERLAT/BI OR INFEDIPINE/BI OR
                MIFEDIPINE/BI OR MODERAT/BI OR MYOGARD/BI OR NIFANGIN/BI OR
                NIFEDICOR/BI OR "NIFEDICOR GOCCE"/BI OR NIFEDINE/BI OR
                NIFEDIPAT/BI OR NIFEHEXAL/BI OR NIFELAT/BI OR NIFENSAR/BI OR
```

```
                NIFEPIDINE/BI OR NIFICAL/BI OR NIFICARD/BI OR NOVONIFEDIN/BI
                OR PHENYGIDINE/BI OR PIDILAT/BI OR "PIDILAT RETARD"/BI OR
                PROCARDIA/BI OR "PROCARDIA XL"/BI OR RONIAN/BI OR SEPAMIT/BI
                OR SLOFEDIPINE/BI OR "SLOFEDIPINE XL"/BI OR UNIDIPINE/BI OR
                ZENUSIN/BI)
L159         4086 SEA ABB=ON  PLU=ON  (L125 OR L126 OR L127)
L160        26142 SEA ABB=ON  PLU=ON  (L157 OR L158 OR L159)
L161        23308 SEA ABB=ON  PLU=ON  (L129 OR L130)
L162         1552 SEA ABB=ON  PLU=ON  (L132 OR L133)
L163         1071 SEA ABB=ON  PLU=ON  L78
L164         1552 SEA ABB=ON  PLU=ON  (L162 OR L163)

     FILE 'STNGUIDE' ENTERED AT 17:32:24 ON 07 MAR 2007

     FILE 'BIOSIS' ENTERED AT 17:38:56 ON 07 MAR 2007
L165         4435 SEA ABB=ON  PLU=ON  L137 OR L81
L166           96 SEA ABB=ON  PLU=ON  L84 OR L141
L167            0 SEA ABB=ON  PLU=ON  L160 AND L161 AND L164 AND L165 AND L166
L168            2 SEA ABB=ON  PLU=ON  L161 AND L164 AND L165 AND L166
                  D SCA
L169            8 SEA ABB=ON  PLU=ON  (L154 OR L155) AND (L157 OR L158 OR L159
                  OR L160 OR L161 OR L162 OR L163 OR L164)

     FILE 'USPATFULL' ENTERED AT 17:45:19 ON 07 MAR 2007
L170            1 SEA ABB=ON  PLU=ON  L154 AND L155

     FILE 'CAPLUS' ENTERED AT 17:46:44 ON 07 MAR 2007
L171           62 SEA ABB=ON  PLU=ON  (L49 OR L50 OR L51 OR L52 OR L53 OR L54)
                  SEL AN
L172           60 SEA ABB=ON  PLU=ON  L171 AND P/DT
                  SEL PN

     FILE 'USPATFULL' ENTERED AT 17:49:03 ON 07 MAR 2007
L173           67 SEA ABB=ON  PLU=ON  (WO2004037226/PN OR EP331385/PN OR
                  EP616508/PN OR EP782846/PN OR AU2003274655/PN OR CA2054822/PN
                  OR CA2411153/PN OR CA2503380/PN OR EP1150722/PN OR EP1296656/PN
                   OR EP1299499/PN OR EP1558222/PN OR EP241178/PN OR EP484186/PN
                  OR EP740528/PN OR EP812545/PN OR EP983326/PN OR US2002012680/PN
                   OR US2002032171/PN OR US2006057204/PN OR US6267985/PN OR
                  US6294192/PN OR US6451339/PN OR US6703044/PN OR US6761903/PN
                  OR WO2002000201/PN OR WO2002005620/PN OR WO2002005660/PN OR
                  WO2002005661/PN OR WO2003080056/PN OR WO2003090693/PN OR
                  WO2004113042/PN OR WO2005046363/PN OR WO2005107713/PN OR
                  WO9517104/PN OR AT103492/PN OR AT180170/PN OR AT188118/PN OR
                  AT203148/PN OR AT228776/PN OR AT235228/PN OR AT254157/PN OR
                  AT305802/PN OR AT334662/PN OR AT338800/PN OR AU2000063445/PN
                  OR AU2001013246/PN OR AU2003213020/PN OR AU2003218058/PN OR
                  AU2003230719/PN OR AU2003234240/PN OR AU2003237944/PN OR
                  AU2003297561/PN OR AU2004249662/PN OR AU2004289248/PN OR
                  AU2005230362/PN OR AU590403/PN OR AU618932/PN OR AU657706/PN
                  OR AU667471/PN OR AU683713/PN OR AU688837/PN OR AU713127/PN OR
                  AU725810/PN OR AU731072/PN OR AU740326/PN OR AU753760/PN OR
                  AU754917/PN OR AU772345/PN OR AU782828/PN OR AU8172030/PN OR
                  AU8770616/PN OR AU8770617/PN OR AU9176742/PN OR AU9186961/PN
                  OR AU9220020/PN OR AU9513020/PN OR AU9514318/PN OR AU9673269/PN
                   OR AU9724856/PN OR AU9856271/PN OR AU9879126/PN OR AU9888405/P
                  N OR AU9892840/PN OR AU9910043/PN OR AU9929241/PN OR AU9956852/
                  PN OR BG64100/PN OR BR2001008145/PN OR BR2001012014/PN OR
                  BR2004015741/PN OR BR9809674/PN OR BR9913227/PN OR CA1164264/PN
                   OR CA1300515/PN OR CA2069759/PN OR CA2177713/PN OR CA2188331/P
```

```
               N OR CA2200620/PN OR CA2269769/PN OR CA2291040/PN OR CA2309380/
               PN OR CA2338688/PN OR CA2361847/PN OR CA2388610/PN OR CA2397832
               /PN OR CA2414161/PN OR CA2414166/PN OR CA24141
L174        6797 SEA ABB=ON  PLU=ON  NIFEDIPINE
L175        1469 SEA ABB=ON  PLU=ON  ISRADIPINE
L176        5820 SEA ABB=ON  PLU=ON  LOVASTATIN
L177        2595 SEA ABB=ON  PLU=ON  GLIPIZIDE
L178          15 SEA ABB=ON  PLU=ON  L173 AND (L174 OR L175 OR L176 OR L177)
L179           0 SEA ABB=ON  PLU=ON  (L154 OR L155) AND L178
               D KWIC L178 1-5
               D IND L178 1
               D KWIC L178 2-15
               SEL RN L178
               DELETE SELECT
               D COST
               D COST FULL
               SEL RN L178

     FILE 'REGISTRY' ENTERED AT 17:55:09 ON 07 MAR 2007
L180           5 SEA ABB=ON  PLU=ON  (12619-70-4/RN OR 25322-68-3/RN OR
               57-55-6/RN OR 57-88-5/RN OR 105-60-2/RN)
               D COST FULL
L181         751 SEA ABB=ON  PLU=ON  (56-81-5/RN OR 616-45-5/RN OR 9003-39-8/RN
               OR 9005-63-4/RN OR 50-70-4/RN OR 9004-65-3/RN OR 9005-37-2/RN
               OR 106392-12-5/RN OR 57-83-0/RN OR 9002-89-5/RN OR 102-76-1/RN
               OR 103628-46-2/RN OR 107-21-1/RN OR 112-80-1/RN OR 115-77-5/RN
               OR 128-13-2/RN OR 1397-89-3/RN OR 1406-18-4/RN OR 162011-90-7/R
               N OR 21829-25-4/RN OR 25322-69-4/RN OR 25618-55-7/RN OR
               49562-28-9/RN OR 50-28-2/RN OR 57-10-3/RN OR 57-11-4/RN OR
               675-20-7/RN OR 69-65-8/RN OR 73963-72-1/RN OR 82626-48-0/RN OR
               9002-96-4/RN OR 9005-32-7/RN OR 100-51-6/RN OR 105-37-3/RN OR
               105-54-4/RN OR 106-32-1/RN OR 107753-78-6/RN OR 110-27-0/RN OR
               111-62-6/RN OR 111-90-0/RN OR 11103-57-4/RN OR 11140-04-8/RN
               OR 113-15-5/RN OR 113665-84-2/RN OR 115-83-3/RN OR 124-07-2/RN
               OR 127-19-5/RN OR 13081-97-5/RN OR 1331-12-0/RN OR 1338-39-2/RN
                OR 1338-43-8/RN OR 141-22-0/RN OR 142-62-1/RN OR 142-91-6/RN
               OR 143-07-7/RN OR 144034-80-0/RN OR 14440-80-3/RN OR 14605-22-2
               /RN OR 150372-93-3/RN OR 151-41-7/RN OR 156259-68-6/RN OR
               159989-64-7/RN OR 169590-42-5/RN OR 18559-94-9/RN OR 1951-25-3/
               RN OR 22882-95-7/RN OR 23288-49-5/RN OR 25168-73-4/RN OR
               25339-99-5/RN OR 25637-97-2/RN OR 25812-30-0/RN OR 26266-57-9/R
               N OR 26266-58-0/RN OR 26446-38-8/RN OR 2687-91-4/RN OR
               2687-94-7/RN OR 2687-96-9/RN OR 27195-16-0/RN OR 3068-88-0/RN
               OR 31692-85-0/RN OR 334-48-5/RN OR 3445-11-2/RN OR 360-65-6/RN
               OR 437-38-7/RN OR 4419-39-0/RN OR 463-40-1/RN OR 474-25-9/RN
               OR 475-31-0/RN OR 4759-48-2/RN OR 511-12-6/RN OR 516-35-8/RN
               OR 516-50-7/RN OR 51938-44-4/RN OR 5306-85-4/RN OR 53168-42-6/R
               N OR 54392-26-6/RN OR 544-35-4/RN OR 544-63-8/RN OR 55142-85-3/
               RN OR 577-11-7/RN OR 59467-70-8/RN OR 595-33-5/RN OR 60-33-3/RN
                OR 623-84-7/RN OR 64-17-5/RN OR 640-79-9/RN OR 67-63-0/RN OR
               68958-64-5/RN OR 74504-64-6/RN OR 76547-98-3/RN OR 7664-93-9/RN
                OR 77-89-4/RN OR 77
               D COST FULL

     FILE 'CAPLUS' ENTERED AT 17:57:50 ON 07 MAR 2007
               SEL HIT RN L49

     FILE 'REGISTRY' ENTERED AT 17:58:09 ON 07 MAR 2007
L182           8 SEA ABB=ON  PLU=ON  (9005-38-3/BI OR 11138-66-2/BI OR 9004-65-3
               /BI OR 9005-37-2/BI OR 9050-31-1/BI OR 71138-97-1/BI OR
```

```
                70535-77-2/BI OR 497236-18-7/BI)

     FILE 'USPATFULL' ENTERED AT 17:58:40 ON 07 MAR 2007
L183         9847 SEA ABB=ON  PLU=ON  L182
L184            9 SEA ABB=ON  PLU=ON  L183 AND L178
                  D KWIC 1-9

     FILE 'REGISTRY' ENTERED AT 18:00:51 ON 07 MAR 2007

     FILE 'CAPLUS' ENTERED AT 18:00:59 ON 07 MAR 2007
               D STAT QUE L65
               D STAT QUE L122

     FILE 'MEDLINE' ENTERED AT 18:01:17 ON 07 MAR 2007
               D STAT QUE L122

     FILE 'EMBASE' ENTERED AT 18:01:22 ON 07 MAR 2007
               D STAT QUE L153

     FILE 'BIOSIS' ENTERED AT 18:01:31 ON 07 MAR 2007
               D STAT QUE L169

     FILE 'USPATFULL' ENTERED AT 18:01:42 ON 07 MAR 2007
               D STAT QUE L170

     FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, USPATFULL' ENTERED AT 18:02:04 ON
     07 MAR 2007
L185           23 DUP REM L65 L122 L153 L169 L170 (12 DUPLICATES REMOVED)
                     ANSWERS '1-4' FROM FILE CAPLUS
                     ANSWERS '5-10' FROM FILE MEDLINE
                     ANSWERS '11-22' FROM FILE EMBASE
                     ANSWER '23' FROM FILE USPATFULL
                  D IBIB ABS HITIND HITSTR L185 1-4
                  D IALL L185 5-22
                  D IBIB ABS L185 23

     FILE 'REGISTRY' ENTERED AT 18:03:14 ON 07 MAR 2007

     FILE 'CAPLUS' ENTERED AT 18:03:17 ON 07 MAR 2007
               D STAT QUE L55
               D STAT QUE L60

     FILE 'MEDLINE' ENTERED AT 18:03:32 ON 07 MAR 2007
               D STAT QUE L109
               D STAT QUE L110
               D STAT QUE L111
               D STAT QUE L121

     FILE 'EMBASE' ENTERED AT 18:03:59 ON 07 MAR 2007
               D STAT QUE L143
L186            2 SEA ABB=ON  PLU=ON  L143 NOT L153

     FILE 'BIOSIS' ENTERED AT 18:04:37 ON 07 MAR 2007
               D STAT QUE L167

     FILE 'USPATFULL' ENTERED AT 18:04:52 ON 07 MAR 2007
               D STAT QUE L184
L187            9 SEA ABB=ON  PLU=ON  L184 NOT L170

     FILE 'CAPLUS' ENTERED AT 18:05:23 ON 07 MAR 2007
```

```
     FILE 'CAPLUS' ENTERED AT 18:05:40 ON 07 MAR 2007
               D STAT QUE L55
               D STAT QUE L60
L188            4 SEA ABB=ON  PLU=ON  L55 OR L60

     FILE 'CAPLUS, EMBASE, USPATFULL' ENTERED AT 18:06:15 ON 07 MAR 2007
L189           14 DUP REM L188 L186 L187 (1 DUPLICATE REMOVED)
                     ANSWERS '1-4' FROM FILE CAPLUS
                     ANSWERS '5-6' FROM FILE EMBASE
                     ANSWERS '7-14' FROM FILE USPATFULL
                  D IBIB ABS HITIND HITSTR L189 1-4
                  D IALL L189 5-6
                  D IBIB ABS KWIC HITSTR L189 7-14

     FILE 'USPATFULL' ENTERED AT 18:10:01 ON 07 MAR 2007

     FILE 'EMBASE, USPATFULL, CAPLUS' ENTERED AT 18:10:37 ON 07 MAR 2007
               D IBIB ABS KWIC HITSTR L189 7-14

     FILE 'USPATFULL' ENTERED AT 18:10:42 ON 07 MAR 2007


     FILE HOME

     FILE STNGUIDE
     FILE CONTAINS CURRENT INFORMATION.
     LAST RELOADED: Mar  2, 2007 (20070302/UP).

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 7 Mar 2007  VOL 146 ISS 11
     FILE LAST UPDATED: 6 Mar 2007  (20070306/ED)

     Effective October 17, 2005, revised CAS Information Use Policies apply.
     They are available for your review at:

     http://www.cas.org/infopolicy.html

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:    5 MAR 2007  HIGHEST RN 924962-30-1
     DICTIONARY FILE UPDATES:   5 MAR 2007  HIGHEST RN 924962-30-1

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006
```

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE MEDLINE
FILE LAST UPDATED: 6 Mar 2007 (20070306/UP). FILE COVERS 1950 TO DATE.

All regular MEDLINE updates from November 15 to December 16 have been added to MEDLINE, along with 2007 Medical Subject Headings (MeSH(R)) and 2007 tree numbers.

The annual reload will be available in early 2007.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE
FILE COVERS 1974 TO 7 Mar 2007 (20070307/ED)

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 28 February 2007 (20070228/ED)

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Mar 2007 (20070306/PD)
FILE LAST UPDATED: 6 Mar 2007 (20070306/ED)
HIGHEST GRANTED PATENT NUMBER: US7188369
HIGHEST APPLICATION PUBLICATION NUMBER: US2007050874
CA INDEXING IS CURRENT THROUGH 6 Mar 2007 (20070306/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Mar 2007 (20070306/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2006

=>